

Report of Head and Neck Cancer Registry of Japan  
Clinical Statistics of Registered Patients, 2018

Japan Society for Head and Neck Cancer  
Cancer Registry Committee

## Contents

<i>Total Cases (2018)</i> .....	11
<i>Oral Cavity (2018)</i> .....	26
<i>Larynx (2018)</i> .....	46
<i>Hypopharynx(2018)</i> .....	74
<i>Oropharynx(2018)</i> .....	103
<i>Oropharynx p16 positive(2018)</i> .....	106
<i>Oropharynx p16 negative and unknown (2018)</i> .....	116
<i>Nasopharynx(2018)</i> .....	126
<i>Nasal Cavity and Paranasal Sinuses (Excluding the Maxillary Sinus) (2018)</i> .....	133
<i>Maxillary Sinus (2018)</i> .....	140
<i>Major Salivary Glands (2018)</i> .....	149
<i>Primary Unknown (2018)</i> .....	162

## Preface

The Head and Neck Cancer Registry in Japan has been supported by the Japan Society for Head and Neck Cancer (JSHNC) since 2003. The annual reports have been published from 2003 to 2005 as supplements of the journal of the JSHNC. Because the Act of the Protection of Personal Information (APPI) was enforced in 2005, JSHNC had decided to discontinue this registration in 2004 and thereafter. After a seven-year interval, the JSHNC restarted the registry using the system of University hospital Medical Information Network (UMIN) Center in Japan. The online registration for patients in 2011 was initiated on May 25, 2012 after renewing the contents and methods of registration. This report is for the seventh year of the registration after its renewal.

The importance of cancer registration has been recognized widely in Japan since the Act of Propulsion of Cancer Registration in 2013. Moreover, the number of participating institutions has increased since the Japanese Society of Head and Neck Surgery (JSHNS) decided a revision in the regime for board-certified head and neck surgeons and training facilities in 2014.

The improved Ethical Guidelines for Medical and Health Research Involving Human Subjects have been publicly announced on Feb 28, 2017 and the revised APPI was enforced on May 30, 2017 in Japan, so that the procedure for informed consent was changed and the data traceability was taken into consideration in this registration thereafter. The minor refinements of the contents are being prepared for introduction of the 8th UICC TNM classification. Moreover, the clinical study support center (CSSC) of Wakayama medical university hospital has participated in this registration system from July 2017. The data collection contents have been expanded to include the information on five-year prognosis from 2017. Hence, the prognosis data about the cases registered in 2012 were also disclosed this time. These reforms and expansion according to social, medical needs are important to achieve the further development of this registry. Actually, the total number of registered cases has remarkably increased by the assistance of data center. We expect that this vast organ-based registry led by doctors and CSSC with an increase in the number of participating institutions, will help better understand the statistics and modes of treatment of head and neck cancer, besides the hospital-based or population-based cancer registry in Japan.

We would like to express our deepest appreciation to all the doctors in the participating institutions. Furthermore, we would like to express our gratitude to the JSHNS, the member of specialists for head and neck cancer, and the members of UMIN Center as well.

May 31, 2021

Ken-ichi Nibu, MD  
Chairperson of the Board of Directors  
Chief Director of Cancer Registry  
Seiichi Yoshimoto MD  
Chairperson of Cancer Registry Committee  
Japan Society for Head and Neck Cancer

Cancer Registry Committee 2021  
Japan Society for Head and Neck Cancer

Directors	Ken-ichi Nibu, Tadaaki Kirita, and Tsuyoshi Kodaira
Supervisor	Munenaga Nakamizo
Chairperson	Seiichi Yoshimoto
Members	Daisuke Kawakita, Wataru Shimbashi, Daisuke Sano, Katsumasa Nakamura, Seiichi Uzawa, and Hideki Nakayama

#### Data Collection

All the doctors who are members of the Japan Society for Head and Neck Cancer are advised to participate in the registration of cancer patients. More than one doctor from an institution could participate in this registration. A participant is provided a UMIN (University hospital Medical Information Network in Japan) ID and a password for INDICE (Internet Data and Information Center for Medical Research) from the UMIN center and registers the data of the cases in their institute to the INDICE system online. The completed registration provides information regarding the patients' age, gender, tumor pathology, TNM classification, therapies (surgery, radiation and chemotherapy), and prognosis. This year, the 8th year of registration, all the data stored in the INDICE system were reviewed by head and neck oncologists and analyzed from all aspects, including the prognosis data about cases registered in 2013.

Registration was restricted to previously untreated malignant head and neck tumor cases which had a confirmed pathological diagnosis, i.e. in the oral cavity, larynx, hypopharynx, oropharynx, nasopharynx, nasal cavity, paranasal sinuses, major salivary glands, and unknown primary. Tumors arising in the cervical esophagus and thyroid gland were excluded from the registry. These head and neck tumors were classified according the General Rules for Clinical Studies on Head and Neck Cancer (The Sixth Edition, June 2018, Japan Society for Head and Neck Cancer), which are based on the TNM Classification of Malignant Tumours (Eighth Edition, 2016) of the International Union Against Cancer (UICC).

A total of 46941 cases (including cases other than in the year 2018 and with unknown presentation of diseases, unknown aim for therapies, previously treated) were registered from January 15, 2018 to Oct. 31, 2020. Data correction by each institution is allowed once by the system, and the data registered before Oct. 31, 2020, were checked and corrected after confirming with each institution, whereas, any data correction after the date by themselves were not verified. The total number of previously untreated patients was 13,149 for the starting date of the initial therapy from Jan. 1 to Dec. 31, 2018, after excluding cases other than in the year 2018 and with unknown presentation of diseases and duplicated registration.

List of 201 Institutions which participate in the Registry in 2018

- 1 Department of Otorhinolaryngology, Japanese Red Cross Kitami Hospital
- 2 Department of Otorhinolaryngology, Asahikawa Medical University Hospital
- 3 Department of Otorhinolaryngology, Kushiro City General Hospital
- 4 Department of Dentistry and Oral Surgery, Hokuto Hospital
- 5 Department of Otorhinolaryngology, Obihiro Kosei Hospital
- 6 Department of Otorhinolaryngology, Keiyukai Sapporo Hospital
- 7 Department of Oral Surgery and Otorhinolaryngology, Sapporo Medical University Hospital
- 8 Department of Oral Surgery, Sapporo City General Hospital
- 9 Department of Otorhinolaryngology, Teine Keijinkai Hospital
- 10 Department of Otorhinolaryngology, KKR Sapporo Medical Center
- 11 Department of Otorhinolaryngology, Hokkaido Medical Center
- 12 Department of Head and Neck Surgery, Hokkaido Cancer Center
- 13 Department of Oral Surgery, Hokkaido Cancer Center
- 14 Department of Oral Surgery, Hokkaido University Hospital
- 15 Department of Otorhinolaryngology, Hokkaido University Hospital
- 16 Department of Oral Surgery, Sapporo Teishinkai Hospital
- 17 Department of Oral Surgery, Tonan Hospital
- 18 Department of Otorhinolaryngology, Hirosaki University Hospital
- 19 Department of Oral Surgery, Hirosaki University Hospital
- 20 Department of Otorhinolaryngology, Akita University Hospital
- 21 Department of Head and Neck Surgery, Miyagi Cancer Center
- 22 Department of Otorhinolaryngology, Sendai Medical Center
- 23 Department of Otorhinolaryngology, Tohoku University Hospital
- 24 Department of Otorhinolaryngology, Iwate Medical University
- 25 Department of Otorhinolaryngology, Yamagata Prefectural Central Hospital
- 26 Department of Otorhinolaryngology, Yamagata University Hospital
- 27 Department of Otorhinolaryngology, Nihonkai General Hospital
- 28 Department of Otorhinolaryngology, Minami Tohoku Hospital
- 29 Department of Otorhinolaryngology, Fukushima Medical University Hospital
- 30 Department of Head and Neck Surgery, Niigata Cancer Center
- 31 Department of Otorhinolaryngology, Niigata University Medical & Dental Hospital
- 32 Department of Department of Tissue Regeneration and Reconstruction, Niigata University Medical & Dental Hospital
- 33 Department of Oral and Maxillofacial Surgery, Niigata University Medical & Dental Hospital
- 34 Department of Oral Surgery, Nippon Dental University Hospital
- 35 Department of Otorhinolaryngology, Japanese Red Cross Nagaoka Hospital

List of 201 Institutions which participate in the Registry in 2018

- 36 Department of Otorhinolaryngology, Ibaraki Prefectural Central Hospital
- 37 Department of Otorhinolaryngology, Tsukuba University Hospital
- 38 Department of Otorhinolaryngology, Saiseikai Utsunomiya Hospital
- 39 Department of Otorhinolaryngology, Jichi University Hospital
- 40 Department of Otorhinolaryngology, Dokkyo Medical University Hospital
- 41 Department of Head and Neck Surgery, Gunma Prefectural Cancer Center
- 42 Department of Otorhinolaryngology, Gunma University Hospital
- 43 Department of Head and Neck Surgery, Saitama Medical University International Medical Center
- 44 Department of Oral Surgery, Saitama Cancer Center
- 45 Department of Head and Neck Surgery, Saitama Cancer Center
- 46 Department of Otorhinolaryngology, Ageo Central General Hospital
- 47 Department of Otorhinolaryngology, National Defense Medical College Hospital
- 48 Department of Otorhinolaryngology, Kameda Medical Center
- 49 Department of Otorhinolaryngology, Kimitsu Chuo Hospital
- 50 Division of Head and Neck Surgery, National Cancer Center Hospital East
- 51 Department of Otorhinolaryngology, Japanese Red Cross Narita Hospital
- 52 Department of Head and Neck Surgery, Chiba Cancer Center
- 53 Department of Oral Surgery, Tokyo Medical University, Chiba Dental Center
- 54 Department of Oral Surgery, Chiba University Hospital
- 55 Department of Otorhinolaryngology, Chiba University Hospital
- 56 Department of Otorhinolaryngology, NTT Medical Center Tokyo
- 57 Department of Head and Neck Surgery, Cancer Institute Hospital
- 58 Department of Otorhinolaryngology, Kyorin University Hospital
- 59 Department of Otorhinolaryngology, Keio University Hospital
- 60 Department of Otorhinolaryngology, Showa General Hospital
- 61 Head and Neck Oncology Center, International University of Health and Welfare, Mita Hospital
- 62 Department of Head and Neck Surgery, National Cancer Center Hospital
- 63 Department of Otorhinolaryngology, Juntendo University Hospital
- 64 Department of Otorhinolaryngology, Showa University Hospital
- 65 Department of Otorhinolaryngology, Teikyo University Hospital
- 66 Department of Otorhinolaryngology, Tokyo Metropolitan Cancer and Infectious Disease Center  
Komagome Hospital
- 67 Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, Tokyo Medical and  
Dental University Hospital
- 68 Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tokyo Medical and Dental  
University Hospital
- 69 Department of Otorhinolaryngology, Tokyo Medical University, Hachioji Medical Center

List of 201 Institutions which participate in the Registry in 2018

- 70 Department of Otorhinolaryngology, Tokyo Medical University, Ichikawa General Hospital
- 71 Department of Otorhinolaryngology, Tokyo Medical University Hospital
- 72 Department of Otorhinolaryngology, Jikei University Hospital
- 73 Department of Otorhinolaryngology, The University of Tokyo Hospital
- 74 Department of Otorhinolaryngology, Tokyo Women's Medical University Hospital
- 75 Department of Otorhinolaryngology, Tokyo Saiseikai Central Hospital
- 76 Department of Otorhinolaryngology, Tokyo Metropolitan Tama Medical Center
- 77 Department of Oral Surgery, Tokyo Metropolitan Tama Medical Center
- 78 Department of Oral Surgery, Tokyo Metropolitan Ohtsuka Hospital
- 79 Department of Otorhinolaryngology and Oral Surgery, Tokyo Medical Center
- 80 Department of Otorhinolaryngology, Japanese Red Cross Musashino Hospital
- 81 Department of Otorhinolaryngology, Nihon University Hospital
- 82 Department of Otorhinolaryngology, Nippon Medical School Hospital
- 83 Department of Otorhinolaryngology, Yokosuka Kyosai Hospital
- 84 Department of Dentistry and Oral Surgery, Yokohama City University Hospital
- 85 Department of Otorhinolaryngology, Yokohama City University Hospital
- 86 Department of Head and Neck Surgery, Kanagawa Cancer Center
- 87 Department of Otorhinolaryngology, St.Marianna University School of Medicine Hospital
- 88 Department of Otorhinolaryngology, Kawasaki Municipal Hospital
- 89 Department of Oral and Maxillofacial Surgery, Tsurumi University Dental Hospital
- 90 Department of Otorhinolaryngology, Tokai University Hospital
- 91 Department of Oral Surgery, Tokai University Hospital
- 92 Department of Otorhinolaryngology, Kitasato University Hospital
- 93 Department of Otorhinolaryngology, Saiseikai Yokohamashi Tobu Hospital
- 94 Department of Otorhinolaryngology, Shinshu University Hospital
- 95 Department of Otorhinolaryngology, Yamanashi University Hospital
- 96 Department of Otorhinolaryngology, Yamanashi Prefectural central hospital
- 97 Department of Otorhinolaryngology, Seirei Hamamatsu General Hospital
- 98 Department of Head and Neck Surgery, Shizuoka Cancer Center
- 99 Department of Oral Surgery, Shizuoka City Shizuoka Hospital
- 100 Department of Otorhinolaryngology, Hamamatsu Medical University Hospital
- 101 Department of Otorhinolaryngology, Japanese Red Cross Shizuoka Hospital
- 102 Department of Dentistry and Oral Surgery, Kouseiren Takaoka Hospital
- 103 Department of Otorhinolaryngology, Toyama University Hospital
- 104 Department of Otorhinolaryngology, Kanazawa University Hospital
- 105 Department of Otorhinolaryngology, Kanazawa Medical University Hospital
- 106 Department of Matsumoto Dental University Hospital

List of 201 Institutions which participate in the Registry in 2018

- 107 Department of Otorhinolaryngology, Gifu University Hospital
- 108 Department of Otorhinolaryngology, Ogaki Municipal Hospital
- 109 Department of Head and Neck Surgery, Aichi Cancer Center
- 110 Department of Otorhinolaryngology, Aichi Medical University Hospital
- 111 Department of Otorhinolaryngology, Toyohashi Municipal Hospital
- 112 Department of Otorhinolaryngology, Fujita Health University Hospital
- 113 Department of Otorhinolaryngology, Nagoya City University Hospital
- 114 Department of Otorhinolaryngology and Oral Surgery, Nagoya University Hospital
- 115 Department of Otorhinolaryngology, Japanese Red Cross Nagoya Daiichi Hospital
- 116 Department of Otorhinolaryngology, Fukui University Hospital
- 117 Department of Otorhinolaryngology, Shiga University of Medical Science Hospital
- 118 Department of Head and Neck Surgery, Kusatsu General Hospital
- 119 Department of Otorhinolaryngology, Japanese Red Cross Otsu Hospital
- 120 Department of Otorhinolaryngology, Shiga General Hospital
- 121 Department of Otorhinolaryngology, Ise Red Cross Hospital
- 122 Department of Otorhinolaryngology, Mie University Hospital
- 123 Department of Otorhinolaryngology, Kyoto Medical Center
- 124 Department of Otorhinolaryngology, Kyoto University Hospital
- 125 Department of Otorhinolaryngology, Japanese Red Cross Kyoto Daiichi Hospital
- 126 Department of Otorhinolaryngology, Japanese Red Cross Kyoto Daini Hospital
- 127 Department of Otorhinolaryngology, Kyoto Prefectural University Hospital
- 128 Department of Otorhinolaryngology, Kinki University Nara Hospital
- 129 Department of Otorhinolaryngology, Nara City Hospital
- 130 Department of Otorhinolaryngology, Tenri Hospital
- 131 Department of Otorhinolaryngology and Oral and Maxillofacial Surgery, Nara Medical University Hospital
- 132 Department of Otorhinolaryngology, Head and Neck Surgery and Oral Surgery, Nara Prefecture General Medical Center
- 133 Department of Otorhinolaryngology, Rinku General Medical Center
- 134 Department of Otorhinolaryngology, Kansai Medical University Hospital
- 135 Department of Otorhinolaryngology, Kitano Hospital
- 136 Department of Oral and Maxillofacial Surgery and Otorhinolaryngology, Kinki University Hospital
- 137 Department of Otorhinolaryngology, Kishiwada City Hospital
- 138 Department of Otorhinolaryngology, Osaka Medical University Hospital
- 139 Department of Otorhinolaryngology, Osaka General Medical Center
- 140 Department of Otorhinolaryngology, Osaka City University Hospital
- 141 Department of Otorhinolaryngology, Osaka City General Hospital

List of 201 Institutions which participate in the Registry in 2018

- 142 Department of Otorhinolaryngology, Japanese Red Cross Osaka Hospital
- 143 Department of Oral Surgery, Osaka University Hospital
- 144 Department of Oral and Maxillofacial Surgery 2, Osaka University Dental Hospital
- 145 Department of Otorhinolaryngology, Osaka Saiseikai Nakatsu Hospital
- 146 Department of Otorhinolaryngology, Osaka Saiseikai Suita Hospital
- 147 Department of Otorhinolaryngology, Yodogawa Christian Hospital
- 148 Department of Otorhinolaryngology, Osaka International Cancer Center
- 149 Department of Otorhinolaryngology, Kansai Rosai Hospital
- 150 Department of Oral Surgery and Otorhinolaryngology, Wakayama Medical University Hospital
- 151 Department of Otorhinolaryngology, Japanese Red Cross Wakayama Medical Center
- 152 Department of Otorhinolaryngology, Kobe City Medical Center General Hospital
- 153 Department of Otorhinolaryngology, Kobe University Hospital
- 154 Department of Oral Surgery, Kobe University Hospital
- 155 Department of Otorhinolaryngology, Hyogo College of Medicine
- 156 Department of Otorhinolaryngology, Hyogo Cancer Center
- 157 Department of Otorhinolaryngology, Hyogo Prefectural Amagasaki General Medical Center
- 158 Department of Otorhinolaryngology, Okayama University Hospital
- 159 Department of Otorhinolaryngology, Himeji Red Cross Hospital
- 160 Department of Otorhinolaryngology, Tottori University Hospital
- 161 Department of Otorhinolaryngology, Kawasaki Medical School Hospital
- 162 Department of Otorhinolaryngology, Kurashiki Central Hospital
- 163 Department of Otorhinolaryngology, Shimane University Hospital
- 164 Department of Otorhinolaryngology, Fukuyama City Hospital
- 165 Department of Otorhinolaryngology, Hiroshima City Hiroshima Citizens Hospital
- 166 Department of Otorhinolaryngology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
- 167 Department of Otorhinolaryngology, Hiroshima University Hospital
- 168 Department of Otorhinolaryngology, Kure Medical Center and Chugoku Cancer Center
- 169 Department of Otorhinolaryngology, Yamaguchi University Hospital
- 170 Department of Otorhinolaryngology, Yamaguchi Prefectural General Medical Center
- 171 Department of Otorhinolaryngology, Ehime Prefectural Central Hospital
- 172 Department of Otorhinolaryngology, Ehime University Hospital
- 173 Department of Otorhinolaryngology, Uwajima City Hospital
- 174 Department of Head and Neck Surgery, Shikoku Cancer Center
- 175 Department of Otorhinolaryngology, Kochi Medical Center
- 176 Department of Otorhinolaryngology, Kochi Medical School Hospital
- 177 Department of Otorhinolaryngology, Kagawa University Hospital
- 178 Department of Otorhinolaryngology, Oita University Hospital

List of 201 Institutions which participate in the Registry in 2018

- 179 Department of Oral Surgery, Oita University Hospital
- 180 Department of Otorhinolaryngology, University of Occupational and Environmental Health
- 181 Department of Otorhinolaryngology, Kokura Memorial Hospital
- 182 Department of Otorhinolaryngology, Kitakushu General Hospital
- 183 Department of Head and Neck Surgery, Kyushu Cancer Center
- 184 Department of Otorhinolaryngology, Kyushu University Hospital
- 185 Department of Otorhinolaryngology, Kyushu Medical Center
- 186 Department of Otorhinolaryngology, Hamanomachi Hospital
- 187 Department of Oral Surgery, Fukuoka University
- 188 Department of Oral Surgery, Fukuoka Dental University
- 189 Department of Otorhinolaryngology, Kurume University Hospital
- 190 Department of Otorhinolaryngology, Saga University Hospital
- 191 Department of Otorhinolaryngology, Sasebo Kyosai Hospital
- 192 Department of Otorhinolaryngology, Sasebo City General Hospital
- 193 Department of Otorhinolaryngology, Nagasaki Medical Center
- 194 Department of Otorhinolaryngology, Nagasaki University Hospital
- 195 Department of Otorhinolaryngology, Kumamoto University Hospital
- 196 Department of Otorhinolaryngology, Miyazaki University Hospital
- 197 Department of Otorhinolaryngology, Kagoshima Medical Center
- 198 Department of Otorhinolaryngology, Kagoshima City Hospital
- 199 Department of Otorhinolaryngology, Kagoshima University Medical and Dental Hospital
- 200 Department of Otorhinolaryngology, Okinawa Prefectural Chubu Hospital
- 201 Department of Otorhinolaryngology, Ryukyu University Hospital

Total Cases (2018)

13149Cases

## Primary Site

Site	Number of patients (%)
1) Oral cavity	3621 ( 27.5 )
2) Larynx	2402 ( 18.3 )
3) Hypopharynx	2814 ( 21.4 )
4) Oropharynx	2273 ( 17.3 )
5) Nasopharynx	408 ( 3.1 )
6) Nasal cavity, etc	436 ( 3.3 )
7) Maxillary sinus	418 ( 3.2 )
8) Major salivary glands	765 ( 5.8 )
9) Unknown primary	12 ( 0.1 )
Total	13149 ( 100 )

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	6	2	8
10 - 19	8	17	25
20 - 29	53	36	89
30 - 39	132	108	240
40 - 49	527	257	784
50 - 59	1366	462	1828
60 - 69	3338	679	4017
70 - 79	3485	744	4229
80 - 89	1263	497	1760
90 - 99	98	66	164
100 - 109	0	2	2
110 - 119	1	2	3
Total	10277	2872	13149

# Head and Neck Cancer ----- 13149 Cases

## Histological Distribution by Primary Site

Histologic type	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
S.C.C., NOS	3061	2113	2535	2060	259	165	309	50	12	10564
S.C.C., keratinizing, NOS	198	118	67	45	5	10	20	1	0	464
S.C.C. in situ, NOS	120	78	120	43	2	5	1	0	0	369
Adenoid cystic ca.	34	6	0	14	4	24	18	109	0	209
Salivary duct ca.	3	0	0	0	0	1	0	181	0	185
Mucoepidermoid ca.	34	0	1	14	1	2	3	107	0	162
Ca., NOS	7	12	9	8	15	14	7	38	0	110
Malig. melanoma, NOS	20	0	0	2	1	72	12	1	0	108
S.C.C., large cell, nonkerat., NOS	4	6	18	22	38	3	8	0	0	99
Adenocarcinoma, NOS	7	4	0	5	2	15	2	51	0	86
Ca. ex pleomorphic adenoma	3	0	0	0	0	2	1	68	0	74
Olfactory neuroblastoma	0	0	0	0	0	60	1	0	0	61
Lymphoepithelial ca.	0	0	2	1	41	0	0	6	0	50
Ca., undiff., NOS	2	0	1	1	17	8	5	7	0	41
S.C.C., microinvasive	12	8	12	7	0	0	0	0	0	39
Neoplasm, Malig.	0	6	8	3	3	7	2	9	0	38
Verrucous ca., NOS	35	1	0	0	0	0	0	0	0	36
Acinar cell ca.	3	0	0	1	0	1	0	30	0	35
Epithelial-myoepithelial ca.	3	0	0	0	1	1	1	27	0	33
Spindle cell ca., NOS	12	7	1	1	0	1	7	1	0	30
Malig. lymphoma, NOS	3	1	0	9	2	3	1	11	0	30
Papillary S.C.C.	7	1	10	8	1	2	0	0	0	29
Basaloid S.C.C.	7	1	8	6	2	2	0	0	0	26
Myoepithelial ca.	3	1	0	3	0	0	1	18	0	26
S.C.C., spindle cell	7	8	5	3	0	0	2	0	0	25
Small cell ca., NOS	1	7	2	2	0	7	1	4	0	24
Adenosquamous ca.	5	5	3	1	0	1	3	3	0	21
Basal cell adenocarcinoma	2	0	0	0	0	0	0	17	0	19
S.C.C., small cell, nonkerat.	1	3	3	0	10	1	0	0	0	18
Basal cell ca., NOS	0	1	0	2	0	2	0	5	0	10
Carcinosarcoma, NOS	0	1	0	1	0	3	1	3	0	9
S.C.C. with horn formation	7	1	1	0	0	0	0	0	0	9
Clear cell ca., NOS	4	0	0	2	0	0	0	1	0	7
Secretory ca. of breast	0	0	0	0	0	0	0	6	0	6
Neuroendocrine ca., NOS	0	1	0	1	0	1	2	0	0	5
Mucinous adenocarcinoma	1	0	0	0	0	1	0	3	0	5
S.C.C. in situ with quest. stromal invasion	2	3	0	0	0	0	0	0	0	5
Alveolar rhabdomyosarcoma	0	0	0	0	0	4	1	0	0	5
Leiomyosarcoma, NOS	1	0	0	1	0	2	0	0	0	4
Large cell ca., NOS	0	1	0	0	0	3	0	0	0	4
Carcinoid tumor, NOS	2	0	0	0	0	2	0	0	0	4
Chondrosarcoma, NOS	0	3	1	0	0	0	0	0	0	4
Liposarcoma, NOS	1	0	2	0	0	0	0	0	0	3
Oncocytic ca.	0	0	0	0	0	0	0	3	0	3
Solitary fibrous tumor, malig.	0	0	0	0	1	1	1	0	0	3
Hemangiosarcoma	1	0	0	1	0	0	1	0	0	3
Osteosarcoma, NOS	0	1	0	0	0	0	2	0	0	3
Polymorphous low grade adenocarcinoma	1	0	0	2	0	0	0	0	0	3
Lipoma-like liposarcoma Sclerosing liposarcoma Inflammatory	0	0	2	0	0	0	0	0	0	2
Malig. teratoma, undiff.	0	0	0	0	1	1	0	0	0	2
Rhabdomyosarcoma, NOS	0	0	0	0	0	2	0	0	0	2
Fibrosarcoma, NOS	1	0	0	1	0	0	0	0	0	2
Transitional cell ca., NOS	1	0	1	0	0	0	0	0	0	2
Spindle cell sarcoma	0	0	0	0	0	2	0	0	0	2
Glandular intraepithelial neoplasia, grade III	0	1	0	1	0	0	0	0	0	2
Cystadenocarcinoma	1	0	0	0	0	0	0	1	0	2
Malig. fibrous histiocytoma	1	1	0	0	0	0	0	0	0	2
Extraskletal Ewing's sarcoma	0	1	0	0	0	0	0	0	0	1
Ameloblastoma, NOS	0	0	0	0	0	0	1	0	0	1
Odontogenic tumor, malig.	1	0	0	0	0	0	0	0	0	1
Basaloid ca.	0	0	1	0	0	0	0	0	0	1
Malig. tumor, spindle cell type	0	0	0	0	0	0	1	0	0	1
Plasmablastic lymphoma	0	0	0	0	0	0	1	0	0	1
Plasmacytoma, extramedullary	0	0	0	1	0	0	0	0	0	1
Alveolar soft part sarcoma	0	0	0	1	0	0	0	0	0	1
Adult T-cell leukemia/lymphoma(HTLV-1positive)	1	0	0	0	0	0	0	0	0	1
Basosquamous ca.	0	0	1	0	0	0	0	0	0	1
Sebaceous ca.	0	0	0	0	0	0	0	1	0	1
S.C.C., adenoid	0	0	0	0	0	0	0	1	0	1
Adenocarcinoma, intestinal type	0	0	0	0	0	1	0	0	0	1
Spindle cell rhabdomyosarcoma	0	0	0	0	0	1	0	0	0	1
Papillary adenocarcinoma, NOS	0	0	0	0	0	1	0	0	0	1
Neuroendocrine tumor	0	1	0	0	0	0	0	0	0	1
Undiff. sarcoma	0	0	0	0	0	0	1	0	0	1
Adenocarcinoma with neuroendocrine differentiation	0	0	0	0	0	1	0	0	0	1
Follicular dendritic cell sarcoma	0	0	0	0	1	0	0	0	0	1
Intraepithelial neoplasia, grade III	1	0	0	0	0	0	0	0	0	1
Mixed tumor, malig., NOS	0	0	0	0	0	0	0	1	0	1
Intraductal ca., noninfiltrating, NOS	0	0	0	0	1	0	0	0	0	1
Malig. lymphoma, large B-cell, diffuse, NOS	0	0	0	0	0	1	0	0	0	1
undiff. pleomorphic sarcoma	0	0	0	0	0	0	1	0	0	1
Low-grade cribriform cystadenocarcinoma	0	0	0	0	0	0	0	1	0	1
<b>Total</b>	<b>3621</b>	<b>2402</b>	<b>2814</b>	<b>2273</b>	<b>408</b>	<b>436</b>	<b>418</b>	<b>765</b>	<b>12</b>	<b>13149</b>

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).  
 NOS: not otherwise specified.  
 undiff.: undifferentiated.  
 nonkerat.: nonkeratinizing.

ca., Ca.: carcinoma.  
 malig., Malig.: malignant.  
 kerat.: keratinizing.

## Head and Neck Cancer ----- 13149 Cases

### Histological Distribution by Primary Site (Male)

Histologic type	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
S.C.C., NOS	1942	1940	2308	1706	194	125	237	38	10	8500
S.C.C., keratinizing, NOS	122	109	59	38	5	8	12	0	0	353
S.C.C. in situ, NOS	71	73	108	35	2	4	0	0	0	293
Salivary duct ca.	3	0	0	0	0	1	0	158	0	162
Adenoid cystic ca.	15	3	0	6	3	10	10	46	0	93
Mucoepidermoid ca.	14	0	1	8	1	2	2	54	0	82
Ca., NOS	6	11	9	8	10	6	5	26	0	81
S.C.C., large cell, nonkerat., NOS	3	6	18	22	26	1	5	0	0	81
Adenocarcinoma, NOS	4	4	0	4	1	10	2	38	0	63
Ca. ex pleomorphic adenoma	3	0	0	0	0	1	1	51	0	56
Malig. melanoma, NOS	10	0	0	0	0	35	5	1	0	51
Lymphoepithelial ca.	0	0	2	1	34	0	0	2	0	39
Olfactory neuroblastoma	0	0	0	0	0	38	0	0	0	38
S.C.C., microinvasive	8	6	11	6	0	0	0	0	0	31
Ca., undiff., NOS	1	0	1	1	13	5	3	3	0	27
Spindle cell ca., NOS	9	6	1	1	0	1	6	1	0	25
Papillary S.C.C.	5	1	10	7	0	1	0	0	0	24
Basaloid S.C.C.	5	1	8	5	2	0	0	0	0	21
Small cell ca., NOS	1	7	2	2	0	3	1	3	0	19
Verrucous ca., NOS	18	1	0	0	0	0	0	0	0	19
Neoplasm, malig.	0	4	6	0	1	1	2	5	0	19
S.C.C., spindle cell	5	6	4	3	0	0	1	0	0	19
Adenosquamous ca.	3	5	3	1	0	0	3	3	0	18
S.C.C., small cell, nonkerat.	0	3	3	0	8	1	0	0	0	15
Malig. lymphoma, NOS	1	0	0	4	2	1	0	7	0	15
Myoepithelial ca.	2	1	0	2	0	0	1	8	0	14
Acinar cell ca.	1	0	0	0	0	1	0	11	0	13
Epithelial-myoepithelial ca.	0	0	0	0	1	0	0	12	0	13
Basal cell adenocarcinoma	2	0	0	0	0	0	0	8	0	10
S.C.C. with horn formation	5	1	1	0	0	0	0	0	0	7
Carcinosarcoma, NOS	0	1	0	1	0	2	0	2	0	6
Basal cell ca., NOS	0	1	0	1	0	1	0	2	0	5
Neuroendocrine ca., NOS	0	1	0	1	0	0	2	0	0	4
Large cell ca., NOS	0	1	0	0	0	3	0	0	0	4
S.C.C. in situ with quest. stromal invasion	1	3	0	0	0	0	0	0	0	4
Liposarcoma, NOS	1	0	2	0	0	0	0	0	0	3
Clear cell ca., NOS	1	0	0	1	0	0	0	1	0	3
Chondrosarcoma, NOS	0	2	1	0	0	0	0	0	0	3
Hemangiosarcoma	1	0	0	1	0	0	1	0	0	3
Secretory ca. of breast	0	0	0	0	0	0	0	3	0	3
Leiomyosarcoma, NOS	0	0	0	1	0	1	0	0	0	2
Lipoma-like liposarcoma Sclerosing liposarcoma Inflammatory	0	0	2	0	0	0	0	0	0	2
Carcinoid tumor, NOS	2	0	0	0	0	0	0	0	0	2
Alveolar rhabdomyosarcoma	0	0	0	0	0	2	0	0	0	2
Rhabdomyosarcoma, NOS	0	0	0	0	0	2	0	0	0	2
Transitional cell ca., NOS	1	0	1	0	0	0	0	0	0	2
Glandular intraepithelial neoplasia, grade III	0	1	0	1	0	0	0	0	0	2
Ameloblastoma, NOS	0	0	0	0	0	0	1	0	0	1
Oncocytic ca.	0	0	0	0	0	0	0	1	0	1
Mucinous adenocarcinoma	0	0	0	0	0	1	0	0	0	1
Basaloid ca.	0	0	1	0	0	0	0	0	0	1
Malignant tumor, spindle cell type	0	0	0	0	0	0	1	0	0	1
Plasmablastic lymphoma	0	0	0	0	0	0	1	0	0	1
Solitary fibrous tumor, Malig.	0	0	0	0	0	0	1	0	0	1
Fibrosarcoma, NOS	0	0	0	1	0	0	0	0	0	1
Basosquamous ca.	0	0	1	0	0	0	0	0	0	1
Osteosarcoma, NOS	0	0	0	0	0	0	1	0	0	1
S.C.C., adenoid	0	0	0	0	0	0	0	1	0	1
Adenocarcinoma, intestinal type	0	0	0	0	0	1	0	0	0	1
Spindle cell rhabdomyosarcoma	0	0	0	0	0	1	0	0	0	1
Spindle cell sarcoma	0	0	0	0	0	1	0	0	0	1
Papillary adenocarcinoma, NOS	0	0	0	0	0	1	0	0	0	1
Neuroendocrine tumor	0	1	0	0	0	0	0	0	0	1
Intraepithelial neoplasia, grade III	1	0	0	0	0	0	0	0	0	1
Mixed tumor, malig., NOS	0	0	0	0	0	0	0	1	0	1
Polymorphous low grade adenocarcinoma	0	0	0	1	0	0	0	0	0	1
Malig. lymphoma, large B-cell, diffuse, NOS	0	0	0	0	0	1	0	0	0	1
Cystadenocarcinoma	0	0	0	0	0	0	0	1	0	1
Undiff. pleomorphic sarcoma	0	0	0	0	0	0	1	0	0	1
Low-grade cribriform cystadenocarcinoma	0	0	0	0	0	0	0	1	0	1
Malig. fibrous histiocytoma	0	1	0	0	0	0	0	0	0	1
<b>Total</b>	<b>2267</b>	<b>2200</b>	<b>2563</b>	<b>1869</b>	<b>303</b>	<b>272</b>	<b>305</b>	<b>488</b>	<b>10</b>	<b>10277</b>

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

NOS: not otherwise specified.

undiff.: undifferentiated.

S.C.C.: squamous cell carcinoma.

quest.: questionable.

ca., Ca.: carcinoma.

malig., Malig.: malignant.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## Head and Neck Cancer ----- 13149 Cases

### Histological Distribution by Primary Site (Female)

Histologic type	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
S.C.C., NOS	1119	173	227	354	65	40	72	12	2	2064
Adenoid cystic ca.	19	3	0	8	1	14	8	63	0	116
S.C.C., keratinizing, NOS	76	9	8	7	0	2	8	1	0	111
Mucoepidermoid ca.	20	0	0	6	0	0	1	53	0	80
S.C.C. in situ, NOS	49	5	12	8	0	1	1	0	0	76
Malig. melanoma, NOS	10	0	0	2	1	37	7	0	0	57
Ca., NOS	1	1	0	0	5	8	2	12	0	29
Salivary duct ca.	0	0	0	0	0	0	0	23	0	23
Adenocarcinoma, NOS	3	0	0	1	1	5	0	13	0	23
Olfactory neuroblastoma	0	0	0	0	0	22	1	0	0	23
Acinar cell ca.	2	0	0	1	0	0	0	19	0	22
Epithelial-myoeptithelial ca.	3	0	0	0	0	1	1	15	0	20
Neoplasm, malig.	0	2	2	3	2	6	0	4	0	19
Ca. ex pleomorphic adenoma	0	0	0	0	0	1	0	17	0	18
S.C.C., large cell, nonkerat., NOS	1	0	0	0	12	2	3	0	0	18
Verrucous ca., NOS	17	0	0	0	0	0	0	0	0	17
Malig. lymphoma, NOS	2	1	0	5	0	2	1	4	0	15
Ca., undiff., NOS	1	0	0	0	4	3	2	4	0	14
Myoepithelial ca.	1	0	0	1	0	0	0	10	0	12
Lymphoepithelial ca.	0	0	0	0	7	0	0	4	0	11
Basal cell adenocarcinoma	0	0	0	0	0	0	0	9	0	9
S.C.C., microinvasive	4	2	1	1	0	0	0	0	0	8
S.C.C., spindle cell	2	2	1	0	0	0	1	0	0	6
Papillary S.C.C.	2	0	0	1	1	1	0	0	0	5
Small cell ca., NOS	0	0	0	0	0	4	0	1	0	5
Spindle cell ca., NOS	3	1	0	0	0	0	1	0	0	5
Basaloid S.C.C.	2	0	0	1	0	2	0	0	0	5
Basal cell ca., NOS	0	0	0	1	0	1	0	3	0	5
Clear cell ca., NOS	3	0	0	1	0	0	0	0	0	4
Mucinous adenocarcinoma	1	0	0	0	0	0	0	3	0	4
S.C.C., small cell, nonkerat.	1	0	0	0	2	0	0	0	0	3
Adenosquamous ca.	2	0	0	0	0	1	0	0	0	3
Carcinosarcoma, NOS	0	0	0	0	0	1	1	1	0	3
Alveolar rhabdomyosarcoma	0	0	0	0	0	2	1	0	0	3
Secretory ca. of breast	0	0	0	0	0	0	0	3	0	3
Leiomyosarcoma, NOS	1	0	0	0	0	1	0	0	0	2
Oncocytic ca.	0	0	0	0	0	0	0	2	0	2
Carcinoid tumor, NOS	0	0	0	0	0	2	0	0	0	2
Malig. teratoma, undiff.	0	0	0	0	1	1	0	0	0	2
Solitary fibrous tumor, malig.	0	0	0	0	1	1	0	0	0	2
Osteosarcoma, NOS	0	1	0	0	0	0	1	0	0	2
S.C.C. with horn formation	2	0	0	0	0	0	0	0	0	2
Polymorphous low grade adenocarcinoma	1	0	0	1	0	0	0	0	0	2
Neuroendocrine ca., NOS	0	0	0	0	0	1	0	0	0	1
Extraskletal Ewing's sarcoma	0	1	0	0	0	0	0	0	0	1
S.C.C. in situ with quest. stromal invasion	1	0	0	0	0	0	0	0	0	1
Chondrosarcoma, NOS	0	1	0	0	0	0	0	0	0	1
Odontogenic tumor, malig.	1	0	0	0	0	0	0	0	0	1
Plasmacytoma, extramedullary	0	0	0	1	0	0	0	0	0	1
Fibrosarcoma, NOS	1	0	0	0	0	0	0	0	0	1
Alveolar soft part sarcoma	0	0	0	1	0	0	0	0	0	1
Adult T-cell leukemia/lymphoma(HTLV-1positive)	1	0	0	0	0	0	0	0	0	1
Sebaceous ca.	0	0	0	0	0	0	0	1	0	1
Spindle cell sarcoma	0	0	0	0	0	1	0	0	0	1
Undiff. sarcoma	0	0	0	0	0	0	1	0	0	1
Adenocarcinoma with neuroendocrine differentiation	0	0	0	0	0	1	0	0	0	1
Follicular dendritic cell sarcoma	0	0	0	0	1	0	0	0	0	1
Intraductal ca., noninfiltrating, NOS	0	0	0	0	1	0	0	0	0	1
Cystadenocarcinoma	1	0	0	0	0	0	0	0	0	1
Malig. fibrous histiocytoma	1	0	0	0	0	0	0	0	0	1
<b>Total</b>	<b>1354</b>	<b>202</b>	<b>251</b>	<b>404</b>	<b>105</b>	<b>164</b>	<b>113</b>	<b>277</b>	<b>2</b>	<b>2872</b>

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

ca., Ca.: carcinoma.

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

malig., Malig.: malignant.

undiff.: undifferentiated.

quest.: questionable.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	15	4	1	0	3	0	3	0	2	0	0	28
T1	1736	261	51	13	93	25	33	0	36	20	4	2272
T1a	566	0	0	0	1	0	0	0	0	0	1	568
T1b	190	0	0	0	0	1	0	0	0	1	0	192
T2	2336	708	130	26	367	149	35	9	105	8	3	3876
T3	1196	411	86	16	477	224	46	3	120	6	2	2587
T4	88	103	142	1	17	11	44	0	2	1	0	409
T4a	835	253	4	17	548	338	13	4	132	3	4	2151
T4b	177	22	2	3	91	53	2	1	37	2	1	391
Tis	369	3	0	0	0	0	0	0	1	7	2	382
TX	22	6	0	0	6	0	2	0	4	81	3	124
T-	11	3	0	0	1	0	0	0	0	0	154	169
<b>Total</b>	<b>7541</b>	<b>1774</b>	<b>416</b>	<b>76</b>	<b>1604</b>	<b>801</b>	<b>178</b>	<b>17</b>	<b>439</b>	<b>129</b>	<b>174</b>	<b>13149</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## T and N Status (M0 Cases)

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	14	4	1	0	3	0	3	0	2	0	0	27
T1	1725	255	48	13	83	23	29	0	32	12	1	2221
T1a	565	0	0	0	1	0	0	0	0	0	1	567
T1b	190	0	0	0	0	1	0	0	0	0	0	191
T2	2311	697	123	23	352	137	30	9	92	7	2	3783
T3	1181	403	79	13	445	202	35	3	104	2	2	2469
T4	86	98	125	1	16	9	34	0	2	0	0	371
T4a	804	243	4	15	513	304	10	4	111	1	2	2011
T4b	164	19	1	3	83	40	2	0	28	1	0	341
Tis	365	3	0	0	0	0	0	0	1	4	1	374
TX	22	5	0	0	5	0	1	0	4	3	1	41
T-	11	3	0	0	1	0	0	0	0	0	5	20
<b>Total</b>	<b>7438</b>	<b>1730</b>	<b>381</b>	<b>68</b>	<b>1502</b>	<b>716</b>	<b>144</b>	<b>16</b>	<b>376</b>	<b>30</b>	<b>15</b>	<b>12416</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## T and N Status (M1 Cases)

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	2	5	3	0	9	2	4	0	3	0	0	28
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	9	9	7	1	13	11	5	0	13	0	0	68
T3	10	7	5	2	26	22	10	0	14	1	0	97
T4	1	3	16	0	1	2	10	0	0	1	0	34
T4a	25	10	0	1	29	30	3	0	20	0	1	119
T4b	11	3	0	0	6	11	0	1	8	0	0	40
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	0	1	0	0	0	0	1	0	0	5	0	7
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>58</b>	<b>38</b>	<b>31</b>	<b>4</b>	<b>84</b>	<b>78</b>	<b>33</b>	<b>1</b>	<b>58</b>	<b>7</b>	<b>1</b>	<b>393</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## T and N Status (MX & M- Cases)

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	1	0	0	0	0	0	0	0	0	0	0	1
T1	9	1	0	0	1	0	0	0	1	8	3	23
T1a	1	0	0	0	0	0	0	0	0	0	0	1
T1b	0	0	0	0	0	0	0	0	0	1	0	1
T2	16	2	0	2	2	1	0	0	0	1	1	25
T3	5	1	2	1	6	0	1	0	2	3	0	21
T4	1	2	1	0	0	0	0	0	0	0	0	4
T4a	6	0	0	1	6	4	0	0	1	2	1	21
T4b	2	0	1	0	2	2	0	0	1	1	1	10
Tis	4	0	0	0	0	0	0	0	0	3	1	8
TX	0	0	0	0	1	0	0	0	0	73	2	76
T-	0	0	0	0	0	0	0	0	0	0	149	149
<b>Total</b>	<b>45</b>	<b>6</b>	<b>4</b>	<b>4</b>	<b>18</b>	<b>7</b>	<b>1</b>	<b>0</b>	<b>5</b>	<b>92</b>	<b>158</b>	<b>340</b>

M-:without reported M classification.

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Treatment Method for the Primary Lesion by Primary Site

Treatment Method	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
Surgery										
without	388	1475	1406	1328	375	199	250	92	6	5519
with	2989	871	1317	866	14	219	155	640	6	7077
unknown	242	55	76	65	19	15	13	32	0	517
Radiotherapy										
without	2654	739	1116	763	18	132	92	400	4	5918
with	723	1607	1607	1431	371	286	313	332	8	6678
unknown	242	55	76	65	19	15	13	32	0	517
Chemotherapy										
without	2646	1683	1353	922	67	239	136	601	7	7654
with	731	663	1370	1272	322	179	269	131	5	4942
unknown	242	55	76	65	19	15	13	32	0	517
Total	3619	2401	2799	2259	408	433	418	764	12	13113

No report patients

Treatment Method for the Primary Lesion by Primary Site was not reported in 36 patients.

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

Head and Neck Cancer ----- 13149 Cases

Treatment Method for the Cervical Lymph Nodes by Primary Site

Treatment Method	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
Surgery										
without	1766	1878	1865	1622	374	393	315	319	3	8535
with	1560	444	850	572	14	16	77	399	9	3941
unknown	249	72	88	70	19	18	15	37	0	568
Radiotherapy										
without	2740	1786	1398	928	69	344	267	495	3	8030
with	586	536	1317	1266	319	65	125	223	9	4446
unknown	249	72	88	70	19	18	15	37	0	568
Chemotherapy										
without	2729	1927	1534	1037	95	341	264	616	6	8549
with	597	395	1181	1157	293	68	128	102	6	3927
unknown	249	72	88	70	19	18	15	37	0	568
Total	3575	2394	2803	2264	407	427	407	755	12	13044

No report patients

Treatment Method for the Primary Lesion by Primary Site was not reported in 105 patients.

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

Head and Neck Cancer ----- 13149 Cases

Sequence of Treatment Methods for the Primary Lesion by Primary Site

Sequence of treatment methods	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
No treatment	97	56	89	45	4	8	14	22	3	338
A) Surg. alone	2292	630	829	559	4	96	48	347	1	4806
F)(Rad.+Chem.)	108	429	670	781	223	67	144	10	3	2435
B) Rad. alone	75	902	297	220	56	55	39	30	0	1674
A)B) Surg.->Rad.	154	82	126	85	4	70	29	193	3	746
A)F) Surg.->(Rad.+Chem.)	196	50	126	82	1	18	15	53	2	543
C)F) Chem. -> (Rad.+Chem.)	10	35	157	128	45	14	14	2	0	405
C) Chem. alone	44	27	86	78	9	16	14	10	0	284
C)A) Chem.->Surg.	129	15	70	47	0	1	6	0	0	268
F)C)(Rad.+Chem.)->Chem.	6	11	31	25	23	9	11	3	0	119
A)C) Surg. -> Chem	51	7	9	12	0	5	2	12	0	98
F)A)(Rad.+Chem.)->Surg.	13	18	21	9	0	8	20	1	0	90
C)A)F) Chem.->Surg.->(Rad.+Chem.)	30	8	30	7	0	0	8	1	0	84
C)B) Chem.->Rad.	12	7	20	18	1	9	0	2	0	69
A)A) Surg.->Surg.	20	10	10	7	0	1	1	5	0	54
C)A)B) Chem.->Surg.->Rad.	19	7	18	2	0	3	3	1	0	53
B)A) Rad.->Surg.	4	16	3	5	0	4	2	0	0	34
C)C) Chem.->Chem.	2	1	15	7	0	2	4	1	0	32
B)C) Rad.->Chem.	1	4	5	7	1	7	1	4	0	30
C)F)C) Chem.-> (Rad.+Chem.)->Chem.	4	1	11	5	4	3	0	1	0	29
A)B)C) Surg.->Rad.->Chem.	6	1	6	2	0	2	2	7	0	26
C)A)C) Chem.->Surg.->Chem.	11	2	6	4	0	0	1	1	0	25
D)(Surg.+Rad.)	6	0	6	1	0	2	1	5	0	21
A)F)C) Surg.->(Rad.+Chem.)->Chem.	9	0	3	0	0	2	1	3	0	18
C)C)F) Chem.->Chem.->(Rad.+Chem.)	0	2	11	3	0	1	0	0	0	17
G)Surg.+Rad.+Chem.	1	2	11	1	0	1	0	0	0	16
C)B) C)Chem.->Rad.->Chem.	3	0	0	4	1	3	1	2	0	14
F)F)(Rad.+Chem.)->(Rad.+Chem.)	2	1	3	2	4	0	0	0	0	12
F)C)(Rad.+Chem.)->Chem.	0	1	3	1	1	1	4	0	0	11
Other	72	21	51	47	8	10	20	16	0	245
Unknown	242	55	76	65	19	15	13	32	0	517
Total	3619	2401	2799	2259	408	433	418	764	12	13113

Sequence of Treatment Methods for the Primary Lesion by Primary Site was not reported in 36 patients.

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

Head and Neck Cancer ----- 13149 Cases  
Surgical Methods for the Primary Lesion by Primary Site

Surgical method	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
No surgery	377	1455	1401	1313	370	198	249	92	6	5461
Partial glossectomy	1115	0	0	0	0	0	0	0	0	1115
Transoral resection	4	252	299	20	0	0	0	0	0	575
Total laryngectomy	0	428	12	4	0	0	0	0	0	444
Total pharyngolaryngectomy	0	18	387	1	0	0	0	0	0	406
Endoscopic resection	0	69	304	8	0	0	0	0	0	381
Unilateral resection of the lateral wall of the oropharynx	4	0	0	344	1	0	0	0	4	353
Segmental mandibulectomy	240	0	0	0	0	0	0	3	0	243
Partial maxillectomy	192	0	0	2	0	22	27	0	0	243
Subtotal glossectomy	221	0	0	9	0	0	0	1	0	231
Resection of the buccal mucosa	207	0	0	2	0	0	0	0	0	209
Total pharyngolaryngo-esophagectomy	0	12	175	4	0	0	0	0	0	191
Resection of the floor of mouth	171	0	0	1	0	0	0	9	0	181
Total parotidectomy	0	0	0	0	0	0	0	179	0	179
Hemiglossectomy	161	0	0	1	0	0	0	0	0	162
Marginal mandibulectomy	152	0	0	0	0	0	0	1	0	153
Superficial parotidectomy	0	0	0	0	0	0	0	146	0	146
Hemiglossectomy (anterior 2/3rds)	133	0	0	0	0	0	0	1	0	134
Submandibulectomy	0	0	0	0	0	0	0	132	0	132
Resection of oral cavity, NOS	116	0	0	1	0	0	0	1	0	118
Total maxillectomy	32	0	0	0	0	5	81	0	0	118
Resection of the oropharynx, other type	1	2	0	100	0	0	0	0	2	105
Resection of the root of tongue 0	0	0	1	103	0	0	0	0	0	104
Maxillectomy, other type	8	0	0	0	2	75	16	0	0	101
Resection of the soft palate	2	0	1	76	0	0	0	0	0	79
Subtotal glossectomy (anterior 2/3rds)	68	0	0	1	0	0	0	0	0	69
Endoscopic skull base surgery	0	0	0	0	0	66	1	0	0	67
Resection of the posterior wall	0	0	1	62	0	0	0	0	0	63
Extended total parotidectomy	1	0	0	0	0	0	0	60	0	61
Total laryngectomy+Partial pharyngectomy	0	8	37	1	0	0	0	0	0	46
Partial parotidectomy	0	0	0	0	0	0	0	46	0	46
Total glossectomy	37	0	0	7	0	0	0	0	0	44
Deep lobe resection of the parotid gland	0	0	0	0	0	0	0	35	0	35
Partial hypopharyngectomy	0	0	34	0	0	0	0	0	0	34
Resection of lower gingiva	32	0	0	0	0	0	0	0	0	32
Unilateral resection of the lateral wall of the oropharynx and soft	0	0	0	32	0	0	0	0	0	32
Partial laryngectomy	0	30	0	1	0	0	0	0	0	31
Others	83	35	45	65	7	51	28	21	0	335
Unknown	261	93	111	114	28	19	16	37	0	679
<b>Total</b>	<b>3618</b>	<b>2402</b>	<b>2808</b>	<b>2272</b>	<b>408</b>	<b>436</b>	<b>418</b>	<b>764</b>	<b>12</b>	<b>13138</b>

Surgical Method for the Primary Lesion by Primary Site was not reported in 11 patients.

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

NOS: not otherwise specified.

Head and Neck Cancer ----- 13149 Cases

Reconstructive Surgery by Primary Site

Reconstructive surgery	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
No reconstruction	2095	2222	2061	1939	377	344	307	563	11	9919
Free jejunal flap	4	29	521	11	0	0	0	0	0	565
Free ALT flap	361	9	34	82	1	3	13	50	0	553
Free RA MC flap	284	7	1	47	0	7	55	10	0	411
Free FA flap	159	1	18	24	0	2	5	5	0	214
PM MC flap	71	18	22	20	0	0	0	19	0	150
Free fibular OC flap	106	0	0	0	0	0	3	1	0	110
Skin graft	72	1	1	1	0	1	6	0	0	82
Local skin flap	33	4	2	7	0	13	2	8	0	69
Mucosal flap	17	0	2	9	0	15	1	0	0	44
Free scapular OC flap	37	0	0	0	0	0	4	2	0	43
Free nerve graft	0	0	0	1	0	0	0	40	0	41
Gastric pull-up	0	1	15	1	0	0	0	0	0	17
DP flap	7	4	1	1	0	0	0	0	1	14
Others	92	3	18	17	0	28	6	25	0	189
Unknown	283	103	118	113	30	23	16	42	0	728
Total	3621	2402	2814	2273	408	436	418	765	12	13149

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh.

FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

Head and Neck Cancer ----- 13149 Cases

Neck Dissection on the Ipsilateral Side by Primary Site

Neck dissection	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
0) No N.D.	1776	1886	1862	1623	369	398	325	326	3	8568
1) Total N.D.	537	107	243	187	3	5	17	124	3	1226
2) Selective N.D.	1008	310	586	358	8	9	58	255	5	2597
3) Lymph node excision	19	7	1	3	0	0	2	17	1	50
8) Others	16	14	15	5	0	3	1	3	0	57
9) Unknown	265	78	107	97	28	21	15	40	0	651
Total	3621	2402	2814	2273	408	436	418	765	12	13149

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

N.D.: neck dissection.

Neck Dissection on the Contralateral Side by Primary Site

Neck dissection	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
0) No N.D.	2902	2030	2106	2057	379	409	389	698	10	10980
2) Selective N.D.	360	227	485	86	1	2	8	17	2	1188
1) Total N.D.	74	50	101	25	0	1	3	3	0	257
3) Lymph node excision	3	1	1	1	0	0	0	2	0	8
8) Others	16	16	14	7	0	3	2	4	0	62
9) Unknown	266	78	107	97	28	21	16	41	0	654
Total	3621	2402	2814	2273	408	436	418	765	12	13149

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

N.D.: neck dissection.

Head and Neck Cancer ----- 13149 Cases

Radiotherapy by Primary Site

Type of radiotherapy	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
0) No radiotherapy	2561	718	1061	740	19	129	83	374	3	5688
1) X-ray (and/or electron beam)	740	1605	1645	1440	361	253	296	324	9	6673
2) Particle beam	6	2	1	7	7	36	22	28	0	109
3) B.T.	16	0	0	2	0	0	0	0	0	18
5) X-ray + B.T.	4	0	0	0	0	0	0	0	0	4
4) X-ray + Particle beam	0	0	0	0	0	0	0	0	0	0
6) Particl beam + B.T.	0	0	0	0	0	0	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0	0	0	0	0	0	0
8) Others	2	0	0	0	0	0	1	0	0	3
9) Unknown	292	77	107	84	21	18	16	39	0	654
Total	3621	2402	2814	2273	408	436	418	765	12	13149

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

B.T.: brachytherapy.

Head and Neck Cancer ----- 13149 Cases

Chemotherapy by Primary site

Route of administration	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
0) No chemotherapy	2617	1684	1343	913	67	238	133	592	6	7593
1) I.V.	522	566	1311	1205	317	161	118	121	6	4327
2) I.A.	58	10	9	29	0	15	132	1	0	254
3) Oral	138	70	42	35	2	2	5	11	0	305
4) I.V.+I.A.	10	0	3	7	0	2	14	0	0	36
5) I.V.+Oral	11	4	18	12	2	3	2	3	0	55
6) I.A.+Oral	6	0	1	0	0	0	0	0	0	7
7) I.V.+I.A.+Oral	2	1	0	0	0	0	0	0	0	3
8) Others	1	0	1	1	0	0	0	0	0	3
9) Unknown	256	67	86	71	20	15	14	37	0	566
Total	3621	2402	2814	2273	408	436	418	765	12	13149

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

I.V.: intravenous. I.A.: intraarterial.

# Oral Cavity (2018)

3621 Cases

## Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
1) Lip	31	(0.9)
2) Buccal mucosa	284	(7.8)
3) Retro-molar area	83	(2.3)
4) Lower gingiva	498	(13.8)
5) Upper gingiva	343	(9.5)
6) Hard palate	109	(3.0)
7) Floor of mouth	277	(7.6)
8) Tongue	1982	(54.7)
9) Oral cavity, NOS	14	(0.4)
<b>Total</b>	<b>3621</b>	<b>(100)</b>

NOS: not otherwise specified

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	4	1	5
10 - 19	1	4	5
20 - 29	28	16	44
30 - 39	70	45	115
40 - 49	169	114	283
50 - 59	313	169	482
60 - 69	643	267	910
70 - 79	700	351	1051
80 - 89	314	335	649
90 - 99	24	50	74
100 - 109	0	2	2
110 - 119	1	0	1
<b>Total</b>	<b>2267</b>	<b>1354</b>	<b>3621</b>

## Carcinoma of the Lip

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	0	1
40 - 49	1	0	1
50 - 59	2	0	2
60 - 69	4	3	7
70 - 79	4	7	11
80 - 89	2	7	9
90 - 99	0	0	0
100 - 109	0	0	0
Total	14	17	31

## Carcinoma of the Buccal Mucosa

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	1	1	2
30 - 39	0	2	2
40 - 49	5	5	10
50 - 59	15	7	22
60 - 69	32	28	60
70 - 79	63	34	97
80 - 89	35	43	78
90 - 99	3	10	13
100 - 109	0	0	0
Total	154	130	284

## Carcinoma of the Retromolar Area

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	2	3
40 - 49	1	0	1
50 - 59	5	2	7
60 - 69	23	7	30
70 - 79	24	2	26
80 - 89	11	4	15
90 - 99	0	1	1
100 - 109	0	0	0
<b>Total</b>	<b>65</b>	<b>18</b>	<b>83</b>

## Carcinoma of the Lower Gingiva

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	1	2
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	2	2	4
40 - 49	11	4	15
50 - 59	27	22	49
60 - 69	81	46	127
70 - 79	94	71	165
80 - 89	53	69	122
90 - 99	4	10	14
100 - 109	0	0	0
<b>Total</b>	<b>273</b>	<b>225</b>	<b>498</b>

## Carcinoma of the Upper Gingiva

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	1	1
20 - 29	0	1	1
30 - 39	2	1	3
40 - 49	3	3	6
50 - 59	18	12	30
60 - 69	43	24	67
70 - 79	56	55	111
80 - 89	34	74	108
90 - 99	3	13	16
100 - 109	0	0	0
<b>Total</b>	<b>159</b>	<b>184</b>	<b>343</b>

## Carcinoma of the Hard Palate

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	1	1	2
40 - 49	1	4	5
50 - 59	6	8	14
60 - 69	20	14	34
70 - 79	19	7	26
80 - 89	8	13	21
90 - 99	3	3	6
100 - 109	0	0	0
<b>Total</b>	<b>59</b>	<b>50</b>	<b>109</b>

## Carcinoma of the Floor of Mouth

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	1	1	2
30 - 39	0	1	1
40 - 49	15	5	20
50 - 59	36	11	47
60 - 69	83	12	95
70 - 79	74	10	84
80 - 89	17	8	25
90 - 99	2	1	3
100 - 109	0	0	0
<b>Total</b>	<b>228</b>	<b>49</b>	<b>277</b>

## Carcinoma of the Tongue

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	3	0	3
10 - 19	1	2	3
20 - 29	25	13	38
30 - 39	63	36	99
40 - 49	132	93	225
50 - 59	202	106	308
60 - 69	355	133	488
70 - 79	362	165	527
80 - 89	153	115	268
90 - 99	9	11	20
100 - 109	0	2	2
110 - 119	1	0	1
<b>Total</b>	<b>1306</b>	<b>676</b>	<b>1982</b>

# Carcinoma of the Oral Cavity, NOS

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	1	1
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	0	0	0
50 - 59	2	1	3
60 - 69	2	0	2
70 - 79	4	0	4
80 - 89	1	2	3
90 - 99	0	1	1
100 - 109	0	0	0
Total	9	5	14

## Carcinoma of the Oral Cavity ----- 3621Cases

### Histological Distribution by Subsite

Histologic type	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
S.C.C., NOS	25	230	66	446	297	53	245	1691	8	3061
S.C.C., keratinizing, NOS	0	10	5	26	16	5	10	125	1	198
S.C.C. in situ, NOS	2	6	2	5	4	4	5	92	0	120
Verrucous ca., NOS	1	5	0	6	3	0	1	19	0	35
Mucoepidermoid ca.	1	8	6	3	1	10	3	1	1	34
Adenoid cystic ca.	1	9	2	2	1	8	4	7	0	34
Malig. melanoma, NOS	0	2	0	1	7	8	0	1	1	20
S.C.C., microinvasive	0	2	0	1	1	0	0	8	0	12
Spindle cell ca., NOS	0	1	0	2	3	0	2	4	0	12
Papillary S.C.C.	0	0	0	0	1	0	1	5	0	7
Ca., NOS	0	1	0	0	2	1	0	2	1	7
Adenoca., NOS	0	0	0	3	0	3	0	1	0	7
Basaloid S.C.C.	0	0	1	0	0	1	0	5	0	7
S.C.C., spindle cell	0	2	0	0	1	0	0	4	0	7
S.C.C. with horn formation	0	0	0	1	2	0	0	4	0	7
Adenosquamous ca.	0	0	0	0	1	0	0	4	0	5
Clear cell ca., NOS	0	0	1	0	0	2	1	0	0	4
S.C.C., large cell, nonkerat., NOS	0	1	0	0	0	0	3	0	0	4
Ca. ex pleomorphic adenoma	0	1	0	0	0	2	0	0	0	3
Salivary duct ca.	0	2	0	0	0	1	0	0	0	3
Acinar cell ca.	0	2	0	0	0	0	0	1	0	3
Epithelial-myoepithelial ca.	0	0	0	0	0	3	0	0	0	3
Malig. lymphoma, NOS	0	0	0	0	0	1	0	1	1	3
Myoepithelial ca.	0	0	0	0	0	3	0	0	0	3
Basal cell adenoca.	0	0	0	0	0	2	0	0	0	2
Ca., undiff., NOS	0	0	0	0	0	1	0	0	1	2
S.C.C. in situ with quest. stromal invasion	0	0	0	0	0	0	0	2	0	2
Carcinoid tumor, NOS	0	1	0	0	0	0	0	1	0	2
Small cell ca., NOS	0	0	0	0	0	1	0	0	0	1
S.C.C., small cell, nonkerat.	0	0	0	0	0	0	1	0	0	1
Leiomyosarcoma, NOS	0	0	0	0	1	0	0	0	0	1
Liposarcoma, NOS	0	0	0	0	0	0	1	0	0	1
Mucinous adenoca.	0	0	0	0	0	0	0	1	0	1
Odontogenic tumor, malig.	0	0	0	1	0	0	0	0	0	1
Fibrosarcoma, NOS	0	0	0	0	1	0	0	0	0	1
Hemangiosarcoma	0	0	0	0	0	0	0	1	0	1
Adult T-cell leukemia/lymphoma(HTLV-1positive)	0	0	0	0	1	0	0	0	0	1
Transitional cell ca., NOS	0	0	0	0	0	0	0	1	0	1
Intraepithelial neoplasia, grade III	0	0	0	0	0	0	0	1	0	1
Polymorphous low grade adenoca.	0	0	0	1	0	0	0	0	0	1
Cystadenoca.	1	0	0	0	0	0	0	0	0	1
Malig. fibrous histiocytoma	0	1	0	0	0	0	0	0	0	1
<b>Total</b>	<b>31</b>	<b>284</b>	<b>83</b>	<b>498</b>	<b>343</b>	<b>109</b>	<b>277</b>	<b>1982</b>	<b>14</b>	<b>3621</b>

ca., Ca.: carcinoma.

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

malig., Malig.: malignant.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	5	0	0	0	0	0	0	0	0	0	0	5
T1	751	21	1	1	12(2)	2	0	0	4(1)	7	1	800
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	844(1)	109	3	3	84(1)	19	3(1)	1	10(1)	1	1	1078
T3	357(2)	127(3)	2	3	164	45	2	1	26(1)	3	0	730
T4	14	3	3(1)	0	6	3	1	0	0	0	0	30
T4a	281(5)	102(3)	0	3	178(2)	96(4)	2	0	23(1)	2	1	688
T4b	36(1)	9(2)	0	1	39	13(3)	0	0	3	1	0	102
Tis	104	0	0	0	0	0	0	0	0	1	1	106
TX	10	1(1)	0	0	0	0	0	0	0	22	1	34
T-	1	0	0	0	0	0	0	0	0	0	47	48
<b>Total</b>	<b>2403</b>	<b>372</b>	<b>9</b>	<b>11</b>	<b>483</b>	<b>178</b>	<b>8</b>	<b>2</b>	<b>66</b>	<b>37</b>	<b>52</b>	<b>3621</b>

M1:36 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Lip

### T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	15	0	0	0	0	0	0	0	0	0	0	15
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	8	1	0	0	0	1	0	0	0	0	0	10
T3	3	0	0	0	0	0	0	0	0	0	0	3
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	3	0	0	0	0	0	0	0	0	0	0	3
T4b	0	0	0	0	0	0	0	0	0	0	0	0
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>29</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>31</b>

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Buccal mucosa T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	1	0	0	0	0	0	0	0	0	0	0	1
T1	57	1	0	0	2(1)	0	0	0	0	0	0	60
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	72	12	0	1	14	0	0	0	0	0	0	99
T3	28(1)	6	0	0	12	0	0	0	1	1	0	48
T4	0	0	0	0	1	0	0	0	0	0	0	1
T4a	12(1)	12(1)	0	0	15(1)	1	0	0	2	0	0	42
T4b	7	1	0	0	5	4(2)	0	0	1	1	0	19
Tis	9	0	0	0	0	0	0	0	0	0	0	9
TX	0	0	0	0	0	0	0	0	0	3	0	3
T-	0	0	0	0	0	0	0	0	0	0	2	2
<b>Total</b>	<b>186</b>	<b>32</b>	<b>0</b>	<b>1</b>	<b>49</b>	<b>5</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>5</b>	<b>2</b>	<b>284</b>

M1:7 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Retromolar Area T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	13	2	0	0	0	0	0	0	0	0	0	15
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	24	4	1	0	3	0	0	1	1	0	0	34
T3	8	2	0	0	1	1	0	0	0	0	0	12
T4	0	0	1	0	0	0	0	0	0	0	0	1
T4a	4	1	0	1	1	0	0	0	0	1	0	8
T4b	5	2	0	0	2	0	0	0	0	0	0	9
Tis	2	0	0	0	0	0	0	0	0	0	0	2
TX	2	0	0	0	0	0	0	0	0	0	0	2
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>58</b>	<b>11</b>	<b>2</b>	<b>1</b>	<b>7</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>83</b>

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Lower Gingiva T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	45	3	1	0	4	2	0	0	1(1)	0	0	56
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	89	11	0	0	10	1	0	0	1	0	1	113
T3	17	5	0	0	8	2	0	0	0	1	0	33
T4	4	1	1	0	2	0	0	0	0	0	0	8
T4a	109(1)	42	0	2	64	17	0	0	6	1	0	241
T4b	10	1	0	1	13	3	0	0	0	0	0	28
Tis	6	0	0	0	0	0	0	0	0	0	0	6
TX	2	0	0	0	0	0	0	0	0	3	0	5
T-	0	0	0	0	0	0	0	0	0	0	8	8
Total	282	63	2	3	101	25	0	0	8	5	9	498

M1:2 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Upper Gingiva T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	28	0	0	0	0	0	0	0	1	0	0	29
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	68	5	0	0	7	1	0	0	2	0	0	83
T3	23	4(1)	0	0	0	2	0	0	1	0	0	30
T4	4	0	0	0	1	1	0	0	0	0	0	6
T4a	74(1)	17	0	0	32(1)	15(1)	0	0	5(1)	0	0	143
T4b	10(1)	5(2)	0	0	13	3(1)	0	0	1	0	0	32
Tis	4	0	0	0	0	0	0	0	0	0	0	4
TX	2	1(1)	0	0	0	0	0	0	0	3	0	6
T-	1	0	0	0	0	0	0	0	0	0	9	10
Total	214	32	0	0	53	22	0	0	10	3	9	343

M1:10 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Hard Palate

### T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	28	0	0	0	1(1)	0	0	0	0	0	0	29
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	15	0	0	0	1	2	0	0	0	0	0	18
T3	12	2	0	0	1	0	0	0	0	0	0	15
T4	2	1	0	0	0	0	0	0	0	0	0	3
T4a	21(2)	5	0	0	5	1	0	0	0	0	0	32
T4b	4	0	0	0	2	1	0	0	1	0	0	8
Tis	1	0	0	0	0	0	0	0	0	0	0	1
TX	0	0	0	0	0	0	0	0	0	1	0	1
T-	0	0	0	0	0	0	0	0	0	0	2	2
<b>Total</b>	<b>83</b>	<b>8</b>	<b>0</b>	<b>0</b>	<b>10</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>109</b>

M1:3 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Floor Mouth

### T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	70	2	0	0	1	0	0	0	0	0	0	73
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	58	12	0	1	9	7	2(1)	0	0	0	0	89
T3	28(1)	7	0	1	16	5	0	0	2	0	0	59
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	10	8(2)	0	0	7	18	0	0	2	0	0	45
T4b	0	0	0	0	1	0	0	0	0	0	0	1
Tis	3	0	0	0	0	0	0	0	0	0	0	3
TX	0	0	0	0	0	0	0	0	0	0	1	1
T-	0	0	0	0	0	0	0	0	0	0	6	6
<b>Total</b>	<b>169</b>	<b>29</b>	<b>0</b>	<b>2</b>	<b>34</b>	<b>30</b>	<b>2</b>	<b>0</b>	<b>4</b>	<b>0</b>	<b>7</b>	<b>277</b>

M1:4 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Tongue T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	4	0	0	0	0	0	0	0	0	0	0	4
T1	494	13	0	1	4	0	0	0	2	7	1	522
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	509(1)	64	2	1	40(1)	7	1	0	6(1)	1	0	631
T3	236	100(1)	2	2	126	35	2	1	22(1)	1	0	527
T4	4	1	1(1)	0	2	2	1	0	0	0	0	11
T4a	46	17	0	0	54	43(3)	2	0	6	0	0	168
T4b	0	0	0	0	2	2	0	0	0	0	0	4
Tis	79	0	0	0	0	0	0	0	0	1	1	81
TX	3	0	0	0	0	0	0	0	0	12	0	15
T-	0	0	0	0	0	0	0	0	0	0	19	19
<b>Total</b>	<b>1375</b>	<b>195</b>	<b>5</b>	<b>4</b>	<b>228</b>	<b>89</b>	<b>6</b>	<b>1</b>	<b>36</b>	<b>22</b>	<b>21</b>	<b>1982</b>

M1:9 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Oral Cavity,NOS T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	1	0	0	0	0	0	0	0	0	0	0	1
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	1	0	0	0	0	0	0	0	0	0	0	1
T3	2	1	0	0	0	0	0	0	0	0	0	3
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	2	0	0	0	0	1	0	0	2	0	1	6
T4b	0	0	0	0	1	0	0	0	0	0	0	1
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	1	0	0	0	0	0	0	0	0	0	0	1
T-	0	0	0	0	0	0	0	0	0	0	1	1
<b>Total</b>	<b>7</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>2</b>	<b>14</b>

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

### Treatment Method for the Primary Lesion by Subsite

Treatment Method	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
Surgery										
without	2	41	11	54	72	27	39	137	5	388
with	23	223	68	401	236	76	221	1733	8	2989
unknown	6	20	4	43	35	4	17	112	1	242
Radiotherapy										
without	23	205	53	355	194	73	191	1551	9	2654
with	2	59	26	100	114	30	69	319	4	723
unknown	6	20	4	43	35	4	17	112	1	242
Chemotherapy										
without	23	215	61	338	213	78	185	1523	10	2646
with	2	49	18	117	95	25	75	347	3	731
unknown	6	20	4	43	35	4	17	112	1	242
Total	31	284	83	498	343	107	277	1982	14	3619

NOS: not otherwise specified.

Treatment Method for the Primary Lesion by Subsite was not reported in 2 patients.

### Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
Surgery										
without	19	154	40	160	202	78	130	976	7	1766
with	5	106	36	288	103	27	130	859	6	1560
unknown	7	21	5	43	35	4	17	116	1	249
Radiotherapy										
without	24	216	58	359	234	88	201	1549	11	2740
with	0	44	18	89	71	17	59	286	2	586
unknown	7	21	5	43	35	4	17	116	1	249
Chemotherapy										
without	24	219	62	349	239	86	197	1542	11	2729
with	0	41	14	99	66	19	63	293	2	597
unknown	7	21	5	43	35	4	17	116	1	249
Total	31	281	81	491	340	109	277	1951	14	3575

NOS: not otherwise specified.

Treatment Method for the Cervical Lymph Nodes by Subsite was not reported in 46 patients.

Carcinoma of the Oral Cavity ----- 3621Cases

Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
No treatment	0	11	1	16	11	6	9	43	0	97
A) Surg. alone	23	181	47	286	162	54	158	1374	7	2292
A)F) Surg.->(Rad.+Chem.)	0	11	5	24	16	3	22	115	0	196
A)B) Surg.->Rad.	0	13	9	27	18	8	12	67	0	154
C)A) Chem.->Surg.	0	7	2	36	6	4	13	61	0	129
F)(Rad.+Chem.)	0	10	5	10	26	9	12	36	0	108
B) Rad. alone	1	10	3	7	21	6	5	19	3	75
A)C) Surg. -> Chem	0	2	1	9	3	4	3	29	0	51
C) Chem. alone	1	6	0	7	3	1	7	18	1	44
C)A)F) Chem.->Surg.->(Rad.+Chem.)	0	1	0	5	5	0	2	17	0	30
A)A) Surg.->Surg.	0	1	1	2	2	1	2	11	0	20
C)A)B) Chem.->Surg.->Rad.	0	1	0	3	3	0	2	10	0	19
F)A)(Rad.+Chem.)->Surg.	0	1	0	3	6	0	0	3	0	13
C)B) Chem.->Rad.	0	1	1	3	2	0	4	1	0	12
C)A)C) Chem.->Surg.->Chem.	0	0	0	1	2	0	1	7	0	11
+ Others	0	8	4	16	22	9	8	59	2	128
Unknown	6	20	4	43	35	4	17	112	1	242
<b>Total</b>	<b>31</b>	<b>284</b>	<b>83</b>	<b>498</b>	<b>343</b>	<b>109</b>	<b>277</b>	<b>1982</b>	<b>14</b>	<b>3621</b>

NOS: not otherwise specified.

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

Carcinoma of the Oral Cavity ----- 3621Cases

**Surgical Methods for the Primary Lesion by Subsite**

Surgical method	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
X0 No surgery	2	40	10	50	71	28	37	134	5	377
A1 Partial glossectomy	0	0	0	0	0	0	3	1111	1	1115
B2 Segmental mandibulectomy	0	11	7	205	3	0	8	3	3	240
A5 Subtotal glossectomy	0	0	0	1	0	0	8	212	0	221
C4 Resection of the buccal mucosa	0	176	30	0	1	0	0	0	0	207
D1 Partial maxillectomy	0	8	0	0	155	29	0	0	0	192
C2 Resection of the floor of mouth	0	0	0	0	0	0	171	0	0	171
A4 Hemiglossectomy	0	0	0	1	0	0	1	159	0	161
B1 Marginal mandibulectomy	1	8	10	124	0	0	9	0	0	152
A2 Hemiglossectomy (anterior 2/3rds)	0	0	0	0	0	0	1	132	0	133
C9 Resection of oral cavity, NOS	0	11	15	4	35	39	8	2	2	116
A3 Subtotal glossectomy (anterior 2/3rds)	0	0	0	0	0	0	5	63	0	68
A6 Total glossectomy	0	0	0	0	0	0	2	34	1	37
C3 Resection of lower gingiva	0	0	0	32	0	0	0	0	0	32
D2 Total maxillectomy	0	1	0	2	27	2	0	0	0	32
+ Others	21	8	6	32	10	6	3	16	1	103
V9 Unknown	6	21	5	47	41	5	19	116	1	261
<b>Total</b>	<b>30</b>	<b>284</b>	<b>83</b>	<b>498</b>	<b>343</b>	<b>109</b>	<b>275</b>	<b>1982</b>	<b>14</b>	<b>3618</b>

Surgical Method for the Primary Lesion by Subsite was not reported in 3 patients.

NOS: not otherwise specified.

Carcinoma of the Oral Cavity ----- 3621Cases

**Reconstructive Surgery by Subsite**

Reconstructive surgery	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
0) No reconstruction	15	155	40	187	217	78	150	1244	9	2095
E) Free ALT flap	1	22	16	34	9	8	30	241	0	361
D) Free RA MC flap	0	17	5	41	22	5	31	163	0	284
C) Free FA flap	1	17	4	15	8	6	14	94	0	159
G) Free fibular OC flap	0	2	1	89	2	2	7	1	2	106
1) Skin graft	1	21	4	8	20	1	7	10	0	72
5) PM MC flap	0	1	2	21	1	0	4	41	1	71
F) Free scapular OC flap	0	3	0	24	5	1	3	1	0	37
2) Local skin flap	5	5	3	4	1	0	8	7	0	33
3) Mucosal flap	1	6	2	4	1	0	1	2	0	17
4) DP flap	0	0	0	0	0	0	0	7	0	7
B) Free jejunal flap	0	1	0	0	0	0	0	3	0	4
7) Gastric pull-up	0	0	0	0	0	0	0	0	0	0
I) Free nerve graft	0	0	0	0	0	0	0	0	0	0
+ Others	0	9	1	26	12	4	4	35	1	92
9) Unknown	7	25	5	45	45	4	18	133	1	283
<b>Total</b>	<b>31</b>	<b>284</b>	<b>83</b>	<b>498</b>	<b>343</b>	<b>109</b>	<b>277</b>	<b>1982</b>	<b>14</b>	<b>3621</b>

NOS: not otherwise specified.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh.

FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

Carcinoma of the Oral Cavity ----- 3621Cases

**Neck Dissection on the Ipsilateral Side by Subsite**

Neck dissection	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
0) No N.D.	19	157	40	163	206	80	130	975	6	1776
2) Selective N.D.	5	63	24	186	61	17	86	564	2	1008
1) Total N.D.	0	41	12	102	40	6	39	294	3	537
3) Lymph node excision	0	0	1	2	0	0	1	15	0	19
8) Others	0	1	1	1	0	2	2	8	1	16
9) Unknown	7	22	5	44	36	4	19	126	2	265
<b>Total</b>	<b>31</b>	<b>284</b>	<b>83</b>	<b>498</b>	<b>343</b>	<b>109</b>	<b>277</b>	<b>1982</b>	<b>14</b>	<b>3621</b>

NOS: not otherwise specified.      N.D.: neck dissection.

**Neck Dissection on the Contralateral Side by Subsite**

Neck dissection	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
0) No N.D.	21	252	76	386	283	97	181	1598	8	2902
2) Selective N.D.	3	5	0	54	15	5	64	213	1	360
1) Total N.D.	0	3	1	12	8	0	11	37	2	74
3) Lymph node excision	0	1	0	0	1	0	0	1	0	3
8) Others	0	1	1	1	0	3	2	7	1	16
9) Unknown	7	22	5	45	36	4	19	126	2	266
<b>Total</b>	<b>31</b>	<b>284</b>	<b>83</b>	<b>498</b>	<b>343</b>	<b>109</b>	<b>277</b>	<b>1982</b>	<b>14</b>	<b>3621</b>

NOS: not otherwise specified.      N.D.: neck dissection.

Carcinoma of the Oral Cavity ----- 3621Cases

**Radiotherapy by Subsite**

Type of radiotherapy	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
0) No radiotherapy	23	198	52	343	184	74	186	1493	8	2561
1) X-ray (and/or electron beam)	1	57	26	102	113	29	69	339	4	740
3) B.T.	0	0	1	1	0	0	3	11	0	16
2) Particle beam	0	2	0	0	2	2	0	0	0	6
5) X-ray + B.T.	0	1	0	0	1	0	0	2	0	4
4) X-ray + Particle beam	0	0	0	0	0	0	0	0	0	0
6) Particl beam + B.T.	0	0	0	0	0	0	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0	0	0	0	0	0	0
8) Others	0	0	0	0	0	0	0	2	0	2
9) Unknown	7	26	4	52	43	4	19	135	2	292
<b>Total</b>	<b>31</b>	<b>284</b>	<b>83</b>	<b>498</b>	<b>343</b>	<b>109</b>	<b>277</b>	<b>1982</b>	<b>14</b>	<b>3621</b>

NOS: not otherwise specified.      B.T.: brachytherapy.

**Chemotherapy by Subsite**

Route of administration	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
0) No chemotherapy	23	213	61	331	213	77	182	1507	10	2617
1) I.V.	0	35	13	76	59	16	59	261	3	522
3) Oral	0	7	4	36	14	4	14	59	0	138
2) I.A.	1	3	0	4	20	5	2	23	0	58
5) I.V.+Oral	0	1	0	3	2	0	1	4	0	11
4) I.V.+I.A.	0	2	1	1	0	1	2	3	0	10
6) I.A.+Oral	0	1	0	1	0	0	0	4	0	6
7) I.V.+I.A.+Oral	0	1	0	0	0	0	0	1	0	2
8) Others	0	0	0	0	0	1	0	0	0	1
9) Unknown	7	21	4	46	35	5	17	120	1	256
<b>Total</b>	<b>31</b>	<b>284</b>	<b>83</b>	<b>498</b>	<b>343</b>	<b>109</b>	<b>277</b>	<b>1982</b>	<b>14</b>	<b>3621</b>

NOS: not otherwise specified.      I.V.: intravenous.      I.A.: intraarterial

# Larynx (2018)

2402 Cases

## Primary Site

Site	Number of patients	(%)
Glottis	1636	( 68.1)
Supraglottis	652	(27.1)
Subglottis	78	( 3.2)
Larynx, NOS	36	( 1.5 )
<b>Total</b>	<b>2402</b>	<b>( 100 )</b>

NOS: not otherwise specified

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	3	1	4
40 - 49	43	14	57
50 - 59	204	24	228
60 - 69	693	56	749
70 - 79	830	69	899
80 - 89	390	34	424
90 - 99	36	4	40
100 - 109	0	0	0
<b>Total</b>	<b>2200</b>	<b>202</b>	<b>2402</b>

NOS: not otherwise specified

## Glottis Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	3	1	4
40 - 49	32	5	37
50 - 59	135	14	149
60 - 69	477	33	510
70 - 79	560	33	593
80 - 89	288	18	306
90 - 99	32	4	36
100 - 109	0	0	0
<b>Total</b>	<b>1528</b>	<b>108</b>	<b>1636</b>

## Supraglottis Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	11	8	19
50 - 59	63	10	73
60 - 69	183	22	205
70 - 79	235	27	262
80 - 89	79	10	89
90 - 99	4	0	4
100 - 109	0	0	0
<b>Total</b>	<b>575</b>	<b>77</b>	<b>652</b>

## Subglottis Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	0	1	1
50 - 59	3	0	3
60 - 69	25	0	25
70 - 79	25	6	31
80 - 89	15	3	18
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>68</b>	<b>10</b>	<b>78</b>

## Carcinoma of the Larynx,NOS Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	0	0	0
50 - 59	3	0	3
60 - 69	8	1	9
70 - 79	10	3	13
80 - 89	8	3	11
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>29</b>	<b>7</b>	<b>36</b>

NOS: not otherwise specified

Carcinoma of the Larynx ----- 2402cases

## Histological Distribution by Subsite

Histologic type	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
S.C.C., NOS	1447	571	64	31	2113
S.C.C., keratinizing, NOS	79	31	7	1	118
S.C.C. in situ, NOS	60	17	1	0	78
Ca., NOS	5	6	0	1	12
S.C.C., microinvasive	6	2	0	0	8
S.C.C., spindle cell	7	1	0	0	8
Small cell ca., NOS	2	4	0	1	7
Spindle cell ca., NOS	4	3	0	0	7
Adenoid cystic ca.	1	3	2	0	6
Neoplasm, malig.	4	1	1	0	6
S.C.C., large cell, nonkerat., NOS	3	3	0	0	6
Adenosquamous ca.	3	1	1	0	5
Adenoca., NOS	2	2	0	0	4
S.C.C., small cell, nonkerat.	2	1	0	0	3
S.C.C. in situ with quest. stromal invasion	2	1	0	0	3
Chondrosarcoma, NOS	0	0	1	2	3
Papillary S.C.C.	1	0	0	0	1
Malig. lymphoma, NOS	1	0	0	0	1
Neuroendocrine ca., NOS	0	1	0	0	1
Basaloid S.C.C.	1	0	0	0	1
Myoepithelial ca.	1	0	0	0	1
Basal cell ca., NOS	1	0	0	0	1
Verrucous ca., NOS	1	0	0	0	1
Extraskletal Ewing's sarcoma	1	0	0	0	1
Large cell ca., NOS	0	1	0	0	1
Carcinosarcoma, NOS	0	1	0	0	1
Osteosarcoma, NOS	0	0	1	0	1
Neuroendocrine tumor	0	1	0	0	1
S.C.C. with horn formation	1	0	0	0	1
Glandular intraepithelial neoplasia, grade III	0	1	0	0	1
Malig. fibrous histiocytoma	1	0	0	0	1
<b>Total</b>	<b>1636</b>	<b>652</b>	<b>78</b>	<b>36</b>	<b>2402</b>

NOS: not otherwise specified.  
malig., Malig.: malignant.

ca., Ca.: carcinoma.  
kerat.: keratinizing.

S.C.C.: squamous cell carcinoma.  
nonkerat.: nonkeratinizing

## T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	3	0	0	0	0	0	0	0	1	0	0	4
T1	145	8	0	1	13(1)	3	0	0	1	0	1	172
T1a	565	0	0	0	0	0	0	0	0	0	1	566
T1b	190	0	0	0	0	1	0	0	0	1	0	192
T2	482	32	2	2	27(1)	28(3)	0	3	11	2	0	589
T3	352	53(2)	3	4(2)	51(1)	41(6)	2	0	19(2)	1(1)	0	526
T4	10	0	1	0	1	2(1)	0	0	0	0	0	14
T4a	113(2)	36	0	3	31	49(3)	1	1	14(2)	0	1	249
T4b	1	0	0	0	1	1	0	0	2	0	0	5
Tis	64	0	0	0	0	0	0	0	0	3	1	68
TX	3	0	0	0	0	0	0	0	0	9	0	12
T-	0	0	0	0	0	0	0	0	0	0	5	5
<b>Total</b>	<b>1928</b>	<b>129</b>	<b>6</b>	<b>10</b>	<b>124</b>	<b>125</b>	<b>3</b>	<b>4</b>	<b>48</b>	<b>16</b>	<b>9</b>	<b>2402</b>

M1:27 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Glottis T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	4	4
T1	3	0	0	0	0	0	0	0	1	0	0	4
T1a	50	1	0	0	1(1)	0	0	0	0	0	0	52
T1b	560	0	0	0	0	0	0	0	0	0	1	561
T2	184	0	0	0	0	1	0	0	0	1	0	186
T3	349	4	1	1	4	1(1)	0	1	2	2	0	365
T4	252	15	1	1	11(1)	4(1)	0	0	2	0	0	286
T4a	6	0	0	0	1	1	0	0	0	0	0	8
T4b	67(1)	15	0	1	7	12	0	0	2	0	0	104
Tis	1	0	0	0	0	1	0	0	0	0	0	2
TX	50	0	0	0	0	0	0	0	0	2	1	53
T-	2	0	0	0	0	0	0	0	0	8	0	10
Total	0	0	0	0	0	0	0	0	0	0	1	1
<b>Total</b>	<b>1524</b>	<b>35</b>	<b>2</b>	<b>3</b>	<b>24</b>	<b>20</b>	<b>0</b>	<b>1</b>	<b>7</b>	<b>13</b>	<b>7</b>	<b>1636</b>

M1:5 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Supraglottis T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	85	6	0	0	12	3	0	0	1	0	0	107
T1a	2	0	0	0	0	0	0	0	0	0	0	2
T1b	2	0	0	0	0	0	0	0	0	0	0	2
T2	110	25	1	0	22(1)	26(2)	0	2	9	0	0	195
T3	88	35(1)	1	3(2)	38	36(5)	2	0	17(2)	1(1)	0	221
T4	1	0	0	0	0	0	0	0	0	0	0	1
T4a	23(1)	16	0	1	20	35(2)	1	1	10(2)	0	0	107
T4b	0	0	0	0	1	0	0	0	2	0	0	3
Tis	13	0	0	0	0	0	0	0	0	1	0	14
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>324</b>	<b>82</b>	<b>2</b>	<b>4</b>	<b>93</b>	<b>100</b>	<b>3</b>	<b>3</b>	<b>39</b>	<b>2</b>	<b>0</b>	<b>652</b>

M1:19 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Subglottis T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	8	0	0	0	0	0	0	0	0	0	0	8
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	19	3	0	0	1	0	0	0	0	0	0	23
T3	8	1	0	0	1	0	0	0	0	0	0	10
T4	3	0	0	0	0	0	0	0	0	0	0	3
T4a	20	4	0	1	2	2(1)	0	0	2	0	1	32
T4b	0	0	0	0	0	0	0	0	0	0	0	0
Tis	1	0	0	0	0	0	0	0	0	0	0	1
TX	1	0	0	0	0	0	0	0	0	0	0	1
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>60</b>	<b>8</b>	<b>0</b>	<b>1</b>	<b>4</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>78</b>

M1:1 case. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Larynx,NOS T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	2	1	0	1	0	0	0	0	0	0	1	5
T1a	3	0	0	0	0	0	0	0	0	0	0	3
T1b	4	0	0	0	0	0	0	0	0	0	0	4
T2	4	0	0	1	0	1	0	0	0	0	0	6
T3	4	2	1	0	1	1	0	0	0	0	0	9
T4	0	0	1	0	0	1	0	0	0	0	0	2
T4a	3	1	0	0	2	0	0	0	0	0	0	6
T4b	0	0	0	0	0	0	0	0	0	0	0	0
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	0	0	0	0	0	0	0	0	0	1	0	1
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>20</b>	<b>4</b>	<b>2</b>	<b>2</b>	<b>3</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>36</b>

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
Surgery					
without	1092	330	38	15	1475
with	508	304	38	21	871
unknown	36	17	2	0	55
Radiotherapy					
without	434	253	32	20	739
with	1166	381	44	16	1607
unknown	36	17	2	0	55
Chemotherapy					
without	1249	358	47	29	1683
with	351	276	29	7	663
unknown	36	17	2	0	55
<b>Total</b>	<b>1636</b>	<b>651</b>	<b>78</b>	<b>36</b>	<b>2401</b>

Treatment Method for the Primary Lesion by Subsite was not reported in one patient.

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
No treatment	31	20	2	3	56
B) Rad. alone	780	100	14	8	902
A) Surg. alone	388	201	28	13	630
F)(Rad.+Chem.)	256	151	20	2	429
A)B) Surg.->Rad.	46	32	2	2	82
A)F) Surg.->(Rad.+Chem.)	17	26	5	2	50
C)F) Chem. -> (Rad.+Chem.)	8	26	1	0	35
C) Chem. alone	10	14	1	2	27
F)A)(Rad.+Chem.)->Surg.	11	7	0	0	18
B)A) Rad.->Surg.	12	2	1	1	16
C)A) Chem.->Surg.	9	5	0	1	15
F)C)(Rad.+Chem.)->Chem.	1	10	0	0	11
A)A) Surg.->Surg.	4	5	0	1	10
Other	27	36	2	1	66
Unknown	36	17	2	0	55
<b>Total</b>	<b>1636</b>	<b>652</b>	<b>78</b>	<b>36</b>	<b>2402</b>

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Carcinoma of the Larynx ----- 2402cases

## Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	1	91	384	166	475	263	5	63	3	20	3	1	1475
with	3	78	170	24	100	247	9	181	2	47	9	1	871
unknown	0	3	12	2	13	16	0	5	0	1	0	3	55
Radiotherapy													
without	1	69	148	11	81	209	10	153	1	49	6	1	739
with	3	100	406	179	494	301	4	91	4	18	6	1	1607
unknown	0	3	12	2	13	16	0	5	0	1	0	3	55
Chemotherapy													
without	2	139	536	180	317	265	9	156	2	66	11	0	1683
with	2	30	18	10	258	245	5	88	3	1	1	2	663
unknown	0	3	12	2	13	16	0	5	0	1	0	3	55
Total	4	172	566	192	588	526	14	249	5	68	12	5	2401

Treatment Method for the Primary Lesion by T Classification was not reported in one patient.

### Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	2	8	1	10	18	1	12	0	2	2	0	56
B) Rad. alone	1	67	368	162	224	54	2	7	1	16	0	0	902
A) Surg. alone	3	62	138	10	65	178	6	118	1	44	4	1	630
F)(Rad.+Chem.)	0	17	8	5	220	157	1	18	2	0	1	0	429
A)B) Surg.->Rad.	0	6	16	5	14	16	0	18	0	2	5	0	82
A)F) Surg.->(Rad.+Chem.)	0	3	0	2	8	15	1	20	1	0	0	0	50
C)F) Chem. -> (Rad.+Chem.)	0	3	0	0	7	16	0	9	0	0	0	0	35
C) Chem. alone	0	1	1	0	4	8	1	10	0	1	0	1	27
F)A)(Rad.+Chem.)->Surg.	0	0	0	0	5	10	0	3	0	0	0	0	18
B)A) Rad.->Surg.	0	2	6	3	3	2	0	0	0	0	0	0	16
C)A) Chem.->Surg.	0	1	0	0	0	4	2	8	0	0	0	0	15
F)C)(Rad.+Chem.)->Chem.	0	0	0	0	2	6	0	3	0	0	0	0	11
A)A) Surg.->Surg.	0	1	3	0	1	4	0	1	0	0	0	0	10
Other	0	4	6	2	12	22	0	17	0	2	0	0	65
Unknown	0	3	12	2	13	16	0	5	0	1	0	3	55
<b>Total</b>	<b>4</b>	<b>172</b>	<b>566</b>	<b>192</b>	<b>588</b>	<b>526</b>	<b>14</b>	<b>249</b>	<b>5</b>	<b>68</b>	<b>12</b>	<b>5</b>	<b>2401</b>

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in one patient.

Carcinoma of the Larynx ----- 2402cases

**Glottis**  
**Treatment Method for the Primary Lesion**  
**by T Classification**

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	1	31	381	161	313	161	3	20	0	18	2	1	1092
with	3	21	168	23	43	118	5	82	2	34	8	1	508
unknown	0	0	12	2	9	7	0	2	0	1	0	3	36
Radiotherapy													
without	1	19	146	11	37	106	5	67	1	36	4	1	434
with	3	33	403	173	319	173	3	35	1	16	6	1	1166
unknown	0	0	12	2	9	7	0	2	0	1	0	3	36
Chemotherapy													
without	2	51	531	174	214	140	6	70	1	51	9	0	1249
with	2	1	18	10	142	139	2	32	1	1	1	2	351
unknown	0	0	12	2	9	7	0	2	0	1	0	3	36
<b>Total</b>	<b>4</b>	<b>52</b>	<b>561</b>	<b>186</b>	<b>365</b>	<b>286</b>	<b>8</b>	<b>104</b>	<b>2</b>	<b>53</b>	<b>10</b>	<b>5</b>	<b>1636</b>

**Glottis**  
**Sequence of Treatment Methods for the Primary Lesion**  
**by T Classification**

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	0	8	1	6	9	0	4	0	2	1	0	31
B) Rad. alone	1	31	365	157	171	38	2	1	0	14	0	0	780
A) Surg. alone	3	19	136	10	28	96	4	55	1	32	3	1	388
F)(Rad.+Chem.)	0	0	8	5	132	100	1	9	0	0	1	0	256
A)B) Surg.->Rad.	0	1	16	5	7	2	0	8	0	2	5	0	46
A)F) Surg.->(Rad.+Chem.)	0	0	0	2	3	4	0	7	1	0	0	0	17
B)A) Rad.->Surg.	0	0	6	3	2	1	0	0	0	0	0	0	12
F)A)(Rad.+Chem.)->Surg.	0	0	0	0	2	7	0	2	0	0	0	0	11
C) Chem. alone	0	0	1	0	2	4	0	1	0	1	0	1	10
Other	0	1	9	1	3	18	1	15	0	1	0	0	49
Unknown	0	0	12	2	9	7	0	2	0	1	0	3	36
<b>Total</b>	<b>4</b>	<b>52</b>	<b>561</b>	<b>186</b>	<b>365</b>	<b>286</b>	<b>8</b>	<b>104</b>	<b>2</b>	<b>53</b>	<b>10</b>	<b>5</b>	<b>1636</b>

**Supraglottis**  
**Treatment Method for the Primary Lesion**  
**by T Classification**

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
<b>Surgery</b>													
without	0	51	2	2	139	95	0	37	3	1	0	0	330
with	0	53	0	0	52	117	1	68	0	13	0	0	304
unknown	0	3	0	0	3	9	0	2	0	0	0	0	17
<b>Radiotherapy</b>													
without	0	49	0	0	38	91	1	61	0	13	0	0	253
with	0	55	2	2	153	121	0	44	3	1	0	0	381
unknown	0	3	0	0	3	9	0	2	0	0	0	0	17
<b>Chemotherapy</b>													
without	0	77	2	2	90	113	1	58	1	14	0	0	358
with	0	27	0	0	101	99	0	47	2	0	0	0	276
unknown	0	3	0	0	3	9	0	2	0	0	0	0	17
<b>Total</b>	0	107	2	2	194	221	1	107	3	14	0	0	651

Treatment Method for the Primary Lesion by T Classification was not reported in one patient.

**Supraglottis**  
**Sequence of Treatment Methods for the Primary Lesion**  
**by T Classification**

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	2	0	0	3	8	0	7	0	0	0	0	20
A) Surg. alone	0	42	0	0	33	73	1	40	0	12	0	0	201
F)(Rad.+Chem.)	0	16	0	0	74	52	0	7	2	0	0	0	151
B) Rad. alone	0	28	2	2	46	15	0	5	1	1	0	0	100
A)B) Surg.->Rad.	0	4	0	0	7	14	0	7	0	0	0	0	32
A)F) Surg.->(Rad.+Chem.)	0	2	0	0	5	10	0	9	0	0	0	0	26
C)F) Chem. -> (Rad.+Chem.)	0	3	0	0	6	11	0	6	0	0	0	0	26
C) Chem. alone	0	1	0	0	1	4	0	8	0	0	0	0	14
F)C)(Rad.+Chem.)->Chem.	0	0	0	0	2	5	0	3	0	0	0	0	10
Other	0	6	0	0	14	20	0	13	0	1	0	0	54
Unknown	0	3	0	0	3	9	0	2	0	0	0	0	17
<b>Total</b>	<b>0</b>	<b>107</b>	<b>2</b>	<b>2</b>	<b>194</b>	<b>221</b>	<b>1</b>	<b>107</b>	<b>3</b>	<b>14</b>	<b>0</b>	<b>0</b>	<b>651</b>

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in one patient.

**Subglottis**  
**Treatment Method for the Primary Lesion**  
**by T Classification**

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
<b>Surgery</b>													
without	0	7	0	0	19	4	1	6	0	1	0	0	38
with	0	1	0	0	3	6	2	25	0	0	1	0	38
unknown	0	0	0	0	1	0	0	1	0	0	0	0	2
<b>Radiotherapy</b>													
without	0	0	0	0	3	5	2	21	0	0	1	0	32
with	0	8	0	0	19	5	1	10	0	1	0	0	44
unknown	0	0	0	0	1	0	0	1	0	0	0	0	2
<b>Chemotherapy</b>													
without	0	7	0	0	9	4	2	23	0	1	1	0	47
with	0	1	0	0	13	6	1	8	0	0	0	0	29
unknown	0	0	0	0	1	0	0	1	0	0	0	0	2
<b>Total</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>0</b>	<b>23</b>	<b>10</b>	<b>3</b>	<b>32</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>78</b>

**Subglottis**  
**Sequence of Treatment Methods for the Primary Lesion**  
**by T Classification**

Sequence of treatment methods	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
A) Surg. alone	0	0	0	0	3	4	1	19	0	0	1	0	28
F)(Rad.+Chem.)	0	1	0	0	13	4	0	2	0	0	0	0	20
B) Rad. alone	0	6	0	0	6	0	0	1	0	1	0	0	14
Other	0	1	0	0	1	2	2	10	0	0	0	0	16
<b>Total</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>0</b>	<b>23</b>	<b>10</b>	<b>3</b>	<b>32</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>78</b>

**Carcinoma of the Larynx,NOS**  
**Treatment Method for the Primary Lesion**  
**by T Classification**

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
<b>Surgery</b>													
without	0	2	1	3	4	3	1	0	0	0	1	0	15
with	0	3	2	1	2	6	1	6	0	0	0	0	21
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Radiotherapy</b>													
without	0	1	2	0	3	7	2	4	0	0	1	0	20
with	0	4	1	4	3	2	0	2	0	0	0	0	16
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Chemotherapy</b>													
without	0	4	3	4	4	8	0	5	0	0	1	0	29
with	0	1	0	0	2	1	2	1	0	0	0	0	7
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>0</b>	<b>5</b>	<b>3</b>	<b>4</b>	<b>6</b>	<b>9</b>	<b>2</b>	<b>6</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>36</b>

**Carcinoma of the Larynx,NOS**  
**Sequence of Treatment Methods for the Primary Lesion**  
**by T Classification**

Sequence of treatment methods	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
No treatment	0	0	0	0	1	1	0	0	0	0	1	0	3
A) Surg. alone	0	1	2	0	1	5	0	4	0	0	0	0	13
B) Rad. alone	0	2	1	3	1	1	0	0	0	0	0	0	8
Other	0	2	0	1	3	2	2	2	0	0	0	0	12
<b>Total</b>	<b>0</b>	<b>5</b>	<b>3</b>	<b>4</b>	<b>6</b>	<b>9</b>	<b>2</b>	<b>6</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>36</b>

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
X0 No surgery	1080	323	37	15	1455
G5 Total laryngectomy	202	178	35	13	428
G2 Transoral resection	201	43	0	1	245
G1 Endoscopic resection	44	17	0	2	63
G3 Partial laryngectomy	22	6	1	1	30
Others	25	57	2	4	88
V9 Unknown	62	28	3	0	93
Total	1636	652	78	36	2402

## Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
X0 No surgery	1	87	384	164	470	259	5	60	3	18	3	1	1455
G5 Total laryngectomy	1	3	3	1	42	211	7	158	1	0	0	1	428
G2 Transoral resection	1	45	120	17	26	0	0	1	1	32	2	0	245
G1 Endoscopic resection	0	16	22	1	9	3	0	0	0	8	4	0	63
G3 Partial laryngectomy	0	2	9	0	6	8	0	1	0	2	2	0	30
Others	0	12	10	2	17	20	2	19	0	5	1	0	88
V9 Unknown	1	7	18	7	19	25	0	10	0	3	0	3	93
<b>Total</b>	<b>4</b>	<b>172</b>	<b>566</b>	<b>192</b>	<b>589</b>	<b>526</b>	<b>14</b>	<b>249</b>	<b>5</b>	<b>68</b>	<b>12</b>	<b>5</b>	<b>2402</b>

NOS: not otherwise specified.

T-: without reported T classification

## Glottis

### Surgical Methods for the Primary Lesion

#### by T Classification

Surgical method		T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
X0	No surgery	1	29	381	159	308	160	3	19	0	17	2	1	1080
F2/G2	Transoral resection	1	19	122	17	16	0	0	0	1	26	2	0	204
G5	Total laryngectomy	1	0	3	1	13	99	4	79	1	0	0	1	202
F1/G1	Endoscopic resection	0	1	22	1	8	2	0	0	0	7	5	0	46
G3	Partial laryngectomy	0	1	9	0	4	7	0	0	0	0	1	0	22
G9	Laryngectomy, other type	0	0	6	1	1	0	0	0	0	1	0	0	9
G4	Subtotal laryngectomy	0	0	0	0	1	5	0	0	0	0	0	0	6
F6	Total pharyngolaryngo-esophagectomy	0	0	0	0	0	0	1	2	0	0	0	0	3
F4	Total laryngectomy+Partial pharyngectomy	0	0	0	0	0	1	0	0	0	0	0	0	1
F5	Total pharyngolaryngectomy	0	0	0	0	0	0	0	1	0	0	0	0	1
V9	Unknown	1	2	18	7	14	12	0	3	0	2	0	3	62
Total		4	52	561	186	365	286	8	104	2	53	10	5	1636

T-: without reported T classification

## Supraglottis

### Surgical Methods for the Primary Lesion

#### by T Classification

Surgical method		T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
X0	No surgery	0	50	2	2	139	92	0	35	3	0	0	0	323
G5	Total laryngectomy	0	2	0	0	25	101	0	50	0	0	0	0	178
F2/G2	Transoral resection	0	28	0	0	10	0	0	1	0	8	0	0	47
F1/G1	Endoscopic resection	0	16	0	0	1	1	0	0	0	3	0	0	21
F5	Total pharyngolaryngectomy	0	0	0	0	3	6	0	6	0	0	0	0	15
G9	Laryngectomy, other type	0	3	0	0	5	2	1	1	0	0	0	0	12
F6	Total pharyngolaryngo-esophagectomy	0	1	0	0	1	1	0	6	0	0	0	0	9
F4	Total laryngectomy+Partial pharyngectomy	0	0	0	0	1	3	0	2	0	0	0	0	6
G3	Partial laryngectomy	0	1	0	0	2	1	0	0	0	2	0	0	6
E2	Resection of the base of tongue and epiglottis	0	1	0	0	1	0	0	0	0	0	0	0	2
E9	Resection of the oropharynx, other type	0	1	0	0	1	0	0	0	0	0	0	0	2
F7	Hypopharyngectomy + Cervical esophagec	0	0	0	0	1	1	0	0	0	0	0	0	2
X9	Others	0	0	0	0	1	0	0	0	0	0	0	0	1
V9	Unknown	0	4	0	0	4	13	0	6	0	1	0	0	28
Total		0	107	2	2	195	221	1	107	3	14	0	0	652

T-: without reported T classification

## Subglottis

### Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
X0 No surgery	0	6	0	0	19	4	1	6	0	1	0	0	37
G5 Total laryngectomy	0	1	0	0	3	5	2	24	0	0	0	0	35
F5 Total pharyngolaryng	0	0	0	0	0	1	0	1	0	0	0	0	2
G3 Partial laryngectomy	0	0	0	0	0	0	0	0	0	0	1	0	1
V9 Unknown	0	1	0	0	1	0	0	1	0	0	0	0	3
Total	0	8	0	0	23	10	3	32	0	1	1	0	78

T-: without reported T classification

## Carcinoma of the Larynx,NOS

### Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
X0 No surgery	0	2	1	3	4	3	1	0	0	0	1	0	15
G5 Total laryngectomy	0	0	0	0	1	6	1	5	0	0	0	0	13
G1 Endoscopic resection	0	1	1	0	0	0	0	0	0	0	0	0	2
F4 Total laryngectomy+Partial pharyngectomy	0	0	0	0	1	0	0	0	0	0	0	0	1
G2 Transoral resection	0	0	1	0	0	0	0	0	0	0	0	0	1
G3 Partial laryngectomy	0	0	0	0	0	0	0	1	0	0	0	0	1
G9 Laryngectomy, other type	0	0	0	1	0	0	0	0	0	0	0	0	1
X9 Others	0	2	0	0	0	0	0	0	0	0	0	0	2
<b>Total</b>	<b>0</b>	<b>5</b>	<b>3</b>	<b>4</b>	<b>6</b>	<b>9</b>	<b>2</b>	<b>6</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>36</b>

NOS: not otherwise specified.

T-: without reported T classification

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
Surgery					
without	1404	408	44	22	1878
with	178	222	30	14	444
unknown	50	19	3	0	72
Radiotherapy					
without	1349	360	49	28	1786
with	233	270	25	8	536
unknown	50	19	3	0	72
Chemotherapy					
without	1436	408	52	31	1927
with	146	222	22	5	395
unknown	50	19	3	0	72
<b>Total</b>	<b>1632</b>	<b>649</b>	<b>77</b>	<b>36</b>	<b>2394</b>

NOS: not otherwise specified.

Treatment Method for the Cervical Lymph Nodes by Subsite was not reported in 8 patients.

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No N.D.	1410	409	44	23	1886
1) Total N.D.	29	72	3	3	107
2) Selective N.D.	133	140	27	10	310
3) Lymph node excision	4	2	1	0	7
8) Others	8	6	0	0	14
9) Unknown	52	23	3	0	78
<b>Total</b>	<b>1636</b>	<b>652</b>	<b>78</b>	<b>36</b>	<b>2402</b>

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No N.D.	1483	465	55	27	2030
2) Selective N.D.	79	122	19	7	227
1) Total N.D.	13	35	1	1	50
3) Lymph node excision	0	0	0	1	1
8) Others	9	7	0	0	16
9) Unknown	52	23	3	0	78
<b>Total</b>	<b>1636</b>	<b>652</b>	<b>78</b>	<b>36</b>	<b>2402</b>

NOS: not otherwise specified.

N.D.: neck dissection

### Reconstructive Surgery by Subsite

Reconststructive surgery	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No reconstruction	1549	573	66	34	2222
B) Free jejunal flap	3	25	1	0	29
5) PM MC flap	6	9	3	0	18
E) Free ALT flap	2	7	0	0	9
D) Free RA MC flap	2	4	1	0	7
2) Local skin flap	2	1	1	0	4
4) DP flap	1	0	2	1	4
1) Skin graft	0	1	0	0	1
7) Gastric pull-up	1	0	0	0	1
C) Free FA flap	0	1	0	0	1
3) Mucosal flap	0	0	0	0	0
F) Free scapular OC flap	0	0	0	0	0
G) Free fibular OC flap	0	0	0	0	0
I) Free nerve graft	0	0	0	0	0
8) Others	1	1	0	1	3
9) Unknown	69	30	4	0	103
<b>Total</b>	<b>1636</b>	<b>652</b>	<b>78</b>	<b>36</b>	<b>2402</b>

NOS: not otherwise specified.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh.

FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

## Radiotherapy by Subsite

Type of radiotherapy	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No radiotherapy	422	246	31	19	718
1) X-ray (and/or electron beam)	1159	386	44	16	1605
2) Particle beam	0	1	1	0	2
3) B.T.	0	0	0	0	0
4) X-ray + Particle beam	0	0	0	0	0
5) X-ray + B.T.	0	0	0	0	0
6) Particle beam + B.T.	0	0	0	0	0
7) X-ray + Particle beam + B.T.	0	0	0	0	0
8) Others	0	0	0	0	0
9) Unknown	55	19	2	1	77
<b>Total</b>	<b>1636</b>	<b>652</b>	<b>78</b>	<b>36</b>	<b>2402</b>

NOS: not otherwise specified

## Chemotherapy by Subsite

Route of administration	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No chemotherapy	1255	354	46	29	1684
1) I.V.	271	261	29	5	566
3) Oral	53	14	1	2	70
2) I.A.	8	2	0	0	10
5) I.V.+Oral	1	3	0	0	4
7) I.V.+I.A.+Oral	1	0	0	0	1
4) I.V.+I.A.	0	0	0	0	0
6) I.A.+Oral	0	0	0	0	0
8) Others	0	0	0	0	0
9) Unknown	47	18	2	0	67
<b>Total</b>	<b>1636</b>	<b>652</b>	<b>78</b>	<b>36</b>	<b>2402</b>

NOS: not otherwise specified

# Hypopharynx(2018)

2814 Cases

## Primary Site

Site	Number of patients	(%)
Postericoid	260	(9.2)
Pyriiform sinus	1997	(71.0)
Posterior wall	422	(15.0)
Hypopharynx, NOS	135	(4.8)
<b>Total</b>	<b>2814</b>	<b>(100)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	2	0	2
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	5	4	9
40 - 49	45	25	70
50 - 59	288	65	353
60 - 69	926	69	995
70 - 79	1014	67	1081
80 - 89	263	18	281
90 - 99	19	1	20
100 - 109	0	0	0
110 - 119	0	2	2
<b>Total</b>	<b>2563</b>	<b>251</b>	<b>2814</b>

NOS: not otherwise specified.

## Postcricoid Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	0	1
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	2	3	5
50 - 59	23	13	36
60 - 69	73	8	81
70 - 79	99	6	105
80 - 89	24	4	28
90 - 99	3	0	3
100 - 109	0	0	0
110 - 119	0	1	1
<b>Total</b>	<b>225</b>	<b>35</b>	<b>260</b>

## Pyriform sinus Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	0	1
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	3	2	5
40 - 49	32	17	49
50 - 59	215	37	252
60 - 69	681	41	722
70 - 79	727	38	765
80 - 89	183	3	186
90 - 99	15	0	15
100 - 109	0	0	0
110 - 119	0	1	1
<b>Total</b>	<b>1858</b>	<b>139</b>	<b>1997</b>

## Posterior wall

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	2	3
40 - 49	11	3	14
50 - 59	36	11	47
60 - 69	140	19	159
70 - 79	133	16	149
80 - 89	40	9	49
90 - 99	0	1	1
100 - 109	0	0	0
Total	361	61	422

## Hypopharynx,NOS

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	0	1
40 - 49	0	2	2
50 - 59	14	4	18
60 - 69	32	1	33
70 - 79	55	7	62
80 - 89	16	2	18
90 - 99	1	0	1
100 - 109	0	0	0
Total	119	16	135

NOS: not otherwise specified.

Carcinoma of the Hypopharynx ----- 2814 Cases

## Histological Distribution by Subsite

Histologic type	Postcricoid (C13.0)	Pyriiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
S.C.C., NOS	241	1796	378	120	2535
S.C.C. in situ, NOS	6	90	20	4	120
S.C.C., keratinizing, NOS	7	43	12	5	67
S.C.C., large cell, nonkerat., NOS	2	15	1	0	18
S.C.C., microinvasive	0	7	5	0	12
Papillary S.C.C.	1	8	0	1	10
Ca, NOS	1	5	2	1	9
Basaloid S.C.C.	0	7	1	0	8
Neoplasm, malig.	0	6	0	2	8
S.C.C., spindle cell	1	3	0	1	5
S.C.C., small cell, nonkerat.	1	2	0	0	3
Adenosquamous ca	0	2	1	0	3
Small cell ca, NOS	0	2	0	0	2
Lymphoepithelial ca	0	2	0	0	2
Lipoma-like liposarcoma Sclerosing liposarcoma Inflammatory liposarcoma	0	1	0	1	2
Liposarcoma, NOS	0	1	1	0	2
Mucoepidermoid ca	0	1	0	0	1
Spindle cell ca, NOS	0	1	0	0	1
Ca, undiff., NOS	0	1	0	0	1
Chondrosarcoma, NOS	0	1	0	0	1
Basaloid ca	0	1	0	0	1
Transitional cell ca, NOS	0	1	0	0	1
Basosquamous ca	0	0	1	0	1
S.C.C. with horn formation	0	1	0	0	1
<b>Total</b>	<b>260</b>	<b>1997</b>	<b>422</b>	<b>135</b>	<b>2814</b>

NOS: not otherwise specified.

ca., Ca.: carcinoma.

S.C.C.: squamous cell carcinoma.

malig., Malig.: malignant.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	4	0	0	0	0	0	0	0	0	0	0	4
T1	410(1)	26	1	7	40(4)	12(1)	4(1)	0	24(2)	5	0	529
T1a	1	0	0	0	0	0	0	0	0	0	0	1
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	463(3)	144(3)	6	14(1)	165(5)	67(3)	5	4	59(7)	3	0	930
T3	136	69(1)	2	5	152(11)	96(7)	8(1)	2	50(6)	1	0	521
T4	4	5	3	1	6	0	2	0	1	1(1)	0	23
T4a	83(4)	56(2)	1	11(1)	215(10)	123(17)	7(2)	1	64(8)	0	0	561
T4b	8(1)	2(1)	2	1	17(2)	13(2)	1	0	19(4)	0	0	63
Tis	152	0	0	0	0	0	0	0	1	2	0	155
TX	1	1	0	0	2	0	1	0	1	5(1)	1	12
T-	0	0	0	0	1	0	0	0	0	0	14	15
Total	1262	303	15	39	598	311	28	7	219	17	15	2814

M1:113 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Postcricoid

## T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	34	3	0	0	2	2	0	0	3	2	0	46
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	57(1)	13	1	1	14	18	1	0	5(1)	0	0	110
T3	23	9	1	0	13	13(2)	0	0	4	0	0	63
T4	0	0	1	0	0	0	0	0	0	0	0	1
T4a	5	3	0	0	6(1)	11(4)	0	0	3(1)	0	0	28
T4b	0	0	0	0	0	0	0	0	2	0	0	2
Tis	7	0	0	0	0	0	0	0	0	0	0	7
TX	0	0	0	0	0	0	0	0	0	1(1)	0	1
T-	0	0	0	0	0	0	0	0	0	0	0	0
Total	126	28	3	1	35	44	1	0	17	3	2	260

M1:11 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Pyramiform sinus

### T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	2	0	0	0	0	0	0	0	0	0	0	2
T1	281(1)	20	1	6	32(3)	3(1)	4(1)	0	19(2)	2	0	368
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	306(1)	103(2)	5	12(1)	132(4)	35(2)	4	3	40(6)	3	0	643
T3	76	46(1)	1	4	120(7)	51(5)	8(1)	2	35(5)	0	0	343
T4	4	4	1	0	6	0	1	0	1	1(1)	0	18
T4a	64(3)	45(2)	0	9(1)	195(7)	79(8)	6(1)	1	52(6)	0	0	451
T4b	5(1)	0	0	0	14(1)	4	1	0	14(3)	0	0	38
Tis	115	0	0	0	0	0	0	0	1	2	0	118
TX	1	1	0	0	2	0	0	0	1	1	0	6
T-	0	0	0	0	1	0	0	0	0	0	9	10
<b>Total</b>	<b>854</b>	<b>219</b>	<b>8</b>	<b>31</b>	<b>502</b>	<b>172</b>	<b>24</b>	<b>6</b>	<b>163</b>	<b>9</b>	<b>9</b>	<b>1997</b>

M1:77 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Posterior wall

### T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	2	0	0	0	0	0	0	0	0	0	0	2
T1	79	2	0	1	3(1)	6	0	0	2	1	0	94
T1a	1	0	0	0	0	0	0	0	0	0	0	1
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	82(1)	24(1)	0	0	15(1)	13(1)	0	0	10	0	0	144
T3	27	13	0	0	11(1)	29	0	0	10(1)	0	0	90
T4	0	0	0	0	0	0	1	0	0	0	0	1
T4a	5	5	0	0	8(1)	19(1)	0	0	5	0	0	42
T4b	2	2(1)	1	1	2(1)	8(2)	0	0	3(1)	0	0	19
Tis	26	0	0	0	0	0	0	0	0	0	0	26
TX	0	0	0	0	0	0	1	0	0	1	0	2
T-	0	0	0	0	0	0	0	0	0	0	1	1
<b>Total</b>	<b>224</b>	<b>46</b>	<b>1</b>	<b>2</b>	<b>39</b>	<b>75</b>	<b>2</b>	<b>0</b>	<b>30</b>	<b>2</b>	<b>1</b>	<b>422</b>

M1:14 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Hypopharynx, NOS

### T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	16	1	0	0	3	1	0	0	0	0	0	21
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	18	4	0	1	4	1	0	1	4	0	0	33
T3	10	1	0	1	8	3	0	0	1	1	0	25
T4	0	1	1	1	0	0	0	0	0	0	0	3
T4a	9	3	1	2	6	14	1	0	4	0	0	40
T4b	1	0	1	0	1	1	0	0	0	0	0	4
Tis	4	0	0	0	0	0	0	0	0	0	0	4
TX	0	0	0	0	0	0	0	0	0	2	1	3
T-	0	0	0	0	0	0	0	0	0	0	2	2
Total	58	10	3	5	22	20	1	1	9	3	3	135

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

### Treatment Method for the Primary Lesion by Subsite

Treatment Method	Postcricoid (C13.0)	Pyriiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
Surgery					
without	147	1009	186	64	1406
with	100	934	218	65	1317
unknown	11	43	17	5	76
Radiotherapy					
without	83	798	182	53	1116
with	164	1145	222	76	1607
unknown	11	43	17	5	76
Chemotherapy					
without	111	982	200	60	1353
with	136	961	204	69	1370
unknown	11	43	17	5	76
Total	258	1986	421	134	2799

Treatment Method for the Primary Lesion by Subsite was not reported 15 patients.

NOS: not otherwise specified.

### Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Posterioricoid (C13.0)	Pyriiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
Surgery					
without	175	1320	292	78	1865
with	72	616	111	51	850
unknown	12	52	18	6	88
Radiotherapy					
without	114	993	223	68	1398
with	133	943	180	61	1317
unknown	12	52	18	6	88
Chemotherapy					
without	133	1101	234	66	1534
with	114	835	169	63	1181
unknown	12	52	18	6	88
<b>Total</b>	<b>259</b>	<b>1988</b>	<b>421</b>	<b>135</b>	<b>2803</b>

Treatment Method for the Cervical Lymph Node by Subsite was not reported in 11 patients.

NOS: not otherwise specified.

Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Posterior wall (C13.0)	Pyriiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
No treatment	11	64	5	9	89
A) Surg. alone	57	588	152	32	829
F)(Rad.+Chem.)	77	470	95	28	670
B) Rad. alone	26	223	33	15	297
C)F) Chem. -> (Rad.+Chem.)	13	113	30	4	160
A)F) Surg.->(Rad.+Chem.)	11	84	20	11	126
A)B) Surg.->Rad.	14	96	11	5	126
C) Chem. alone	10	61	12	3	86
C)A) Chem.->Surg.	3	51	10	6	70
F)C)(Rad.+Chem.)->Chem.	6	22	3	0	31
C)A)F) Chem.->Surg.->(Rad.+Chem.)	1	24	5	0	30
F)A)(Rad.+Chem.)->Surg.	0	16	3	2	21
C)B) Chem.->Rad.	2	13	2	3	20
C)A)B) Chem.->Surg.->Rad.	2	11	4	1	18
C)C) Chem.->Chem.	1	11	2	1	15
C)C)F) Chem.->Chem.->(Rad.+Chem.)	0	9	2	0	11
C)F)C) Chem.-> (Rad.+Chem.)->Chem.	0	10	1	0	11
G)Surg.+Rad.+Chem.	2	6	3	0	11
A)A) Surg.->Surg.	0	9	1	0	10
A)C) Surg. -> Chem	0	5	2	2	9
A)B)C) Surg.->Rad.->Chem.	3	2	1	0	6
C)A)C) Chem.->Surg.->Chem.	0	6	0	0	6
D)(Surg.+Rad.)	1	4	1	0	6
B)C) Rad.->Chem.	0	3	2	0	5
Other	7	42	4	7	60
Unknown	11	43	17	5	76
Total	258	1986	421	134	2799

Sequence of treatment method by Subsite was not reported in 15 patients.

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

### Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	1	167	1	0	639	287	16	234	45	10	6	0	1406
with	3	346	0	0	263	223	7	310	15	142	6	2	1317
unknown	0	11	0	0	20	9	0	17	3	3	0	13	76
Radiotherapy													
without	3	332	0	0	234	178	9	192	21	140	6	1	1116
with	1	181	1	0	668	332	14	352	39	12	6	1	1607
unknown	0	11	0	0	20	9	0	17	3	3	0	13	76
Chemotherapy													
without	3	398	1	0	371	187	9	218	12	144	10	0	1353
with	1	115	0	0	531	323	14	326	48	8	2	2	1370
unknown	0	11	0	0	20	9	0	17	3	3	0	13	76
<b>Total</b>	<b>4</b>	<b>524</b>	<b>1</b>	<b>0</b>	<b>922</b>	<b>519</b>	<b>23</b>	<b>561</b>	<b>63</b>	<b>155</b>	<b>12</b>	<b>15</b>	<b>2799</b>

T-: without reported T classification

Treatment Method for the Primary Lesion by T Classification was not reported in 15 patients.

## Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	7	0	0	19	19	2	33	5	1	3	0	89
A) Surg. alone	3	301	0	0	172	101	4	107	2	136	3	0	829
F)(Rad.+Chem.)	0	58	0	0	373	133	6	82	13	5	0	0	670
B) Rad. alone	0	72	1	0	147	35	3	27	4	4	3	1	297
C)F) Chem. -> (Rad.+Chem.)	0	11	0	0	52	51	0	38	8	0	0	0	160
A)F) Surg.->(Rad.+Chem.)	0	12	0	0	17	33	1	58	3	1	1	0	126
A)B) Surg.->Rad.	0	15	0	0	27	30	0	51	1	1	1	0	126
C) Chem. alone	0	10	0	0	22	32	1	16	5	0	0	0	86
C)A) Chem.->Surg.	0	8	0	0	9	21	0	25	5	1	0	1	70
F)C)(Rad.+Chem.)->Chem.	1	1	0	0	10	8	0	10	1	0	0	0	31
C)A)F) Chem.->Surg.->(Rad.+Chem.)	0	0	0	0	1	10	0	18	1	0	0	0	30
F)A)(Rad.+Chem.)->Surg.	0	0	0	0	11	5	0	5	0	0	0	0	21
C)B) Chem.->Rad.	0	3	0	0	5	2	1	7	2	0	0	0	20
C)A)B) Chem.->Surg.->Rad.	0	0	0	0	2	3	0	13	0	0	0	0	18
C)C) Chem.->Chem.	0	1	0	0	5	4	0	4	1	0	0	0	15
C)C)F) Chem.->Chem.->(Rad.+Chem.)	0	0	0	0	4	2	0	5	0	0	0	0	11
C)F)C) Chem.-> (Rad.+Chem.)->Chem.	0	2	0	0	2	0	0	7	0	0	0	0	11
G)Surg.+Rad.+Chem.	0	0	0	0	1	2	0	8	0	0	0	0	11
A)A) Surg.->Surg.	0	4	0	0	3	1	0	0	0	2	0	0	10
Other	0	8	0	0	20	18	5	30	9	1	1	0	92
Unknown	0	11	0	0	20	9	0	17	3	3	0	13	76
<b>Total</b>	<b>4</b>	<b>524</b>	<b>1</b>	<b>0</b>	<b>922</b>	<b>519</b>	<b>23</b>	<b>561</b>	<b>63</b>	<b>155</b>	<b>12</b>	<b>15</b>	<b>2799</b>

T-: without reported T classification

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in 15 patients.

## Postcricoid

### Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	0	16	0	0	80	34	1	13	2	0	1	0	147
with	0	27	0	0	26	29	0	12	0	6	0	0	100
unknown	0	1	0	0	4	0	0	3	0	1	0	2	11
Radiotherapy													
without	0	22	0	0	20	27	0	7	0	6	1	0	83
with	0	21	0	0	86	36	1	18	2	0	0	0	164
unknown	0	1	0	0	4	0	0	3	0	1	0	2	11
Chemotherapy													
without	0	31	0	0	36	28	0	8	1	6	1	0	111
with	0	12	0	0	70	35	1	17	1	0	0	0	136
unknown	0	1	0	0	4	0	0	3	0	1	0	2	11
<b>Total</b>	<b>0</b>	<b>44</b>	<b>0</b>	<b>0</b>	<b>110</b>	<b>63</b>	<b>1</b>	<b>28</b>	<b>2</b>	<b>7</b>	<b>1</b>	<b>2</b>	<b>258</b>

T-: without reported T classification

Treatment Method for the Primary Lesion by T Classification was not reported in 2 patients.

## Postcricoid

### Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	1	0	0	2	5	0	2	0	0	1	0	11
F)(Rad.+Chem.)	0	6	0	0	50	17	0	4	0	0	0	0	77
A) Surg. alone	0	20	0	0	15	13	0	3	0	6	0	0	57
B) Rad. alone	0	8	0	0	14	2	0	1	1	0	0	0	26
A)B) Surg.->Rad.	0	2	0	0	4	6	0	2	0	0	0	0	14
C)F) Chem. -> (Rad.+Chem.)	0	1	0	0	8	4	0	0	0	0	0	0	13
A)F) Surg.->(Rad.+Chem.)	0	4	0	0	1	3	0	3	0	0	0	0	11
C) Chem. alone	0	0	0	0	2	7	0	1	0	0	0	0	10
F)(Rad.+Chem.) -> C) Chem. alone	0	0	0	0	3	0	0	3	0	0	0	0	6
Other	0	1	0	0	7	6	1	6	1	0	0	0	22
Unknown	0	1	0	0	4	0	0	3	0	1	0	2	11
<b>Total</b>	<b>0</b>	<b>44</b>	<b>0</b>	<b>0</b>	<b>110</b>	<b>63</b>	<b>1</b>	<b>28</b>	<b>2</b>	<b>7</b>	<b>1</b>	<b>2</b>	<b>258</b>

T-: without reported T classification

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in 2 patients.

## Pyriiform sinus

### Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
<b>Surgery</b>													
without	1	123	0	0	449	201	11	185	29	6	4	0	1009
with	1	234	0	0	179	133	7	257	9	110	2	2	934
unknown	0	8	0	0	9	7	0	9	0	2	0	8	43
<b>Radiotherapy</b>													
without	1	227	0	0	165	111	8	162	11	109	3	1	798
with	1	130	0	0	463	223	10	280	27	7	3	1	1145
unknown	0	8	0	0	9	7	0	9	0	2	0	8	43
<b>Chemotherapy</b>													
without	1	277	0	0	265	117	8	187	10	112	5	0	982
with	1	80	0	0	363	217	10	255	28	4	1	2	961
unknown	0	8	0	0	9	7	0	9	0	2	0	8	43
<b>Total</b>	<b>2</b>	<b>365</b>	<b>0</b>	<b>0</b>	<b>637</b>	<b>341</b>	<b>18</b>	<b>451</b>	<b>38</b>	<b>118</b>	<b>6</b>	<b>10</b>	<b>1986</b>

T-: without reported T classification

Treatment Method for the Primary Lesion by T Classification was not reported in 11 patients.

## Pyriiform sinus

## Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	5	0	0	14	9	1	27	5	1	2	0	64
A) Surg. alone	1	203	0	0	117	64	4	92	1	105	1	0	588
F)(Rad.+Chem.)	0	42	0	0	255	93	4	65	8	3	0	0	470
B) Rad. alone	0	54	0	0	111	24	3	23	3	2	2	1	223
C)F) Chem. -> (Rad.+Chem.)	0	6	0	0	32	41	0	30	4	0	0	0	113
A)B) Surg.->Rad.	0	11	0	0	19	18	0	46	1	1	0	0	96
A)F) Surg.->(Rad.+Chem.)	0	8	0	0	12	12	1	47	2	1	1	0	84
C) Chem. alone	0	8	0	0	18	21	1	12	1	0	0	0	61
C)A) Chem.->Surg.	0	7	0	0	6	12	0	22	3	0	0	1	51
C)A)F) Chem.->Surg.->(Rad.+Chem.)	0	0	0	0	0	9	0	14	1	0	0	0	24
F)C)(Rad.+Chem.)->Chem.	1	1	0	0	6	6	0	7	1	0	0	0	22
F)A)(Rad.+Chem.)->Surg.	0	0	0	0	8	5	0	3	0	0	0	0	16
C)B) Chem.->Rad.	0	3	0	0	3	0	0	5	2	0	0	0	13
C)A)B) Chem.->Surg.->Rad.	0	0	0	0	1	2	0	8	0	0	0	0	11
C)C) Chem.->Chem.	0	0	0	0	4	4	0	2	1	0	0	0	11
C)F)C) Chem.-> (Rad.+Chem.)->Chem.	0	2	0	0	1	0	0	7	0	0	0	0	10
A)A) Surg.->Surg.	0	4	0	0	2	1	0	0	0	2	0	0	9
C)C)F) Chem.->Chem.->(Rad.+Chem.)	0	0	0	0	3	1	0	5	0	0	0	0	9
Other	0	3	0	0	16	12	4	27	5	1	0	0	68
Unknown	0	8	0	0	9	7	0	9	0	2	0	8	43
<b>Total</b>	<b>2</b>	<b>365</b>	<b>0</b>	<b>0</b>	<b>637</b>	<b>341</b>	<b>18</b>	<b>451</b>	<b>38</b>	<b>118</b>	<b>6</b>	<b>10</b>	<b>1986</b>

T-: without reported T classification

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in 11 patients.

## Posterior wall

### Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	0	21	1	0	86	44	1	16	13	4	0	0	186
with	2	71	0	0	50	44	0	23	4	22	2	0	218
unknown	0	2	0	0	7	2	0	3	2	0	0	1	17
Radiotherapy													
without	2	70	0	0	44	27	0	11	7	21	0	0	182
with	0	22	1	0	92	61	1	28	10	5	2	0	222
unknown	0	2	0	0	7	2	0	3	2	0	0	1	17
Chemotherapy													
without	2	75	1	0	56	31	0	11	1	22	1	0	200
with	0	17	0	0	80	57	1	28	16	4	1	0	204
unknown	0	2	0	0	7	2	0	3	2	0	0	1	17
<b>Total</b>	<b>2</b>	<b>94</b>	<b>1</b>	<b>0</b>	<b>143</b>	<b>90</b>	<b>1</b>	<b>42</b>	<b>19</b>	<b>26</b>	<b>2</b>	<b>1</b>	<b>421</b>

T-: without reported T classification

Treatment Method for the Primary Lesion by T Classification was not reported in one patient.

## Posterior wall

### Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	0	0	0	2	2	0	1	0	0	0	0	5
A) Surg. alone	2	67	0	0	37	17	0	7	1	21	0	0	152
F)(Rad.+Chem.)	0	7	0	0	53	19	1	8	5	2	0	0	95
B) Rad. alone	0	6	1	0	14	9	0	1	0	2	0	0	33
C)F) Chem. -> (Rad.+Chem.)	0	4	0	0	12	6	0	4	4	0	0	0	30
A)F) Surg.->(Rad.+Chem.)	0	0	0	0	3	13	0	3	1	0	0	0	20
C) Chem. alone	0	1	0	0	2	4	0	1	4	0	0	0	12
A)B) Surg.->Rad.	0	2	0	0	2	5	0	1	0	0	1	0	11
C)A) Chem.->Surg.	0	1	0	0	1	5	0	1	1	1	0	0	10
C)A)F) Chem.->Surg.->(Rad.+Chem.)	0	0	0	0	1	0	0	4	0	0	0	0	5
Other	0	4	0	0	9	8	0	8	1	0	1	0	31
Unknown	0	2	0	0	7	2	0	3	2	0	0	1	17
<b>Total</b>	<b>2</b>	<b>94</b>	<b>1</b>	<b>0</b>	<b>143</b>	<b>90</b>	<b>1</b>	<b>42</b>	<b>19</b>	<b>26</b>	<b>2</b>	<b>1</b>	<b>421</b>

T-: without reported T classification

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in one patient.

## Hypopharynx,NOS

### Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	0	7	0	0	24	8	3	20	1	0	1	0	64
with	0	14	0	0	8	17	0	18	2	4	2	0	65
unknown	0	0	0	0	0	0	0	2	1	0	0	2	5
Radiotherapy													
without	0	13	0	0	5	13	1	12	3	4	2	0	53
with	0	8	0	0	27	12	2	26	0	0	1	0	76
unknown	0	0	0	0	0	0	0	2	1	0	0	2	5
Chemotherapy													
without	0	15	0	0	14	11	1	12	0	4	3	0	60
with	0	6	0	0	18	14	2	26	3	0	0	0	69
unknown	0	0	0	0	0	0	0	2	1	0	0	2	5
<b>Total</b>	<b>0</b>	<b>21</b>	<b>0</b>	<b>0</b>	<b>32</b>	<b>25</b>	<b>3</b>	<b>40</b>	<b>4</b>	<b>4</b>	<b>3</b>	<b>2</b>	<b>134</b>

NOS: not otherwise specified.

T-: without reported T classification

Treatment Method for the Primary Lesion by T Classification was not reported in one patient.

## Hypopharynx,NOS

### Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	1	0	0	1	3	1	3	0	0	0	0	9
A) Surg. alone	0	11	0	0	3	7	0	5	0	4	2	0	32
F)(Rad.+Chem.)	0	3	0	0	15	4	1	5	0	0	0	0	28
B) Rad. alone	0	4	0	0	8	0	0	2	0	0	1	0	15
A)F) Surg.->(Rad.+Chem.)	0	1	0	0	1	5	0	5	0	0	0	0	12
C)A) Chem.->Surg.	0	0	0	0	1	2	0	2	1	0	0	0	6
A)B) Surg.->Rad.	0	0	0	0	2	1	0	2	0	0	0	0	5
C)F) Chem. -> (Rad.+Chem.)	0	0	0	0	0	0	0	4	0	0	0	0	4
Other	0	1	0	0	1	3	1	10	2	0	0	0	18
Unknown	0	0	0	0	0	0	0	2	1	0	0	2	5
<b>Total</b>	<b>0</b>	<b>21</b>	<b>0</b>	<b>0</b>	<b>32</b>	<b>25</b>	<b>3</b>	<b>40</b>	<b>4</b>	<b>4</b>	<b>3</b>	<b>2</b>	<b>134</b>

NOS: not otherwise specified.

T-: without reported T classification

Sequence of Treatment Method for the Primary Lesion by T Classification was not reported in one patient.

### Surgical Methods for the Primary Lesion by Subsite

Surgical method		Postericoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
X0	No surgery	146	1009	187	59	1401
F5	Total pharyngolaryngectomy	30	284	53	20	387
F2/G2	Transoral resection	20	213	65	4	299
F1	Endoscopic resection	18	200	57	14	289
F6	Total pharyngolaryngo-esophagectomy	14	127	20	14	175
F4	Total laryngectomy+Partial pharyngectomy	3	33	0	1	37
F3	Partial hypopharyngectomy	2	22	9	1	34
F7	Hypopharyngectomy + Cervical esophagec + Others	3 8	11 32	3 12	4 2	21 54
V9	Unknown	15	66	19	11	111
Total		259	1997	422	130	2808

NOS: not otherwise specified.

Surgical Method for the Primary Lesion by Subsite was not reported in 6 patients.

## Surgical Methods for the Primary Lesion by T Classification

Surgical method		T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
X0	No surgery	1	169	1	0	637	287	16	231	43	10	6	0	1401
F5	Total pharyngolaryngectomy	0	1	0	0	60	122	2	192	8	1	1	0	387
F2/G2	Transoral resection	1	144	0	0	86	9	0	0	0	57	2	0	299
F1	Endoscopic resection	2	174	0	0	41	0	0	0	0	71	1	0	289
F6	Total pharyngolaryngo-esophagectomy	0	3	0	0	19	51	4	92	5	0	0	1	175
F4	Total laryngectomy+Partial pharyngectomy	0	2	0	0	10	11	1	13	0	0	0	0	37
F3	Partial hypopharyngectomy	0	7	0	0	21	3	0	2	0	0	1	0	34
F7	Hypopharyngectomy + Cervical esophagec	0	0	0	0	5	8	0	6	2	0	0	0	21
	+Others	0	12	0	0	13	14	0	1	0	13	1	0	54
V9	Unknown	0	15	0	0	37	15	0	23	4	3	0	14	111
Total		4	527	1	0	929	520	23	560	62	155	12	15	2808

T-: without reported T classification

Surgical Method for the Primary Lesion by T Classification was not reported in 6 patients.

## Postcricoid

### Surgical Methods for the Primary Lesion by T Classification

Surgical method		T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
X0	No surgery	0	17	0	0	79	33	1	13	2	0	1	0	146
F5	Total pharyngolaryngectomy	0	0	0	0	11	13	0	6	0	0	0	0	30
F1/G1	Endoscopic resection	0	12	0	0	3	0	0	0	0	5	0	0	20
F2	Transoral resection	0	12	0	0	5	2	0	0	0	1	0	0	20
V9	Unknown	0	2	0	0	5	2	0	3	0	1	0	2	15
F6	Total pharyngolaryngo-esophagectomy	0	0	0	0	3	7	0	4	0	0	0	0	14
G5	Total laryngectomy	0	0	0	0	1	3	0	0	0	0	0	0	4
F4	Total laryngectomy+Partial pharyngectomy	0	0	0	0	0	3	0	0	0	0	0	0	3
F7	Hypopharyngectomy + Cervical esophagec	0	0	0	0	1	0	0	2	0	0	0	0	3
F3	Partial hypopharyngectomy	0	1	0	0	1	0	0	0	0	0	0	0	2
	+Others	0	1	0	0	1	0	0	0	0	0	0	0	2
V9	Unknown	0	2	0	0	5	2	0	3	0	1	0	2	15
Total		0	45	0	0	110	63	1	28	2	7	1	2	259

T-: without reported T classification

Surgical Method for the Primary Lesion by T Classification was not reported in one patient.

## Pyriiform sinus

### Surgical Methods for the Primary Lesion by T Classification

Surgical method		T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
X0	No surgery	1	125	0	0	448	202	11	184	28	6	4	0	1009
F5	Total pharyngolaryngectomy	0	1	0	0	38	74	2	164	5	0	0	0	284
F2/G2	Transoral resection	1	96	0	0	64	5	0	0	0	46	1	0	213
F1/G1	Endoscopic resection	0	120	0	0	30	0	0	0	0	62	0	0	212
F6	Total pharyngolaryngo-esophagectomy	0	3	0	0	12	32	4	73	2	0	0	1	127
F4	Total laryngectomy+Partial pharyngectomy	0	2	0	0	10	8	1	12	0	0	0	0	33
F3	Partial hypopharyngectomy	0	5	0	0	12	2	0	2	0	0	1	0	22
F7	Hypopharyngectomy + Cervical esophagec	0	0	0	0	3	3	0	3	2	0	0	0	11
G5	Total laryngectomy	0	2	0	0	2	3	0	0	0	0	0	0	7
E8	Resection of the soft palate	0	0	0	0	1	0	0	0	0	0	0	0	1
G9	Laryngectomy, other type	0	1	0	0	0	0	0	0	0	0	0	0	1
	+Others	0	4	0	0	1	4	0	0	0	2	0	0	11
V9	Unknown	0	9	0	0	22	10	0	13	1	2	0	9	66
	<b>Total</b>	<b>2</b>	<b>368</b>	<b>0</b>	<b>0</b>	<b>643</b>	<b>343</b>	<b>18</b>	<b>451</b>	<b>38</b>	<b>118</b>	<b>6</b>	<b>10</b>	<b>1997</b>

T-: without reported T classification

## Posterior wall

### Surgical Methods for the Primary Lesion by T Classification

Surgical method		T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
X0	No surgery	0	21	1	0	87	44	1	16	13	4	0	0	187
F2/G2	Transoral resection	0	34	0	0	17	2	0	0	0	9	0	0	62
F1/G1	Endoscopic resection	2	34	0	0	10	0	0	0	0	12	0	0	58
F5	Total pharyngolaryngectomy	0	0	0	0	9	26	0	14	2	1	1	0	53
F6	Total pharyngolaryngo-esophagectomy	0	0	0	0	3	7	0	8	2	0	0	0	20
F3	Partial hypopharyngectomy	0	1	0	0	7	1	0	0	0	0	0	0	9
F7	Hypopharyngectomy + Cervical esophagec	0	0	0	0	0	3	0	0	0	0	0	0	3
E5	Unilateral resection of the lateral wall of the oropharynx, soft palate and the base of tongue	0	0	0	0	0	0	0	1	0	0	0	0	1
E6	Resection of the posterior wall	0	1	0	0	0	0	0	0	0	0	0	0	1
G5	Total laryngectomy	0	0	0	0	0	1	0	0	0	0	0	0	1
	+Others	0	1	0	0	3	3	0	0	0	0	1	0	8
V9	Unknown	0	2	0	0	8	3	0	3	2	0	0	1	19
Total		2	94	1	0	144	90	1	42	19	26	2	1	422

T-: without reported T classification

## Hypopharynx,NOS

### Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
X0 No surgery	0	6	0	0	23	8	3	18	0	0	1	0	59
F5 Total pharyngolaryngectomy	0	0	0	0	2	9	0	8	1	0	0	0	20
F1 Endoscopic resection	0	9	0	0	1	0	0	0	0	3	1	0	14
F6 Total pharyngolaryngo-esophagectomy	0	0	0	0	1	5	0	7	1	0	0	0	14
F2 Transoral resection	0	2	0	0	0	0	0	0	0	1	1	0	4
F7 Hypopharyngectomy + Cervical esophagec	0	0	0	0	1	2	0	1	0	0	0	0	4
E1 Resection of the root of tongue 0	0	0	0	0	1	0	0	0	0	0	0	0	1
F3 Partial hypopharyngectomy	0	0	0	0	1	0	0	0	0	0	0	0	1
F4 Total laryngectomy+Partial pharyngectomy	0	0	0	0	0	0	0	1	0	0	0	0	1
X9 Others	0	1	0	0	0	0	0	0	0	0	0	0	1
V9 Unknown	0	2	0	0	2	0	0	4	1	0	0	2	11
Total	0	20	0	0	32	24	3	39	3	4	3	2	130

NOS: not otherwise specified.

T-: without reported T classification

Surgical Method for the Primary Lesion by T Classification was not reported in 5 patients.

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Postericoid (C13.0)	Pyriiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No N.D.	172	1318	293	79	1862
2) Selective N.D.	51	426	73	36	586
1) Total N.D.	22	179	33	9	243
3) Lymph node excision	1	0	0	0	1
8) Others	0	10	4	1	15
9) Unknown	14	64	19	10	107
<b>Total</b>	<b>260</b>	<b>1997</b>	<b>422</b>	<b>135</b>	<b>2814</b>

NOS: not otherwise specified.

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Postericoid (C13.0)	Pyriiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No N.D.	195	1508	316	87	2106
2) Selective N.D.	41	350	64	30	485
1) Total N.D.	9	66	19	7	101
3) Lymph node excision	1	0	0	0	1
8) Others	0	9	4	1	14
9) Unknown	14	64	19	10	107
<b>Total</b>	<b>260</b>	<b>1997</b>	<b>422</b>	<b>135</b>	<b>2814</b>

NOS: not otherwise specified.

N.D.: neck dissection.

Carcinoma of the Hypopharynx ----- 2814 Cases

## Reconstructive Surgery by Subsite

Reconstructive surgery	Postcricoid (C13.0)	Pyramiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0 ) No reconstruction	193	1469	314	80	2056
B ) Free jejunal flap	41	375	74	31	521
E ) Free ALT flap	0	26	4	4	34
5 ) PM MC flap	4	14	3	1	22
C ) Free FA flap	1	13	3	1	18
7 ) Gastric pull-up	3	9	2	1	15
2 ) Local skin flap	0	2	0	0	2
3 ) Mucosal flap	1	1	0	0	2
1 ) Skin graft	0	1	0	0	1
4 ) DP flap	0	1	0	0	1
D ) Free RA MC flap	0	1	0	0	1
F ) Free scapular OC flap	0	0	0	0	0
G ) Free fibular OC flap	0	0	0	0	0
I ) Free nerve graft	0	0	0	0	0
NA ) Others	1	15	2	0	18
9 ) Unknown	16	69	20	12	117
<b>Total</b>	<b>260</b>	<b>1996</b>	<b>422</b>	<b>130</b>	<b>2808</b>

RA: rectus abdominis. MC: musculocutaneous. ALT: anterolateral thigh. FA: forearm.

PM: pectoralis major. OC: osteocutaneous. DP: deltopectoral.

NOS: not otherwise specified.

Reconstructive Surgery by Subsite was not reported in 6 patients.

## Radiotherapy by Subsite

Type of radiotherapy	Posterioricoid (C13.0)	Pyriiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No radiotherapy	75	759	180	47	1061
1) X-ray (and/or electron beam)	171	1174	222	78	1645
2) Particle beam	0	1	0	0	1
3) B.T.	0	0	0	0	0
4) X-ray + Particle beam	0	0	0	0	0
5) X-ray + B.T.	0	0	0	0	0
6) Particl beam + B.T.	0	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0	0
8) Others	0	0	0	0	0
9) Unknown	14	63	20	10	107
Total	260	1997	422	135	2814

NOS: not otherwise specified.

## Chemotherapy by Subsite

Route of administration	Posterioricoid (C13.0)	Pyriiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No chemotherapy	109	971	201	62	1343
1) I.V.	133	925	186	67	1311
3) Oral	4	30	7	1	42
5) I.V.+Oral	2	12	4	0	18
2) I.A.	0	7	2	0	9
4) I.V.+I.A.	0	3	0	0	3
6) I.A.+Oral	0	1	0	0	1
7) I.V.+I.A.+Oral	0	0	0	0	0
8) Others	0	0	1	0	1
9) Unknown	12	48	21	5	86
Total	260	1997	422	135	2814

NOS: not otherwise specified.

# Oropharynx(2018)

2273 Cases

## Primary Site

Site	Number of patients	(%)
Superior wall	205	(9.0)
Lateral wall	1354	(59.6)
Posterior wall	164	(7.2)
Anterior wall	491	(21.6)
Oropharynx,NOS	59	(2.6)
<b>Total</b>	<b>2273</b>	<b>(100)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	1	1
10 - 19	0	1	1
20 - 29	0	0	0
30 - 39	9	9	18
40 - 49	126	42	168
50 - 59	326	90	416
60 - 69	665	126	791
70 - 79	572	101	673
80 - 89	163	33	196
90 - 99	8	1	9
100 - 109	0	0	0
<b>Total</b>	<b>1869</b>	<b>404</b>	<b>2273</b>

## p16 status

	<b>Total</b>
p16 positive	1138
p16 negative	775
p16 unknown	311
not reported	49
<b>Total</b>	<b>2273</b>

Oropharynx p16 positive(2018)

1138 Cases

## Primary Site

Site	Number of patients	(%)
Superiorwall	25	(2.2)
Lateralwall	880	(77.3)
Posteriorwall	17	(1.5)
Anteriorwall	191	(16.8)
OropharynxNOS	25	(2.2)
<b>Total</b>	<b>1138</b>	<b>(100.0)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	7	3	10
40 - 49	96	21	117
50 - 59	219	52	271
60 - 69	297	75	372
70 - 79	235	55	290
80 - 89	58	15	73
90 - 99	5	0	5
100 - 109	0	0	0
<b>Total</b>	<b>917</b>	<b>221</b>	<b>1138</b>

Carcinoma of the Oropharynx p16 positive ----- 1138Cases

## Histological Distribution by Subsite

Histologic type	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
S.C.C., NOS	24	846	17	187	24	1098
S.C.C., keratinizing, NOS	0	12	0	1	0	13
S.C.C., large cell, nonkerat., NOS	0	9	0	2	0	11
Papillary S.C.C.	0	4	0	0	0	4
Basaloid S.C.C.	0	2	0	0	1	3
S.C.C. in situ, NOS	1	1	0	0	0	2
S.C.C., spindle cell	0	2	0	0	0	2
Adenoid cystic ca.	0	0	0	1	0	1
Small cell ca., NOS	0	1	0	0	0	1
S.C.C., microinvasive	0	1	0	0	0	1
Ca., NOS	0	1	0	0	0	1
Adenocarcinoma, NOS	0	1	0	0	0	1
<b>Total</b>	<b>25</b>	<b>880</b>	<b>17</b>	<b>191</b>	<b>25</b>	<b>1138</b>

NOS: not otherwise specified.  
malig., Malig.: malignant.

S.C.C.: squamous cell carcinoma.  
kerat.: keratinizing.

ca., Ca.: carcinoma.  
nonkerat.: nonkeratinizing.

## T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	57	138(3)	21(1)	0	1	0	13	0	0	2	1	233
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	101	321(3)	78(3)	0	2	0	18(4)	0	0	1	2	523
T3	32	91(1)	43(1)	0	1	0	8	0	0	0	0	175
T4	20	63(1)	94(11)	0	0	0	21(4)	0	0	0	0	198
T4a	0	1	0	0	0	0	0	0	0	0	0	1
T4b	0	0	0	0	0	1	0	0	0	0	0	1
Tis	0	3	0	0	0	0	0	0	0	0	0	3
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	1	0	0	0	0	0	0	0	0	3	4
<b>Total</b>	<b>210</b>	<b>618</b>	<b>236</b>	<b>0</b>	<b>4</b>	<b>1</b>	<b>60</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>6</b>	<b>1138</b>

M1:32 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
Surgery						
without	18	583	11	146	12	770
with	7	288	6	38	11	350
unknown	0	7	0	2	1	10
Radiotherapy						
without	7	210	6	35	7	265
with	18	661	11	149	16	855
unknown	0	7	0	2	1	10
Chemotherapy						
without	14	280	7	51	8	360
with	11	591	10	133	15	760
unknown	0	7	0	2	1	10
<b>Total</b>	<b>25</b>	<b>878</b>	<b>17</b>	<b>186</b>	<b>24</b>	<b>1130</b>

Treatment Method for the Primary Lesion by Subsite was not reported in 8 patients.

### Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
Surgery						
without	20	614	15	151	13	813
with	5	255	2	38	11	311
unknown	0	9	0	2	1	12
Radiotherapy						
without	11	251	8	47	8	325
with	14	618	9	142	16	799
unknown	0	9	0	2	1	12
Chemotherapy						
without	17	313	8	61	10	409
with	8	556	9	128	14	715
unknown	0	9	0	2	1	12
<b>Total</b>	<b>25</b>	<b>878</b>	<b>17</b>	<b>191</b>	<b>25</b>	<b>1136</b>

Treatment Method for the Cervical Lymph Nodes by Subsite was not reported in 2 patients.

### Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No treatment	0	8	0	1	0	9
F)(Rad.+Chem.)	8	394	5	96	11	514
A) Surg. alone	6	152	4	24	8	194
B) Rad. alone	8	78	3	22	0	111
C)F) Chem. -> (Rad.+Chem.)	2	55	2	18	1	78
A)F) Surg.->(Rad.+Chem.)	0	45	1	0	2	48
A)B) Surg.->Rad.	0	36	0	4	1	41
C)A) Chem.->Surg.	0	19	1	4	0	24
C) Chem. alone	0	18	1	4	0	23
F)C)(Rad.+Chem.)->Chem.	0	12	0	3	0	15
C)B) Chem.->Rad.	0	7	0	1	0	8
A)C) Surg. -> Chem	1	4	0	1	0	6
Other	0	43	0	6	0	49
Unknown	0	7	0	2	1	10
<b>Total</b>	<b>25</b>	<b>878</b>	<b>17</b>	<b>186</b>	<b>24</b>	<b>1130</b>

Sequence of Treatment Method for the Primary Lesion by Subsite was not reported in 8 patients.

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

Carcinoma of the Oropharynx p16 positive ----- 1138Cases

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No surgery	16	572	11	147	13	759
Unilateral resection of the lateral wall of the oropharynx	0	214	0	0	5	219
Resection of the oropharynx, other type	0	31	2	2	2	37
Resection of the root of tongue 0	0	3	0	29	0	32
Unilateral resection of the lateral wall of the oropharynx and soft	1	16	0	0	0	17
Unilateral resection of the lateral wall of the oropharynx, soft palate and the base of tongue	0	7	0	0	1	8
Resection of the soft palate	5	2	0	0	0	7
Resection of the posterior wall	0	0	4	0	1	5
Others	1	7	0	6	2	16
Unknown	2	28	0	7	1	38
<b>Total</b>	<b>25</b>	<b>880</b>	<b>17</b>	<b>191</b>	<b>25</b>	<b>1138</b>

NOS: not otherwise specified.

### Reconstructive Surgery by Subsite

Reconststructive surgery	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0 ) No reconstruction	22	801	17	176	19	1035
E ) Free ALT flap	0	27	0	3	3	33
D ) Free RA MC flap	1	9	0	1	1	12
C ) Free FA flap	1	7	0	0	0	8
5 ) PM MC flap	0	3	0	3	0	6
2 ) Local skin flap	0	2	0	0	0	2
1 ) Skin graft	0	1	0	0	0	1
3 ) Mucosal flap	0	1	0	0	0	1
I ) Free nerve graft	0	0	0	0	1	1
4 ) DP flap	0	0	0	0	0	0
7 ) Gastric pull-up	0	0	0	0	0	0
B ) Free jejunal flap	0	0	0	0	0	0
F Free scapular OC flap	0	0	0	0	0	0
G ) Free fibular OC flap	0	0	0	0	0	0
N.) Others	0	8	0	1	0	9
9 ) Unknown	1	21	0	7	1	30
<b>Total</b>	<b>25</b>	<b>880</b>	<b>17</b>	<b>191</b>	<b>25</b>	<b>1138</b>

NOS: not otherwise specified.

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	19	614	15	148	13	809
2) Selective N.D.	4	172	2	21	6	205
1) Total N.D.	1	75	0	15	5	96
3) Lymph node excision	0	1	0	0	0	1
8) Others	0	0	0	1	0	1
9) Unknown	1	18	0	6	1	26
<b>Total</b>	<b>25</b>	<b>880</b>	<b>17</b>	<b>191</b>	<b>25</b>	<b>1138</b>

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	23	842	17	175	24	1081
2) Selective N.D.	0	18	0	8	0	26
1) Total N.D.	1	1	0	1	0	3
3) Lymph node excision	0	0	0	0	0	0
8) Others	0	1	0	1	0	2
9) Unknown	1	18	0	6	1	26
<b>Total</b>	<b>25</b>	<b>880</b>	<b>17</b>	<b>191</b>	<b>25</b>	<b>1138</b>

NOS: not otherwise specified.

N.D.: neck dissection.

### Radiotherapy by Subsite

Type of radiotherapy	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No radiotherapy	7	195	6	35	7	250
1) X-ray (and/or electron beam)	18	671	11	154	16	870
2) Particle beam	0	2	0	0	0	2
3) B.T.	0	0	0	0	0	0
4) X-ray + Particle beam	0	0	0	0	0	0
5) X-ray + B.T.	0	0	0	0	0	0
6) Particl beam + B.T.	0	0	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0	0	0
8) Others	0	0	0	0	0	0
9) Unknown	0	12	0	2	2	16
<b>Total</b>	<b>25</b>	<b>880</b>	<b>17</b>	<b>191</b>	<b>25</b>	<b>1138</b>

NOS: not otherwise specified.

B.T.: brachytherapy.

### Chemotherapy by Subsite

Route of administration	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No chemotherapy	14	271	6	52	10	353
1) I.V.	11	573	11	129	14	738
2) I.A.	0	12	0	5	0	17
3) Oral	0	11	0	1	0	12
4) I.V.+I.A.	0	0	0	0	0	0
5) I.V.+Oral	0	5	0	2	0	7
6) I.A.+Oral	0	0	0	0	0	0
7) I.V.+I.A.+Oral	0	0	0	0	0	0
8) Others	0	1	0	0	0	1
9) Unknown	0	7	0	2	1	10
<b>Total</b>	<b>25</b>	<b>880</b>	<b>17</b>	<b>191</b>	<b>25</b>	<b>1138</b>

I.V.: intravenous.

I.A.: intraarterial.

NOS: not otherwise specified.

Oropharynx p16 negative and unknown  
(2018)

1086 Cases

## Primary Site

Site	Number of patients	(%)
Superiorwall	173	(15.9)
Lateralwall	455	(41.9)
Posteriorwall	143	(13.2)
Anteriorwall	281	(25.9)
OropharynxNOS	34	(3.1)
<b>Total</b>	<b>1086</b>	<b>(100)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	1	1
10 - 19	0	1	1
20 - 29	0	0	0
30 - 39	1	5	6
40 - 49	28	21	49
50 - 59	103	34	137
60 - 69	352	48	400
70 - 79	331	44	375
80 - 89	96	17	113
90 - 99	3	1	4
100 - 109	0	0	0
<b>Total</b>	<b>914</b>	<b>172</b>	<b>1086</b>

## Histological Distribution by Subsite

Histologic type	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
S.C.C., NOS	142	391	121	231	33	918
S.C.C. in situ, NOS	6	17	13	4	0	40
S.C.C., keratinizing, NOS	6	12	3	9	0	30
Mucoepidermoid ca.	2	3	0	7	1	13
Adenoid cystic ca.	6	0	0	6	0	12
S.C.C., large cell, nonkerat., NOS	1	5	1	4	0	11
Malig. lymphoma, NOS	0	6	0	3	0	9
Ca., NOS	1	2	1	3	0	7
S.C.C., microinvasive	2	2	0	2	0	6
Papillary S.C.C.	2	1	0	1	0	4
Adenocarcinoma, NOS	1	1	0	2	0	4
Basaloid S.C.C.	0	1	1	1	0	3
Myoepithelial ca.	3	0	0	0	0	3
Neoplasm, malig.	0	2	0	1	0	3
Malig. melanoma, NOS	0	1	0	1	0	2
Basal cell ca., NOS	0	1	0	1	0	2
Clear cell ca., NOS	1	1	0	0	0	2
Polymorphous low grade adenocarcinoma	0	0	0	2	0	2
Small cell ca., NOS	0	0	1	0	0	1
Acinar cell ca.	0	1	0	0	0	1
Spindle cell ca., NOS	0	1	0	0	0	1
Lymphoepithelial ca.	0	1	0	0	0	1
Ca., undiff., NOS	0	1	0	0	0	1
Neuroendocrine ca., NOS	0	1	0	0	0	1
Leiomyosarcoma, NOS	0	0	1	0	0	1
Adenosquamous ca.	0	1	0	0	0	1
S.C.C., spindle cell	0	0	0	1	0	1
Carcinosarcoma, NOS	0	1	0	0	0	1
Plasmacytoma, extramedullary	0	0	0	1	0	1
Fibrosarcoma, NOS	0	1	0	0	0	1
Hemangiosarcoma	0	1	0	0	0	1
Alveolar soft part sarcoma	0	0	0	1	0	1
Glandular intraepithelial neoplasia, grade III	0	0	1	0	0	1
<b>Total</b>	<b>173</b>	<b>455</b>	<b>143</b>	<b>281</b>	<b>34</b>	<b>1086</b>

NOS: not otherwise specified.  
malig., Malig.: malignant.

S.C.C.: squamous cell carcinoma.  
kerat.: keratinizing.

ca., Ca.: carcinoma.  
nonkerat.: nonkeratinizing.

## T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	2	0	1	0	0	0	0	3
T1	172	17	2(1)	3	22(2)	7(1)	1	0	7	5	1	237
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	174(3)	63(1)	8(1)	5	61(3)	32(3)	2	1	20(3)	0	0	366
T3	58(1)	21	0	1	43(2)	30(5)	3(1)	0	16(3)	1	1	174
T4	4	5	7	0	0	3	1	0	1	0	0	21
T4a	41	14	2	0	47(2)	45(2)	2	2	19(2)	0	1(1)	173
T4b	3	0	0	0	8	15(2)	1	0	6(1)	0	0	33
Tis	46	0	0	0	0	0	0	0	0	0	0	46
TX	0	1	0	0	2	0	1(1)	0	2	8	1	15
T-	0	0	0	0	0	0	0	0	0	0	18	18
<b>Total</b>	<b>498</b>	<b>121</b>	<b>19</b>	<b>9</b>	<b>185</b>	<b>132</b>	<b>12</b>	<b>3</b>	<b>71</b>	<b>14</b>	<b>22</b>	<b>1086</b>

M1:41cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
Surgery						
without	65	257	67	147	18	554
with	104	191	73	126	15	509
unknown	3	6	3	4	1	17
Radiotherapy						
without	104	172	78	121	17	492
with	65	276	62	152	16	571
unknown	3	6	3	4	1	17
Chemotherapy						
without	124	193	82	140	14	553
with	45	255	58	133	19	510
unknown	3	6	3	4	1	17
<b>Total</b>	<b>172</b>	<b>454</b>	<b>143</b>	<b>277</b>	<b>34</b>	<b>1080</b>

Treatment Method for the Primary Lesion by Subsite was not reported in 6 patients.

### Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
Surgery						
without	148	321	121	186	25	801
with	21	121	18	91	8	259
unknown	3	7	4	4	1	19
Radiotherapy						
without	131	212	86	149	19	597
with	38	230	53	128	14	463
unknown	3	7	4	4	1	19
Chemotherapy						
without	133	224	86	160	16	619
with	36	218	53	117	17	441
unknown	3	7	4	4	1	19
<b>Total</b>	<b>172</b>	<b>449</b>	<b>143</b>	<b>281</b>	<b>34</b>	<b>1079</b>

Treatment Method for the Cervical Lymph Nodes by Subsite was not reported in 7 patients.

### Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No treatment	8	12	2	11	2	35
A) Surg. alone	85	117	66	79	12	359
F)(Rad.+Chem.)	24	136	38	61	7	266
B) Rad. alone	18	43	12	31	2	106
C) Chem. alone	6	21	6	19	3	55
C)F) Chem. -> (Rad.+Chem.)	7	24	5	14	0	50
A)B) Surg.->Rad.	9	20	2	13	0	44
A)F) Surg.->(Rad.+Chem.)	1	20	2	10	1	34
C)A) Chem.->Surg.	1	15	1	6	0	23
F)C)(Rad.+Chem.)->Chem.	0	7	1	3	0	11
C)B) Chem.->Rad.	2	5	1	2	0	10
A)C) Surg. -> Chem	2	2	1	1	0	6
C)C) Chem.->Chem.	0	1	2	2	1	6
A)A) Surg.->Surg.	0	2	0	3	0	5
C)F)A) Chem.-> (Rad.+Chem.)->Surg.	0	1	0	4	0	5
F)A)(Rad.+Chem.)->Surg.	0	3	0	1	1	5
Other	6	19	1	13	4	43
Unknown	3	6	3	4	1	17
<b>Total</b>	<b>172</b>	<b>454</b>	<b>143</b>	<b>277</b>	<b>34</b>	<b>1080</b>

Sequence of Treatment Method for the Primary Lesion by Subsite was not reported in 6 patients.

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

Carcinoma of the Oropharynx p16 negative and unknown ----- 1086Cases  
**Surgical Methods for the Primary Lesion by Subsite**

Surgical method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
X0 No surgery	64	257	64	150	16	551
E3 Unilateral resection of the lateral wall of the oropharynx	4	116	1	2	1	124
E1 Resection of the root of tongue 0	0	4	0	66	0	70
E8 Resection of the soft palate	66	3	0	0	0	69
E9 Resection of the oropharynx, other type	4	27	7	14	9	61
E6 Resection of the posterior wall	0	4	52	0	1	57
E7 Resection of the uvula	17	0	0	0	0	17
E4 Unilateral resection of the lateral wall of the oropharynx and soft	6	9	0	0	0	15
F2 Transoral resection	0	4	5	5	0	14
E2 Resection of the base of tongue and epiglottis	0	2	1	10	0	13
E5 Unilateral resection of the lateral wall of the oropharynx, soft palate and the base of tongue	0	9	0	2	0	11
A5 Subtotal glossectomy	0	1	0	7	0	8
A6 Total glossectomy	0	1	0	4	1	6
F1 Endoscopic resection	1	0	4	0	0	5
F6 Total pharyngolaryngo-esophagectomy	0	2	2	0	0	4
G5 Total laryngectomy	0	1	0	3	0	4
Others	6	3	1	9	2	21
V9 Unknown	5	12	6	8	4	35
<b>Total</b>	<b>173</b>	<b>455</b>	<b>143</b>	<b>280</b>	<b>34</b>	<b>1085</b>

NOS: not otherwise specified.

Surgical Method for the Primary Lesion by Subsite was not reported in one patient.

### Reconstructive Surgery by Subsite

Reconststructive surgery	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0 ) No reconstruction	149	374	127	221	25	896
E ) Free ALT flap	5	25	1	16	2	49
D ) Free RA MC flap	1	15	0	17	2	35
C ) Free FA flap	3	6	1	6	0	16
5 ) PM MC flap	1	4	1	7	1	14
B ) Free jejunal flap	0	3	6	2	0	11
3 ) Mucosal flap	5	2	0	0	1	8
2 ) Local skin flap	3	1	0	1	0	5
4 ) DP flap	0	1	0	0	0	1
7 ) Gastric pull-up	0	1	0	0	0	1
1 ) Skin graft	0	0	0	0	0	0
F ) Free scapular OC flap	0	0	0	0	0	0
G ) Free fibular OC flap	0	0	0	0	0	0
I ) Free nerve graft	0	0	0	0	0	0
Others	0	6	0	2	0	8
9 ) Unknown	6	17	7	9	3	42
<b>Total</b>	<b>173</b>	<b>455</b>	<b>143</b>	<b>281</b>	<b>34</b>	<b>1086</b>

NOS: not otherwise specified.

Carcinoma of the Oropharynx p16 negative and unknown ----- 1086Cases

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	145	329	121	187	24	806
1) Total N.D.	9	38	2	38	4	91
2) Selective N.D.	12	74	12	49	4	151
3) Lymph node excision	0	1	0	1	0	2
8) Others	1	2	1	0	0	4
9) Unknown	6	11	7	6	2	32
<b>Total</b>	<b>173</b>	<b>455</b>	<b>143</b>	<b>281</b>	<b>34</b>	<b>1086</b>

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	158	418	125	235	30	966
1) Total N.D.	4	5	2	10	1	22
2) Selective N.D.	4	18	7	30	1	60
3) Lymph node excision	0	0	1	0	0	1
8) Others	1	3	1	0	0	5
9) Unknown	6	11	7	6	2	32
<b>Total</b>	<b>173</b>	<b>455</b>	<b>143</b>	<b>281</b>	<b>34</b>	<b>1086</b>

NOS: not otherwise specified.

N.D.: neck dissection.

### Radiotherapy by Subsite

Type of radiotherapy	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No radiotherapy	101	168	77	121	17	484
1) X-ray (and/or electron beam)	65	272	62	153	14	566
2) Particle beam	1	1	0	3	0	5
3) B.T.	2	0	0	0	0	2
4) X-ray + Particle beam	0	0	0	0	0	0
5) X-ray + B.T.	0	0	0	0	0	0
6) Particl beam + B.T.	0	0	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0	0	0
8) Others	0	0	0	0	0	0
9) Unknown	4	14	4	4	3	29
<b>Total</b>	<b>173</b>	<b>455</b>	<b>143</b>	<b>281</b>	<b>34</b>	<b>1086</b>

NOS: not otherwise specified.

B.T.: brachytherapy.

### Chemotherapy by Subsite

Route of administration	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No chemotherapy	124	191	81	139	16	551
1) I.V.	37	240	55	120	14	466
3) Oral	7	7	3	5	1	23
2) I.A.	1	4	0	7	0	12
4) I.V.+I.A.	0	3	0	4	0	7
5) I.V.+Oral	1	1	0	2	1	5
6) I.A.+Oral	0	0	0	0	0	0
7) I.V.+I.A.+Oral	0	0	0	0	0	0
8) Others	0	0	0	0	0	0
9) Unknown	3	9	4	4	2	22
<b>Total</b>	<b>173</b>	<b>455</b>	<b>143</b>	<b>281</b>	<b>34</b>	<b>1086</b>

I.V.: intravenous.

I.A.: intraarterial.

NOS: not otherwise specified.

# Nasopharynx(2018)

408 Cases

## Primary Site

Site	Number of patients	(%)
Posteriosuperior wall	188	(46.1)
Lateral wall	154	(37.7)
Inferior wall	7	(1.7)
Nasopharynx, NOS	59	(14.5)
Total	408	(100)

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	3	2	5
20 - 29	7	3	10
30 - 39	9	8	17
40 - 49	40	9	49
50 - 59	57	22	79
60 - 69	99	36	135
70 - 79	71	16	87
80 - 89	17	7	24
90 - 99	0	2	2
100 - 109	0	0	0
110 - 119	0	0	0
Total	303	105	408

Carcinoma of the Nasopharynx ----- 408 Cases  
**Histological Distribution by Subsite**

Histologic type	Posterior-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
S.C.C., NOS	124	93	6	36	259
Lymphoepithelial ca.	19	18	0	4	41
S.C.C., large cell, nonkerat., NOS	17	17	0	4	38
Ca., undiff., NOS	4	9	0	4	17
Ca., NOS	5	6	0	4	15
S.C.C., small cell, nonkerat.	5	4	0	1	10
S.C.C., keratinizing., NOS	3	1	0	1	5
Adenoid cystic ca.	1	1	0	2	4
Neoplasm, malig.	1	1	0	1	3
S.C.C. in situ, NOS	2	0	0	0	2
Malig. lymphoma, NOS	1	1	0	0	2
Adenoca., NOS	2	0	0	0	2
Basaloid S.C.C.	0	1	0	1	2
Mucoepidermoid ca.	1	0	0	0	1
Papillary S.C.C.	0	1	0	0	1
Malig. melanoma, NOS	0	1	0	0	1
Epithelial-myoepithelial ca.	1	0	0	0	1
Malig. teratoma, undiff.	1	0	0	0	1
Solitary fibrous tumor, malig.	0	0	1	0	1
Follicular dendritic cell sarcoma	1	0	0	0	1
Intraductal ca., noninfiltrating, NOS	0	0	0	1	1
<b>Total</b>	<b>188</b>	<b>154</b>	<b>7</b>	<b>59</b>	<b>408</b>

NOS: not otherwise specified.  
malig., Malig.: malignant.

ca., Ca.: carcinoma.  
kerat.: keratinizing.

S.C.C.: squamous cell carcinoma.  
nonkerat.: nonkeratinizing.

## T and N Status

	N0	N1	N2	N3	NX	N-	Total
T1	37	43(2)	26(1)	14(3)	0	0	120
T2	20	25	32(3)	7	0	0	84
T3	12	32	35(4)	22(7)	0	1	102
T4	18	25(2)	32(4)	18(6)	0	0	93
TX	0	0	0	0	2	0	2
T-	0	0	0	0	0	7	7
<b>Total</b>	<b>87</b>	<b>125</b>	<b>125</b>	<b>61</b>	<b>2</b>	<b>8</b>	<b>408</b>

M1:32 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

### Treatment Method for the Primary Lesion by Subsite

Treatment Method	Posterior-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
Surgery					
without	179	141	3	52	375
with	4	6	2	2	14
unknown	5	7	2	5	19
Radiotherapy					
without	5	8	1	4	18
with	178	139	4	50	371
unknown	5	7	2	5	19
Chemotherapy					
without	37	19	2	9	67
with	146	128	3	45	322
unknown	5	7	2	5	19
<b>Total</b>	<b>188</b>	<b>154</b>	<b>7</b>	<b>59</b>	<b>408</b>

NOS: not otherwise specified.

### Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Posterior-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
Surgery					
without	178	141	4	51	374
with	5	5	1	3	14
unknown	5	7	2	5	19
Radiotherapy					
without	32	24	2	11	69
with	151	122	3	43	319
unknown	5	7	2	5	19
Chemotherapy					
without	49	30	3	13	95
with	134	116	2	41	293
unknown	5	7	2	5	19
<b>Total</b>	<b>188</b>	<b>153</b>	<b>7</b>	<b>59</b>	<b>407</b>

NOS: not otherwise specified.

Treatment Method for the Cervical Lymph Nodes by Subsite was not reported in one patient.

### Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
F)(Rad.+Chem.)	101	93	2	27	223
B) Rad. alone	34	12	2	8	56
C)F) Chem. -> (Rad.+Chem.)	21	16	0	8	45
F)C)(Rad.+Chem.)->Chem.	12	8	0	3	23
C) Chem. alone	3	3	0	3	9
F)F)(Rad.+Chem.)->(Rad.+Chem.)	2	2	0	1	5
Other	10	13	1	4	28
Unknown	5	7	2	5	19
<b>Total</b>	<b>188</b>	<b>154</b>	<b>7</b>	<b>59</b>	<b>408</b>

NOS: not otherwise specified.

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

### Surgical Methods for the Primary Lesion by Subsite

Surgical method	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
X0 No surgery	173	141	4	52	370
+ Others	4	4	1	1	10
V9 Unknown	11	9	2	6	28
<b>Total</b>	<b>188</b>	<b>154</b>	<b>7</b>	<b>59</b>	<b>408</b>

NOS: not otherwise specified.

### Reconstructive Surgery by Subsite

Reconstuctive surgery	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No reconstruction	176	144	4	53	377
E) Free ALT flap	1	0	0	0	1
9) Unknown	11	10	3	6	30
<b>Total</b>	<b>188</b>	<b>154</b>	<b>7</b>	<b>59</b>	<b>408</b>

NOS: not otherwise specified.

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Posterior-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No N.D.	173	140	4	52	369
2) Selective N.D.	5	2	0	1	8
1) Total N.D.	0	2	0	1	3
3) Lymph node excision	0	0	0	0	0
9) Unknown	10	10	3	5	28
<b>Total</b>	<b>188</b>	<b>154</b>	<b>7</b>	<b>59</b>	<b>408</b>

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Posterior-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No N.D.	178	143	4	54	379
2) Selective N.D.	0	1	0	0	1
9) Unknown	10	10	3	5	28
<b>Total</b>	<b>188</b>	<b>154</b>	<b>7</b>	<b>59</b>	<b>408</b>

NOS: not otherwise specified.

N.D.: neck dissection.

### Radiotherapy by Subsite

Type of radiotherapy	Posterior-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No radiotherapy	5	8	1	5	19
1) X-ray (and/or electron beam)	174	137	4	46	361
2) Particle beam	4	0	0	3	7
9) Unknown	5	9	2	5	21
<b>Total</b>	<b>188</b>	<b>154</b>	<b>7</b>	<b>59</b>	<b>408</b>

NOS: not otherwise specified.

### Chemotherapy by Subsite

Route of administration	Posterior-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No chemotherapy	36	18	3	10	67
1) I.V.	145	126	2	44	317
3) Oral	2	0	0	0	2
5) I.V.+Oral	0	2	0	0	2
9) Unknown	5	8	2	5	20
<b>Total</b>	<b>188</b>	<b>154</b>	<b>7</b>	<b>59</b>	<b>408</b>

NOS: not otherwise specified.

I.V.: intravenous.

I.A.: intraarterial.

Nasal Cavity and Paranasal Sinuses  
(Excluding the Maxillary Sinus)  
(2018)

436 Cases

## Primary Site

Site	Number of patients	(%)
Nasalcavity	257	(58.9)
Ethmoidsinus	75	(17.2)
Frontalsinus	7	(1.6)
Sphenoidsinus	27	(6.2)
Paranasalsinus, NOS	70	(16.1)
<b>Total</b>	<b>436</b>	<b>(100)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	2	1	3
20 - 29	6	3	9
30 - 39	11	11	22
40 - 49	31	15	46
50 - 59	39	26	65
60 - 69	79	32	111
70 - 79	74	44	118
80 - 89	27	29	56
90 - 99	3	3	6
100 - 109	0	0	0
110 - 119	0	0	0
<b>Total</b>	<b>272</b>	<b>164</b>	<b>436</b>

NOS: not otherwise specified.

Carcinoma of the Nasal Cavity and Paranasal Sinuses -----436Cases

## Histological Distribution by Subsite

Histologic type	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
S.C.C., NOS	80	36	5	16	28	165
Malig. melanoma, NOS	64	2	0	1	5	72
Olfactory neuroblastoma	34	5	0	0	21	60
Adenoid cystic ca.	13	4	0	2	5	24
Adenoca., NOS	10	4	0	0	1	15
Ca., NOS	6	4	0	2	2	14
S.C.C., kerat. , NOS	6	3	0	0	1	10
Ca., undiff., NOS	4	2	0	1	1	8
Small cell ca., NOS	2	3	0	1	1	7
Neoplasm, malig.	2	3	0	0	2	7
S.C.C. in situ, NOS	3	0	1	0	1	5
Alveolar rhabdomyosarcoma	4	0	0	0	0	4
Malig. lymphoma, NOS	1	1	0	1	0	3
Large cell ca., NOS	1	1	0	0	1	3
S.C.C., large cell, nonkerat. , NOS	2	1	0	0	0	3
Carcinosarcoma, NOS	1	1	1	0	0	3
Ca. ex pleomorphic adenoma	2	0	0	0	0	2
Mucoepidermoid ca.	0	0	0	2	0	2
Papillary S.C.C.	2	0	0	0	0	2
Leiomyosarcoma, NOS	2	0	0	0	0	2
Basaloid S.C.C.	1	1	0	0	0	2
Basal cell ca., NOS	2	0	0	0	0	2
Carcinoid tumor, NOS	1	0	0	1	0	2
Rhabdomyosarcoma, NOS	1	1	0	0	0	2
Spindle cell sarcoma	1	1	0	0	0	2
Salivary duct ca.	1	0	0	0	0	1
S.C.C., small cell, nonkerat.	1	0	0	0	0	1
Acinar cell ca.	1	0	0	0	0	1
Spindle cell ca., NOS	1	0	0	0	0	1
Epithelial-myoepithelial ca.	0	1	0	0	0	1
Neuroendocrine ca., NOS	1	0	0	0	0	1
Adenosquamous ca.	1	0	0	0	0	1
Mucinous adenoca.	1	0	0	0	0	1
Malig. teratoma, undiff.	1	0	0	0	0	1
Solitary fibrous tumor, malig.	0	0	0	0	1	1
Adenoca., intestinal type	1	0	0	0	0	1
Spindle cell rhabdomyosarcoma	0	1	0	0	0	1
Papillary adenoca., NOS	1	0	0	0	0	1
Adenoca. with neuroendocrine differentiation	1	0	0	0	0	1
Malig. lymphoma, large B-cell, diffuse, NOS	1	0	0	0	0	1
Total	257	75	7	27	70	436

NOS: not otherwise specified.

malig., Malig.: malignant.

ca., Ca.: carcinoma.

kerat.: keratinizing.

S.C.C.: squamous cell carcinoma.

nonkerat.: nonkeratinizing.

## T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T1	58	1	1	1	0	0	0	0	61
T2	50(1)	2	0	0	0	1	0	0	53
T3	60(1)	2	0	1	1(1)	1(1)	0	0	65
T4	9	1	1	1	0	0	0	0	12
T4a	92(9)	4(3)	1	5	0	1(1)	1	0	104
T4b	68(6)	4	3	3(1)	0	1(1)	0	0	79
Tis	2	0	0	0	0	0	0	0	2
TX	6	0	1	0	0	0	6(2)	0	13
T-	10	0	0	0	0	0	0	37	47
<b>Total</b>	<b>355</b>	<b>14</b>	<b>7</b>	<b>11</b>	<b>1</b>	<b>4</b>	<b>7</b>	<b>37</b>	<b>436</b>

M1:27 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
Surgery						
without	110	44	3	22	20	199
with	133	31	3	5	48	220
unknown	13	0	1	0	2	16
Radiotherapy						
without	88	17	1	6	21	133
with	155	58	5	21	47	286
unknown	13	0	1	0	2	16
Chemotherapy						
without	151	30	3	9	47	240
with	92	45	3	18	21	179
unknown	13	0	1	0	2	16
<b>Total</b>	<b>256</b>	<b>75</b>	<b>7</b>	<b>27</b>	<b>70</b>	<b>435</b>

NOS: not otherwise specified.

### Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
Surgery						
without	228	71	6	27	62	394
with	10	3	0	0	3	16
unknown	15	0	1	0	3	19
Radiotherapy						
without	201	60	5	22	57	345
with	37	14	1	5	8	65
unknown	15	0	1	0	3	19
Chemotherapy						
without	198	60	5	22	57	342
with	40	14	1	5	8	68
unknown	15	0	1	0	3	19
<b>Total</b>	<b>253</b>	<b>74</b>	<b>7</b>	<b>27</b>	<b>68</b>	<b>429</b>

NOS: not otherwise specified.

Treatment Method for the Cervical Lymph Nodes by Primary Site was not reported in 7 patients.

### Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
No treatment	5	2	0	0	1	8
A) Surg. alone	64	11	1	3	18	97
A)B) Surg.->Rad.	41	8	2	0	19	70
F)(Rad.+Chem.)	35	14	2	8	8	67
B) Rad. alone	33	9	0	6	7	55
A)F) Surg.->(Rad.+Chem.)	9	6	0	1	2	18
C) Chem. alone	12	2	0	1	1	16
C)F) Chem. -> (Rad.+Chem.)	5	6	1	1	1	14
C)B) Chem.->Rad.	5	2	0	1	1	9
F)C)(Rad.+Chem.)->Chem.	2	4	0	2	1	9
F)A)(Rad.+Chem.)->Surg.	3	2	0	0	3	8
B)C) Rad.->Chem.	6	1	0	0	0	7
A)C) Surg. -> Chem	3	0	0	1	1	5
Other	20	8	0	3	5	36
Unknown	13	0	1	0	2	16
<b>Total</b>	<b>256</b>	<b>75</b>	<b>7</b>	<b>27</b>	<b>70</b>	<b>435</b>

NOS: not otherwise specified.

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

Sequence of Treatment Methods for the Primary Lesion by Subsite was not reported in one patient.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
No surgery	109	44	3	22	20	198
Maxillectomy, other type	50	12	1	3	9	75
Endoscopic skull base surgery	34	7	0	2	23	66
Partial maxillectomy	17	3	0	0	2	22
Skull base surgery	7	4	1	0	3	15
Total maxillectomy	3	2	0	0	0	5
+Others	22	3	1	0	10	36
Unknown	15	0	1	0	3	19
<b>Total</b>	<b>257</b>	<b>75</b>	<b>7</b>	<b>27</b>	<b>70</b>	<b>436</b>

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

Reconstructive surgery	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No reconstruction	210	63	4	26	41	344
3) Mucosal flap	7	1	0	0	7	15
2) Local skin flap	8	2	0	1	2	13
D) Free RA MC flap	3	3	1	0	0	7
E) Free ALT flap	1	1	0	0	1	3
C) Free FA flap	0	1	1	0	0	2
1) Skin graft	1	0	0	0	0	1
8) Others	8	4	0	0	16	28
9) Unknown	19	0	1	0	3	23
<b>Total</b>	<b>257</b>	<b>75</b>	<b>7</b>	<b>27</b>	<b>70</b>	<b>436</b>

NOS: not otherwise specified.

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No N.D.	229	73	6	27	63	398
2) Selective N.D.	5	1	0	0	3	9
1) Total N.D.	3	1	0	0	1	5
3) Lymph node excision	0	0	0	0	0	0
8) Others	2	0	0	0	1	3
9) Unknown	18	0	1	0	2	21
<b>Total</b>	<b>257</b>	<b>75</b>	<b>7</b>	<b>27</b>	<b>70</b>	<b>436</b>

NOS: not otherwise specified.

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No N.D.	236	74	6	27	66	409
2) Selective N.D.	1	1	0	0	0	2
1) Total N.D.	0	0	0	0	1	1
8) Others	2	0	0	0	1	3
9) Unknown	18	0	1	0	2	21
<b>Total</b>	<b>257</b>	<b>75</b>	<b>7</b>	<b>27</b>	<b>70</b>	<b>436</b>

NOS: not otherwise specified.

N.D.: neck dissection.

## Radiotherapy by Subsite

Type of radiotherapy	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No radiotherapy	85	17	1	6	20	129
1) X-ray (and/or electron beam)	135	48	5	18	47	253
2) Particle beam	22	10	0	3	1	36
9) Unknown	15	0	1	0	2	18
<b>Total</b>	<b>257</b>	<b>75</b>	<b>7</b>	<b>27</b>	<b>70</b>	<b>436</b>

NOS: not otherwise specified.

B.T.: brachytherapy.

## Chemotherapy by Subsite

Route of administration	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No chemotherapy	148	30	3	9	48	238
1) I.V.	91	33	3	15	19	161
2) I.A.	5	7	0	2	1	15
3) Oral	0	2	0	0	0	2
4) I.V.+I.A.	0	2	0	0	0	2
5) I.V.+Oral	0	1	0	1	1	3
9) Unknown	13	0	1	0	1	15
<b>Total</b>	<b>257</b>	<b>75</b>	<b>7</b>	<b>27</b>	<b>70</b>	<b>436</b>

NOS: not otherwise specified.

I.V.: intravenous.

I.A.: intraarterial.

# Maxillary Sinus (2018)

418 Cases

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	4	4	8
40 - 49	24	5	29
50 - 59	52	22	74
60 - 69	101	30	131
70 - 79	93	33	126
80 - 89	28	15	43
90 - 99	2	4	6
100 - 109	0	0	0
<b>Total</b>	<b>305</b>	<b>113</b>	<b>418</b>

## Histological Distribution by Subsite

Histologic type	Maxillary sinus	Total
S.C.C., NOS	309	( 73.9 )
S.C.C.,keratinizing, NOS	20	( 4.8 )
Adenoid cystic ca.	18	( 4.3 )
Malig. melanoma, NOS	12	( 2.9 )
S.C.C., large cell, nonkerat., NOS	8	( 1.9 )
Ca., NOS	7	( 1.7 )
Spindle cell ca., NOS	7	( 1.7 )
Ca., undiff., NOS	5	( 1.2 )
Mucoepidermoid ca.	3	( 0.7 )
Adenosquamous ca.	3	( 0.7 )
Adenoca., NOS	2	( 0.5 )
Neuroendocrine ca., NOS	2	( 0.5 )
Neoplasm, malig.	2	( 0.5 )
S.C.C., spindle cell	2	( 0.5 )
Osteosarcoma, NOS	2	( 0.5 )
Ca. ex pleomorphic adenoma	1	( 0.2 )
Small cell ca., NOS	1	( 0.2 )
S.C.C. in situ, NOS	1	( 0.2 )
Epithelial-myoepithelial ca.	1	( 0.2 )
Malig. lymphoma, NOS	1	( 0.2 )
Myoepithelial ca.	1	( 0.2 )
Olfactory neuroblastoma	1	( 0.2 )
Ameloblastoma, NOS	1	( 0.2 )
Carcinosarcoma, NOS	1	( 0.2 )
Alveolar rhabdomyosarcoma	1	( 0.2 )
Malig. tumor, spindle cell type	1	( 0.2 )
Plasmablastic lymphoma	1	( 0.2 )
Solitary fibrous tumor, malig.	1	( 0.2 )
Hemangiosarcoma	1	( 0.2 )
Undiff. sarcoma	1	( 0.2 )
Undiff. pleomorphic sarcoma	1	( 0.2 )
<b>Total</b>	<b>418</b>	<b>( 100 )</b>

ca., Ca.: carcinoma.  
kerat.: keratinizing.

S.C.C.: squamous cell carcinoma.  
nonkerat.: nonkeratinizing.

malig., Malig.: malignant.

## T and N Status

	N0	N1	N2a	N2b	N2c	N3b	NX	N-	Total
T1	3	0	0	0	0	0	0	0	3
T1a	0	0	0	1	0	0	0	0	1
T2	17	0	0	1	0	0	0	0	18
T3	77(2)	6	1	14(1)	5(2)	2	0	0	105
T4	6(1)	0	0	0	0	0	0	0	6
T4a	141(2)	19(1)	0	20(3)	7	0	0	1	188
T4b	52(2)	7	1	17(3)	5(2)	4(1)	1	0	87
Tis	0	0	0	0	0	0	1	0	1
TX	0	0	0	0	0	0	3	0	3
T-	0	0	0	0	0	0	0	6	6
<b>Total</b>	<b>296</b>	<b>32</b>	<b>2</b>	<b>53</b>	<b>17</b>	<b>6</b>	<b>5</b>	<b>7</b>	<b>418</b>

M1:20 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Maxillary sinus	Total
Surgery		
without	250	( 59.8 )
with	155	( 37.1 )
unknown	13	( 3.1 )
Radiotherapy		
without	92	( 22.0 )
with	313	( 74.9 )
unknown	13	( 3.1 )
Chemotherapy		
without	136	( 32.5 )
with	269	( 64.4 )
unknown	13	( 3.1 )
<b>Total</b>	<b>418</b>	<b>( 100 )</b>

### Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Maxillary sinus	Total
Surgery		
without	315 ( 77.4 )	
with	77 ( 18.9 )	
unknown	15 ( 3.7 )	
Radiotherapy		
without	267 ( 65.6 )	
with	125 ( 30.7 )	
unknown	15 ( 3.7 )	
Chemotherapy		
without	264 ( 64.9 )	
with	128 ( 31.4 )	
unknown	15 ( 3.7 )	
Total	407	( 100 )

Treatment Method for the Cervical Lymph Nodes by Subsite was not reported in 11 patients.

Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Maxillary sinus	Total
No treatment	14	( 3.3 )
F)(Rad.+Chem.)	144	( 34.4 )
A) Surg. alone	48	( 11.5 )
B) Rad. alone	39	( 9.3 )
A)B) Surg.->Rad.	29	( 6.9 )
F)A)(Rad.+Chem.)->Surg.	20	( 4.8 )
A)F) Surg.->(Rad.+Chem.)	15	( 3.6 )
C) Chem. alone	14	( 3.3 )
C)F) Chem. -> (Rad.+Chem.)	14	( 3.3 )
F)C)(Rad.+Chem.)->Chem.	11	( 2.6 )
C)A)F) Chem.->Surg.->(Rad.+Chem.)	8	( 1.9 )
C)A) Chem.->Surg.	6	( 1.4 )
C)C) Chem.->Chem.	4	( 1.0 )
F)C)C)(Rad.+Chem.)->Chem.->Chem.	4	( 1.0 )
Other	35	( 8.4 )
Unknown	13	( 3.1 )
<b>Total</b>	<b>418</b>	<b>( 100 )</b>

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Maxillary sinus	Total
X0 No surgery	249	( 59.6 )
D2 Total maxillectomy	81	( 19.4 )
D1 Partial maxillectomy	27	( 6.5 )
D3 Extended maxillectomy	20	( 4.8 )
D9 Maxillectomy, other type	16	( 3.8 )
D4 Skull base surgery	6	( 1.4 )
+Others	3	( 0.7 )
V9 Unknown	16	( 3.8 )
Total	418	( 100 )

## Reconstructive Surgery by Subsite

Reconststructive surgery	Maxillary sinus	Total
0 ) No reconstruction	307	( 73.4 )
D) Free RA MC flap	55	( 13.2 )
E ) Free ALT flap	13	( 3.1 )
1 ) Skin graft	6	( 1.4 )
C) Free FA flap	5	( 1.2 )
F ) Free scapular OC flap	4	( 1.0 )
G) Free fibular OC flap	3	( 0.7 )
2 ) Local skin flap	2	( 0.5 )
3 ) Mucosal flap	1	( 0.2 )
Others	6	( 1.4 )
9 ) Unknown	16	( 3.8 )
Total	418	( 100 )

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh.

FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Maxillary sinus	Total
0) No N.D.	325	( 77.8 )
2) Selective N.D.	58	( 13.9 )
1) Total N.D.	17	( 4.1 )
3) Lymph node excision	2	( 0.5 )
8) Others	1	( 0.2 )
9) Unknown	15	( 3.6 )
<b>Total</b>	<b>418</b>	<b>( 100 )</b>

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Maxillary sinus	Total
0) No N.D.	389	( 93.1 )
2) Selective N.D.	8	( 1.9 )
1) Total N.D.	3	( 0.7 )
8) Others	2	( 0.5 )
9) Unknown	16	( 3.8 )
<b>Total</b>	<b>418</b>	<b>( 100 )</b>

N.D.: neck dissection.

### Radiotherapy by Subsite

Type of radiotherapy	Maxillary sinus	Total
0) No radiotherapy	83	( 19.9 )
1) X-ray (and/or electron beam)	296	( 70.8 )
2) Particle beam	22	( 5.3 )
8) Others	1	( 0.2 )
9) Unknown	16	( 3.8 )
<b>Total</b>	<b>418</b>	<b>( 100 )</b>

B.T.: brachytherapy.

### Chemotherapy by Subsite

Route of administration	Maxillary sinus	Total
0) No chemotherapy	133	( 31.8 )
2) I.A.	132	( 31.6 )
1) I.V.	118	( 28.2 )
4) I.V.+I.A.	14	( 3.3 )
3) Oral	5	( 1.2 )
5) I.V.+Oral	2	( 0.5 )
9) Unknown	14	( 3.3 )
<b>Total</b>	<b>418</b>	<b>( 100 )</b>

I.V.: intravenous.

I.A.: intraarterial.

# Major Salivary Glands (2018)

765 Cases

## Primary Site

Site	Number of patients	(%)
Parotid gland	564	( 73.7 )
Submandibular gland	172	( 22.5 )
Sublingual gland	21	( 2.7 )
Majorsalivary gland, NOS	8	( 1.0 )
Total	765	( 100 )

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	2	9	11
20 - 29	9	14	23
30 - 39	21	26	47
40 - 49	48	33	81
50 - 59	83	43	126
60 - 69	131	63	194
70 - 79	127	62	189
80 - 89	61	26	87
90 - 99	6	1	7
100 - 109	0	0	0
Total	488	277	765

NOS: not otherwise specified.

## Parotid gland

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	2	8	10
20 - 29	8	11	19
30 - 39	18	21	39
40 - 49	32	25	57
50 - 59	63	34	97
60 - 69	94	46	140
70 - 79	89	41	130
80 - 89	49	18	67
90 - 99	4	1	5
100 - 109	0	0	0
Total	359	205	564

## Submandibular gland

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	1	1
20 - 29	1	3	4
30 - 39	3	4	7
40 - 49	14	5	19
50 - 59	20	8	28
60 - 69	31	13	44
70 - 79	33	17	50
80 - 89	9	8	17
90 - 99	2	0	2
100 - 109	0	0	0
Total	113	59	172

## Sublingual gland

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	1	1
40 - 49	0	1	1
50 - 59	0	0	0
60 - 69	6	4	10
70 - 79	3	4	7
80 - 89	2	0	2
90 - 99	0	0	0
100 - 109	0	0	0
Total	11	10	21

## Major salivary gland, NOS

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	2	2	4
50 - 59	0	1	1
60 - 69	0	0	0
70 - 79	2	0	2
80 - 89	1	0	1
90 - 99	0	0	0
100 - 109	0	0	0
Total	5	3	8

Carcinoma of the Major Salivary Glands -----765 Cases

Histological Distribution by Primary Site

Histologic type	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
Salivary duct ca.	135	45	0	1	181
Adenoid cystic ca.	50	44	13	2	109
Mucoepidermoid ca.	94	10	3	0	107
Ca. ex pleomorphic adenoma	47	19	0	2	68
Adenoca., NOS	41	7	2	1	51
S.C.C., NOS	39	10	1	0	50
Ca., NOS	32	6	0	0	38
Acinar cell ca.	27	3	0	0	30
Epithelial-myoepithelial ca.	26	1	0	0	27
Myoepithelial ca.	11	7	0	0	18
Basal cell adenoca.	16	1	0	0	17
Malig. lymphoma, NOS	6	3	1	1	11
Neoplasm, malig.	4	5	0	0	9
Ca., undiff., NOS	4	3	0	0	7
Lymphoepithelial ca.	5	0	0	1	6
Secretory ca. of breast	5	1	0	0	6
Basal cell ca., NOS	4	1	0	0	5
Small cell ca., NOS	4	0	0	0	4
Adenosquamous ca.	3	0	0	0	3
Oncocytic ca.	1	2	0	0	3
Mucinous adenoca.	2	1	0	0	3
Carcinosarcoma, NOS	2	1	0	0	3
S.C.C., keratinizing, NOS	0	1	0	0	1
Malig. melanoma, NOS	1	0	0	0	1
Spindle cell ca., NOS	1	0	0	0	1
Clear cell ca., NOS	0	0	1	0	1
Sebaceous ca.	1	0	0	0	1
S.C.C., adenoid	1	0	0	0	1
Mixed tumor, Malig., NOS	0	1	0	0	1
Cystadenoca.	1	0	0	0	1
Low-grade cribriform cystadenoca.	1	0	0	0	1
Total	564	172	21	8	765

NOS: not otherwise specified.

ca., Ca.: carcinoma.

S.C.C.: squamous cell carcinoma.

malig., Malig.: malignant.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	3	0	0	0	1	0	0	0	0	0	0	4
T1	91(1)	4	0	1	4	0	1	0	0	1	0	102
T2	178(1)	10(2)	1	2	24(3)	3(2)	0	0	4(2)	1	0	223
T3	112(4)	9	1	1	52(11)	6(2)	0	0	4(1)	0	0	185
T4	2	1	0	0	3(1)	2(1)	0	0	0	0	0	8
T4a	82(3)	21(1)	1	0	56(12)	10(4)	0	0	11(6)	0	0	181
T4b	9(1)	0	0	0	6(1)	1(1)	0	1(1)	2(1)	0	1	20
TX	2	1	0	0	1	0	0	0	0	21(2)	0	25
T-	0	0	0	0	0	0	0	0	0	0	17	17
<b>Total</b>	<b>479</b>	<b>46</b>	<b>3</b>	<b>4</b>	<b>147</b>	<b>22</b>	<b>1</b>	<b>1</b>	<b>21</b>	<b>23</b>	<b>18</b>	<b>765</b>

M1:64 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Parotid gland

### T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	3	0	0	0	0	0	0	0	0	0	0	3
T1	74(1)	1	0	1	3	0	1	0	0	1	0	81
T2	136(1)	3	0	0	10	1	0	0	1(1)	1	0	152
T3	79(2)	3	1	1	32(5)	3	0	0	2	0	0	121
T4	2	1	0	0	3(1)	0	0	0	0	0	0	6
T4a	74(3)	18	0	0	49(9)	6(3)	0	0	10(6)	0	0	157
T4b	7(1)	0	0	0	5	1(1)	0	1(1)	1	0	0	15
TX	2	1	0	0	1	0	0	0	0	16(1)	0	20
T-	0	0	0	0	0	0	0	0	0	0	9	9
<b>Total</b>	<b>377</b>	<b>27</b>	<b>1</b>	<b>2</b>	<b>103</b>	<b>11</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>18</b>	<b>9</b>	<b>564</b>

M1:36 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Submandibular gland

### T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	1	0	0	0	0	0	0	1
T1	10	3	0	0	1	0	0	0	0	0	0	14
T2	36	6(2)	1	1	13(3)	1(1)	0	0	3(1)	0	0	61
T3	27(1)	6	0	0	20(6)	3(2)	0	0	2(1)	0	0	58
T4	0	0	0	0	0	1(1)	0	0	0	0	0	1
T4a	7	3(1)	1	0	7(3)	4(1)	0	0	1	0	0	23
T4b	2	0	0	0	1(1)	0	0	0	1(1)	0	0	4
TX	0	0	0	0	0	0	0	0	0	4(1)	0	4
T-	0	0	0	0	0	0	0	0	0	0	6	6
<b>Total</b>	<b>82</b>	<b>18</b>	<b>2</b>	<b>1</b>	<b>43</b>	<b>9</b>	<b>0</b>	<b>0</b>	<b>7</b>	<b>4</b>	<b>6</b>	<b>172</b>

M1:26 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Sublingual gland

### T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	4	0	0	0	0	0	0	0	0	0	0	4
T2	4	1	0	1	1	1(1)	0	0	0	0	0	8
T3	6(1)	0	0	0	0	0	0	0	0	0	0	6
T4	0	0	0	0	0	1	0	0	0	0	0	1
T4a	1	0	0	0	0	0	0	0	0	0	0	1
T4b	0	0	0	0	0	0	0	0	0	0	0	0
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	1	1
<b>Total</b>	<b>15</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>21</b>

M1:2 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Majorsalivary gland,NOS T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	3	0	0	0	0	0	0	0	0	0	0	3
T2	2	0	0	0	0	0	0	0	0	0	0	2
T3	0	0	0	0	0	0	0	0	0	0	0	0
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	0	0	0	0	0	0	0	0	0	0	0	0
T4b	0	0	0	0	0	0	0	0	0	0	1	1
TX	0	0	0	0	0	0	0	0	0	1	0	1
T-	0	0	0	0	0	0	0	0	0	0	1	1
Total	5	0	0	0	0	0	0	0	0	1	2	8

M1:0 case.

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

### Treatment Method for the Primary Lesion by Subsite

Treatment Method	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
Surgery					
without	72	17	2	1	92
with	470	144	19	7	640
unknown	21	11	0	0	32
Radiotherapy					
without	293	90	14	3	400
with	249	71	7	5	332
unknown	21	11	0	0	32
Chemotherapy					
without	446	133	17	5	601
with	96	28	4	3	131
unknown	21	11	0	0	32
Total	563	172	21	8	764

NOS: not otherwise specified.

Treatment Method for the Primary Lesion by Subsite was not reported in one patient.

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
Surgery					
without	277	30	5	7	319
with	255	128	15	1	399
unknown	24	13	0	0	37
Radiotherapy					
without	377	97	15	6	495
with	155	61	5	2	223
unknown	24	13	0	0	37
Chemotherapy					
without	462	131	16	7	616
with	70	27	4	1	102
unknown	24	13	0	0	37
Total	556	171	20	8	755

Treatment Method for the Cervical Lymph Node by Subsite was not reported in 10 patients.

NOS: not otherwise specified.

Carcinoma of the Major Salivary Glands -----765 Cases

**Sequence of Treatment Methods for the Primary Lesion by Subsite**

Sequence of treatment methods	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
No treatment	16	6	0	0	22
A) Surg. alone	261	71	12	3	347
A)B) Surg.->Rad.	137	50	4	2	193
A)F) Surg.->(Rad.+Chem.)	40	10	1	2	53
B) Rad. alone	27	3	0	0	30
A)C) Surg. -> Chem	4	7	1	0	12
C) Chem. alone	6	4	0	0	10
F)(Rad.+Chem.)	6	2	2	0	10
A)B)C) Surg.->Rad.->Chem.	6	1	0	0	7
A)A) Surg.->Surg.	3	1	1	0	5
D)(Surg.+Rad.)	4	1	0	0	5
B)C) Rad.->Chem.	3	0	0	1	4
A)F)C) Surg.->(Rad.+Chem.)->Chem.	3	0	0	0	3
F)C)(Rad.+Chem.)->Chem.	3	0	0	0	3
Other	23	5	0	0	28
Unknown	21	11	0	0	32
<b>Total</b>	<b>563</b>	<b>172</b>	<b>21</b>	<b>8</b>	<b>764</b>

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

NOS: not otherwise specified.

Sequence of Treatment Methods for the Primary Lesion by Subsite was not reported in one patient.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
X0 No surgery	72	17	2	1	92
H4 Total parotidectomy	177	2	0	0	179
H2 Superficial parotidectomy	145	0	0	1	146
H6 Submandibulectomy	0	131	0	1	132
H5 Extended total parotidectomy	59	0	0	1	60
H1 Partial parotidectomy	44	0	0	2	46
H3 Deep lobe resection of the parotid gland	35	0	0	0	35
H9 Paroticectomy,NOS	3	5	2	2	12
C2 Resection of the floor of mouth	0	0	9	0	9
H7 Resection of the sublingual gland	0	0	7	0	7
Others	2	6	1	0	9
V9 Unknown	26	11	0	0	37
Total	563	172	21	8	764

Treatment Method for the Cervical Lymph Node by Subsite was not reported in one patient.

NOS: not otherwise specified.

Surgical Method for the Primary Lesion by Subsite was not reported in one patient.

## Reconstructive Surgery by Subsite

Reconstuctive surgery	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No reconstruction	402	145	8	8	563
E) Free ALT flap	38	4	8	0	50
I) Free nerve graft	40	0	0	0	40
5) PM MC flap	15	4	0	0	19
D) Free RA MC flap	8	2	0	0	10
2) Local skin flap	8	0	0	0	8
C) Free FA flap	1	0	4	0	5
F) Free scapular OC flap	2	0	0	0	2
G) Free fibular OC flap	0	1	0	0	1
Others	22	2	1	0	25
9) Unknown	28	14	0	0	42
Total	564	172	21	8	765

RA: rectus abdominis.

FA: forearm.

DP: deltopectoral.

NOS: not otherwise specified.

MC: musculocutaneous.

PM: pectoralis major.

ALT: anterolateral thigh.

OC: osteocutaneous.

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No N.D.	283	31	5	7	326
2) Selective N.D.	158	83	13	1	255
1) Total N.D.	80	42	2	0	124
3) Lymph node excision	13	3	1	0	17
8) Others	3	0	0	0	3
9) Unknown	27	13	0	0	40
<b>Total</b>	<b>564</b>	<b>172</b>	<b>21</b>	<b>8</b>	<b>765</b>

N.D.: neck dissection.

NOS: not otherwise specified.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No N.D.	523	151	16	8	698
2) Selective N.D.	9	4	4	0	17
1) Total N.D.	1	2	0	0	3
3) Lymph node excision	0	2	0	0	2
8) Others	3	0	1	0	4
9) Unknown	28	13	0	0	41
<b>Total</b>	<b>564</b>	<b>172</b>	<b>21</b>	<b>8</b>	<b>765</b>

N.D.: neck dissection.

NOS: not otherwise specified.

## Radiotherapy by Subsite

Type of radiotherapy	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No radiotherapy	275	82	14	3	374
1) X-ray (and/or electron beam)	244	68	7	5	324
2) Particle beam	21	7	0	0	28
9) Unknown	24	15	0	0	39
Total	564	172	21	8	765

NOS: not otherwise specified.

## Chemotherapy by Subsite

Route of administration	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No chemotherapy	443	128	16	5	592
1) I.V.	85	30	4	2	121
3) Oral	7	2	1	1	11
2) I.A.	1	0	0	0	1
5) I.V.+Oral	3	0	0	0	3
9) Unknown	25	12	0	0	37
Total	564	172	21	8	765

NOS: not otherwise specified.

I.V.: intravenous.

I.A.: intraarterial.

# Primary Unknown (2018)

12 Cases

## Subtype

<b>Subtype</b>	<b>Number of patients</b>	<b>(%)</b>
EBV positive	0	(0.0)
p16 positive	10	(83.3)
Other	2	(16.7)
<b>Total</b>	<b>12</b>	<b>(100)</b>

Patients with both EBV-positive and p16-positive are classified as "EBV-positive" in all the tables.

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	1	0	1
50 - 59	4	1	5
60 - 69	1	0	1
70 - 79	4	1	5
80 - 89	0	0	0
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>10</b>	<b>2</b>	<b>12</b>

Primary Unknown-----12 Cases

EBV positive  
Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	0	0	0
50 - 59	0	0	0
60 - 69	0	0	0
70 - 79	0	0	0
80 - 89	0	0	0
90 - 99	0	0	0
100 - 109	0	0	0
Total	0	0	0

p16 positive  
Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	1	0	1
50 - 59	3	1	4
60 - 69	1	0	1
70 - 79	3	1	4
80 - 89	0	0	0
90 - 99	0	0	0
100 - 109	0	0	0
Total	8	2	10

Other

Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	0	0	0
50 - 59	1	0	1
60 - 69	0	0	0
70 - 79	1	0	1
80 - 89	0	0	0
90 - 99	0	0	0
100 - 109	0	0	0
Total	2	0	2

EBV positive  
N and M Status

	N1	N2	N3	NX	N-	Total
M0	0	0	0	0	0	0
M1	0	0	0	0	0	0
MX	0	0	0	0	0	0
M-	0	0	0	0	0	0
Total	0	0	0	0	0	0

## p16 positive N and M Status

	N1	N2	N3	NX	N-	Total
M0	7	1	2	0	0	10
M1	0	0	0	0	0	0
MX	0	0	0	0	0	0
M-	0	0	0	0	0	0
<b>Total</b>	<b>7</b>	<b>1</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>10</b>

## Other N and M Status

	N1	N2a	N2b	N2c	N3a	N3b	NX	N-	Total
M0	0	0	0	0	0	2	0	0	2
M1	0	0	0	0	0	0	0	0	0
MX	0	0	0	0	0	0	0	0	0
M-	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>2</b>

### Treatment Methods for the Primary Lesion by Subsite

Treatment Method	EBV positive	p16 positive	Other	Total
Surgery				
without	0	4	2	6
with	0	6	0	6
unknown	0	0	0	0
Radiotherapy				
without	0	3	1	4
with	0	7	1	8
unknown	0	0	0	0
Chemotherapy				
without	0	6	1	7
with	0	4	1	5
unknown	0	0	0	0
Total	0	10	2	12

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	EBV positive	p16 positive	Other	Total
Surgery				
without	0	3	0	3
with	0	7	2	9
unknown	0	0	0	0
Radiotherapy				
without	0	2	1	3
with	0	8	1	9
unknown	0	0	0	0
Chemotherapy				
without	0	5	1	6
with	0	5	1	6
unknown	0	0	0	0
Total	0	10	2	12

## Sequence of Treatment Methods for the Cervical Lymph Nodes by Subtype

Sequence of treatment methods	EBV positive	p16 positive	Other	Total
A) Surg. alone	0	2	1	3
A)B) Surg.->Rad.	0	3	0	3
A)F) Surg.->(Rad.+Chem.)	0	2	1	3
F)(Rad.+Chem.)	0	3	0	3
Total	0	10	2	12

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

### Neck Dissection on the Ipsilateral Side by Subtype

Neck dissection	EBV positive	p16 positive	Other	Total
0) No N.D.	0	3	0	3
2) Selective N.D.	0	4	1	5
1) Total N.D.	0	2	1	3
3) Lymph node excision	0	1	0	1
8) Others	0	0	0	0
9) Unknown	0	0	0	0
<b>Total</b>	<b>0</b>	<b>10</b>	<b>2</b>	<b>12</b>

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subtype

Neck dissection	EBV positive	p16 positive	Other	Total
0) No N.D.	0	8	2	10
2) Selective N.D.	0	2	0	2
1) Total N.D.	0	0	0	0
3) Lymph node excision	0	0	0	0
8) Others	0	0	0	0
9) Unknown	0	0	0	0
<b>Total</b>	<b>0</b>	<b>10</b>	<b>2</b>	<b>12</b>

N.D.: neck dissection.

## Radiotherapy by Subtype

Type of radiotherapy	EBV positive	p16 positive	Other	Total
0) No radiotherapy	0	2	1	3
1) X-ray (and/or electron beam)	0	8	1	9
2) Particle beam	0	0	0	0
3) B.T.	0	0	0	0
4) X-ray + Particle beam	0	0	0	0
5) X-ray + B.T.	0	0	0	0
6) Particl beam + B.T.	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0
8) Others	0	0	0	0
9) Unknown	0	0	0	0
Total	0	10	2	12

B.T.: brachytherapy.

## Chemotherapy by Subtype

Route of administration	EBV positive	p16 positive	Other	Total
0) No chemotherapy	0	5	1	6
1) I.V.	0	5	1	6
2) I.A.	0	0	0	0
3) Oral	0	0	0	0
4) I.V.+I.A.	0	0	0	0
5) I.V.+Oral	0	0	0	0
6) I.A.+Oral	0	0	0	0
7) I.V.+I.A.+Oral	0	0	0	0
8) Others	0	0	0	0
9) Unknown	0	0	0	0
Total	0	10	2	12

I.V.: intravenous.

I.A.: intraarterial.